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The trajectory of functional status before and after vascular events 
Mandip S. Dhamoon 
Background: Previous studies that have examined functional status in relation to vascular events have 
focused on the short term after events and have measured functional status a limited number of times.  
The trajectories of functional status before and after vascular events are not well characterized, and the 
factors influencing these trajectories are not well known.   
Methods: A comprehensive, structured, narrative review was performed on the topic of trajectories of 
disability and cognition surrounding vascular events.  Then using 2 large population-based epidemiologic 
cohorts, the Northern Manhattan Study (NOMAS) and the Cardiovascular Health Study (CHS), 
trajectories of functional status were examined.  In Analysis A, in NOMAS, the effect of inflammatory 
biomarkers (interleukin-6 [IL6], tumor necrosis factor receptor-1 [TNFR1], C-reactive protein [CRP], and 
lipoprotein-associated phospholipase-A2 [LpPLA2]) on the intercept and slope of functional status was 
determined over a median of 13 years, measured with yearly assessments by the Barthel index.  In 
Analysis B, in NOMAS, a similar modeling strategy was used to examine whether subclinical ischemic 
disease on brain MRIs, measured by subclinical brain infarct (SBI) and white matter hyperintensity 
volume (WMHV), was associated with functional trajectories.  In Analysis C, in CHS, participants had 
yearly assessments of disability with a combined activities of daily living (ADL) and instrumental ADL 
scale.  The slope of change in disability was compared before and after vascular events (stroke and 
myocardial infarction [MI]).   
Results: In Analysis A, CRP (-0.41 BI points per 1 SD increase, 95% CI -0.82 to 0.002) and LpPLA2 (-
0.40, 95% CI -0.75 to -0.04) were associated with baseline BI but not change over time.  TNFR1 was 
associated with baseline BI (-0.93, 95% CI -1.59 to -0.26) and change over time (-0.36 BI points per year, 
95% CI -0.69 to -0.03).  In Analysis B, functional change was -0.85 BI points per year (95%CI -1.01 to -
0.69); among those with SBI there were -0.88 additional points annually (-1.44 to -0.32).  In WMHV 
models, annual functional change was -1.04 points (-1.2 to -0.88), with -0.74 additional points annually 
per SD WMHV increase (-0.99 to -0.49).  In Analysis C, stroke (0.88, 95% CI 0.57-1.20, p<0.0001) was 
associated with a greater acute increase in disability than MI (0.20, 0.06-0.35, p=0.006).  The annual 
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increase in disability before stroke (0.06 points per year, 0.002-0.12, p=0.04) more than tripled after 
stroke (0.15 additional points per year, 0.004-0.30, p=0.04).  The annual increase in disability before MI 
(0.04 points per year, 0.004-0.08, p=0.03) did not change significantly after MI (0.02 additional points per 
year, -0.07-0.11, p=0.7).   
Conclusions: In these large population-based studies with repeated measures of functional status and 
disability over long-term follow-up, several trajectories were found.  In Analysis A, TNFR1 predicted worse 
overall functional status as well as accelerated decline over time.  In Analysis B, both SBI and WMHV 
were associated with accelerated decline.  In Analysis C, there was a steeper decline in function after 
stroke but not MI.  These findings help to elucidate the course and potential etiologies of long-term 
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In this review, I will summarize prior studies that have examined trajectories of patient-centered outcomes 
surrounding vascular events.  I will first introduce the concept of disability, review factors that influence 
disability, and then outline the traditional conception of stroke.  I will then introduce a new paradigm, in 
which cerebrovascular disease is conceived as a progressive condition with cumulative effects on 
functional status instead of just a condition that causes discrete events.   
I will discuss several lines of research that support this paradigm.  The first area of research has 
shown that vascular risk factors cause not only discrete stroke events but also progressive 
cerebrovascular dysfunction.  The second line of research has shown that subclinical brain infarcts (SBIs) 
and white matter hyperintensities (WMHs) are common, influenced by vascular risk factors, and are 
associated with functional status.  Newer imaging technology is also beginning to reveal other markers of 
structural cerebrovascular dysfunction that might illuminate the progressive nature of cerebrovascular 
disease and its long-term effects on functional status.  Next, I will briefly discuss traumatic brain injury 
(TBI) as a condition analogous to stroke in that it involves a sudden brain injury but manifests beyond the 
acute recovery period with accelerated decline in functional status and cognitive ability.  This similarity 
may be exploited in research to lead to the identification of pathophysiologies that overlap with those of 
stroke, and it may inform study designs that attempt to model long-term patient-centered outcomes.   
Neurodegenerative diseases are a class of progressive neurological conditions causing cognitive 
and functional decline, and aside from vascular dementia, these have traditionally been thought of as 
distinct from cerebrovascular disease.  However, recent research has shown similar risk factors and 
pathological processes for both neurodegenerative disease and cerebrovascular disease, and these 
processes may contribute to some of the long-term decline seen with stroke.  Inflammatory processes, 
both systemic and specific to the nervous system, have been implicated not only in neurodegenerative 
diseases but also cerebrovascular disease, and these processes may play a role in progressive vascular 
and cerebral dysfunction related to vascular events.   
With this as background, I will review recent research on patient-centered outcome trajectories 
surrounding vascular events.  In turn, I will discuss studies examining disability, those examining 
cognition, and those examining other outcomes.  Then, I will review the few studies comparing 
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trajectories before and after vascular events, and then summarize studies that have examined functional 
trajectories immediately before death.  I will close with the specific aims and hypotheses for the analyses 
in this dissertation.   
 
Disability and factors influencing it 
An individual’s functional status is closely tied to disease.  The World Health Organization classifies 
functioning on a continuum and identifies three levels: impairment in a body part, disability (or “activity”) 
on the level of an individual, and handicap (or “participation”) defined by the person’s position in an 
environment or social context.1 Disability is an important patient-centered outcome whose relationship 
with vascular disease requires further elucidation.  Disability is commonly measured by an individual’s 
performance in activities of daily living (ADLs), including tasks such as personal hygiene, dressing and 
undressing, feeding, transfers and ambulation, and bowel and bladder management.2, 3 Instrumental 
ADLs (IADLs) assess more complex activities required for community participation, such as handling 
personal finances, meal preparation, shopping, travelling, doing housework, using the telephone, and 
taking medications.4 There is a hierarchical relationship between some IADL items and ADL items, with 
IADL impairment becoming evident with less severe dysfunction.5 
As diverse organizations have highlighted,6 disability is essential to study, for several reasons.  
This outcome may more accurately reflect the burden of disease in a population compared to discrete 
events such as MI, which have a differential functional impact in different people.  By focusing on events 
or mortality, one may underestimate the burden of diseases.7 Understanding the population impact of 
diseases on disability is important considering the aging of the population, which will increase the number 
of disabled individuals over the next few decades.8, 9 The pattern and time course of disability in older age 
has also been changing.  Recent studies suggest that there has been a “compression of morbidity” over 
time, with disability and health conditions occurring closer to the end of life currently compared to earlier 
time periods.10, 11    
Several factors affect long-term disability, including age, cognitive function, self-rated health, and 
social supports.12-14 Several diseases also cause disability, including but not limited to cerebrovascular 
disease, arthritis, cardiac disease, depression, and cognitive disorders.  Among the disease states that 
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affect disability, stroke causes perhaps the greatest burden.15-17 Three months after a stroke, 30-50% of 
stroke survivors are functionally dependent, 15-30% are permanently disabled, and 20% require 
institutional care.18 Considering the staggering prevalence of stroke – 5.8 million among those age 20 and 
above in 200519 – post-stroke disability is of primary public health importance.  In a longitudinal analysis 
in the Health and Retirement Survey (HRS) among 24,186 individuals with a mean of 10.2 years of 
follow-up,20 physical functioning  was assessed biennially and was compared among those with different 
diseases.  Memory-related disease and stroke were associated with the most disability, and the 
combination of both was associated with 5.75 physical functioning difficulties.  Disability is costly, to an 
individual and to society, and places a burden not only on the disabled but also on family and caregivers.  
In the Survey of Health, Ageing and Retirement in Europe (SHARE), 62,127 individuals were surveyed in 
2 waves in several European countries, 1256 of whom had stroke.21 About one third had moderate ADL 
limitations and 6.6% had severe limitations.  Those with severe ADL limitations had 1.45 more hospital 
days, used 14.86 more hours of paid home nursing, and used 100 more hours in a month of informal 
help.  The burden of stroke is large, and more research is needed to lessen the impact of post-stroke 
disability.   
 
Stroke: traditional conception and new paradigm 
With a stroke, there is sudden vessel blockage (with ischemic stroke) or rupture (with hemorrhagic stroke) 
in the brain causing damage or dysfunction of the brain region fed by the vascular territory affected.  
There are several major, well-established, individual-level attributes and disease states that have been 
associated with increased risk of ischemic and hemorrhagic stroke, including age, sex, hypertension, 
smoking, diabetes, dyslipidemia, and others.22 Perhaps due to a focus on the acute vessel blockage or 
rupture event, stroke is traditionally seen as a discrete event.  The damage caused by a stroke in a 
particular brain region results in an impairment, such as unilateral weakness, dysarthria, or ataxia.  There 
is often an improvement in impairment in the weeks and months after stroke, due to unclear mechanisms 
that may include reduction in edema, regrowth of damaged neurons, increased neural activity in 
contralateral or supplementary brain regions, or change in brain network performance.23, 24 Even if there is 
no reduction in impairment through these processes, there may be improvement in disability as an 
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individual learns compensatory strategies and starts to use assistive devices such as a cane or walker.  
Hence, there is a predictable degree of recovery25 within 3-6 months of the stroke, and prior research on 
the natural history of disability after stroke has shown varying degrees of functional recovery within 6-12 
months.26-33  
Using the traditional paradigm of stroke as a discrete event, it is assumed that, following the 3-6 
month recovery period after stroke, functional status would more or less stabilize unless recurrent events 
occur34-37 (Figure i), and that the same slope of functional decline prior to stroke – which was due to the 
cumulative effects of aging -- would resume after recovery from stroke.  However, there is growing 
evidence that a paradigm may be more appropriate in which the effect of cerebrovascular disease on 
disability is viewed in a continuous, ongoing manner.  In other words, stroke may be more effectively 
considered as an ongoing, chronic condition with effects on function, instead of a discrete event.  Stroke 
may accelerate functional decline over time, over and above the slight progressive decline in function 
over time resulting from cognitive aging,38 which is a non-pathological process that is as yet not well 
understood.  There is a link between cognitive function and functional status, and it appears that cognitive 
deficits pre-date physical functional limitations and likely play a causal role in their development.39, 40 
According to this new paradigm of the effect of cerebrovascular disease on functional status, there may 
be an accelerated decline over time after recovery from stroke, even in the absence of recurrent clinical 
events (Figure i).   
There have been recent advances in epidemiological studies that have examined decline 
surrounding vascular events such as stroke.  First, there has been an expansion of the time-line in 
studies on this topic, with longer term follow-up in larger cohorts.  Second, there has been a focus more 
on patient-centered outcomes rather than just vascular events and mortality.  Third, there has been a shift 
of focus from the surveillance of discrete events such as stroke, myocardial infarction (MI), and death, to 
the repeated measurement of outcomes such as disability, quality of life, cognitive function, and mood.  
This has allowed researchers to analyze the trajectories of these important patient-centered outcomes 
over time, and in relation to vascular events.  This new ability has enabled researchers to clarify the 
pathophysiology of vascular dysfunction and its population impact.  In this review, I will outline the 
conceptual basis for this new paradigm of cerebrovascular disease as a progressive condition and then 
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discuss recent epidemiological studies that have focused on trajectories of patient-centered outcomes in 
relation to vascular events.   
 
Vascular risk factors and progressive cerebrovascular dysfunction 
There are several lines of evidence that support a paradigm of progressive cerebrovascular dysfunction.  
First, stroke is caused by conditions that may have an ongoing and cumulative effect on vessel 
dysfunction, including vascular risk factors and inflammatory states.41 Diabetes diagnosed in those in 
“mid-life” (those with an age range of 48-67 years) has been shown to be associated with a 19% greater 
cognitive decline over 20 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) study.42 
The degree of decline was sensitive to the degree of control and duration of diabetes as well.  In the 
Framingham Heart Study,43 the third generation cohort had their first examination between 2002-2005, 
when baseline diabetes and covariate status was ascertained, and their second examination between 
2008-11, when cognitive screening and MRI were performed.  Diabetes was associated with poorer 
cognitive performance on multiple measures after adjustment for confounders.  The relationship between 
diabetes and attention was mediated through reduced volume in the total cerebrum, frontal lobe, and 
occipital gray matter.  The relationship between diabetes and visual memory was also mediated by these 
measures as well as by hippocampal size.  Recent studies have suggested that insulin resistance in cells 
of the central nervous system, specifically the hippocampus, may play a causal role in cognitive 
dysfunction and Alzheimer’s dementia.44 Diabetes is usually conceived as a condition involving systemic 
insulin resistance, but the cognitive effects of insulin resistance and related changes in cell signaling may 
be specific to cells of the nervous system.   
Furthermore, pulse pressure has been associated with quicker progression to dementia in those 
free of dementia at baseline.45 Elevated blood pressure has been shown to be associated with 
accelerated decline in gait speed, even in those who had controlled hypertension, and even after 
adjustment for confounders.46 Elevated blood pressure and blood pressure variability have also been 
associated with impaired white matter integrity measured by fractional anisotropy among 311 individuals 
with 10 years of follow-up.47 Finally, higher blood pressure and pulse pressure were cross-sectionally 
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associated with subclinical cerebrovascular disease among the “youngest old” in a study of 113 
individuals without stroke and dementia.48 
 
Subclinical infarcts and white matter hyperintensities 
Subclinical infarcts are discrete brain infarcts that by definition are not associated with discrete events but 
are rather detectable only by brain imaging.  Similarly, white matter disease (also called leukoaraiosis) 
has been measured according to different definitions but generally refers to areas of white matter 
structural damage in the brain due to vessel dysfunction, which are only detectable by brain imaging.  
Specifically, small vessel disease causes chronic ischemia which leads to demyelination and axonal loss.  
In a study that examined the molecular structure of axons in regions surrounding lacunar infarcts and 
microinfarcts,49 node of Ranvier segments and adjacent paranodal segments were examined.  There was 
evidence of impaired cell to cell adhesion and signaling between axons and oligodendrocytes, suggesting 
that the area of dysfunction surrounding microinfarcts extends beyond visibly injured tissue.  Future 
studies will hopefully clarify the pathophysiology of WMHs.   
In terms of the epidemiology of subclinical cerebrovascular disease, subclinical infarcts have 
been found to be at least 5 times as prevalent as clinical strokes, suggesting that a focus on discrete 
clinical stroke events reveals only the tip of the iceberg of the burden of cerebrovascular disease.50, 51 In 
the Northern Manhattan Study, SBI was present in 18% of 892 stroke-free individuals.52 WMHs were 
present in 96% of individuals older than 60 years of age in CHS and in 95% in the Rotterdam Scan 
Study.53 Silent acute infarcts have also been detected in up to 4.2% of individuals with dementia in 
previous studies.54  
Traditional vascular risk factors and inflammatory states cause subclinical infarcts and WMH in 
addition to recurrent clinically evident strokes.55 For example, elevated blood pressure and blood 
pressure variability have been shown to have a dose-dependent effect on WMHV and SBI.56 The vascular 
causes of worsening white matter grade have been shown to have a differential impact depending upon 
initial grade.57 In the Rush Memory and Aging Project, 167 dementia-free elderly individuals had 
actigraphy to measure physical activity, and had measurements of WMHV on MRI.58 In a cross-sectional 
analysis, there was a significant interaction between physical activity and WMHV.  Specifically, although 
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there was an association between greater WMHV and lower motor function among those with average 
and low physical activity, there was no association among those with high activity, suggesting a protective 
effect of high levels of physical activity.  The progression of white matter lesions over time has not been 
found to have a significant genetic component, and it is likely that behavioral and environmental factors, 
as well as the above medical conditions, have a more causative role.59 
Subclinical infarcts and WMHs have been associated with the occurrence of “hard” vascular 
outcomes and mortality in multiple studies.  White matter disease may predict future stroke independently 
of traditional risk factors.60 The extent of WMHV has been associated with recurrent stroke within 90 days 
of stroke.61 In CHS, white matter grade and ventricular volume were associated with longevity.62 In the 
ARIC study, among those who had 2 MRIs spaced about 10 years apart, there was WMH progression in 
23% of 972 participants, and smoking showed a dose-dependent association with progression.63 In 
another analysis in ARIC,64 metabolic syndrome and an insulin resistance score (created using principal 
components analysis of 11 factors) were associated with new lacunar infarcts but not progression of 
WMHV.  In the Athens Stroke Registry, among 1892 stroke patients, leukoaraiosis independently 
predicted stroke recurrence, with a hazard ratio of 1.86.65 In a longitudinal analysis in the ARIC study, 
1884 individuals aged 50-73 years had MRI in 1993-1995 and were followed for a mean of 14.5 years.66 
Subclinical brain lesions <3 mm (HR 3.47) and >=3 mm (HR 1.94) were associated with increased risk of 
stroke, as was WMHV.  The presence of both sizes of subclinical lesions was associated with a marked 
8-fold increase in risk, and these lesions also increased risk of fatal stroke.   In addition to causing direct 
injury to white matter regions, WMH may work through other mechanisms.  For example, among 575 
patients with arterial disease (including cerebrovascular, cardiac, peripheral, and aortic), 2 MRIs were 
performed around 4 years apart.67 Deep and periventricular WMHs were associated with reduced 
parenchymal cerebral blood flow between the 2 time-points.   
Subclinical infarcts and WMHs have been associated not only with vascular events but also with 
cognitive impairment68, 69 and reduced functional status over the long term.50, 70 White matter disease may 
mediate the relationship between hypertension and disability.71 Even in younger individuals free of 
cardiovascular disease but at risk due to a family history of early cardiac disease, white matter lesion 
burden was inversely associated with manual dexterity (as measured by the Grooved Pegboard test).72 
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When regional WMHV was tested separately in adjusted models, this association was also seen for 
WMHV in each brain lobe except for the temporal and occipital lobes.  Asymptomatic brain MRI 
abnormalities, including WMHs and infarcts, have been associated with functional impairment cross-
sectionally,73 at 3 months,74 and over 4 years of follow-up.70 In a case-control study performed in 
Singapore, the burden of small vessel disease and large vessel disease was summarized in a weighted 
score of “cerebrovascular disease” among 305 cases with cognitive impairment and 94 controls.75 A 
higher cerebrovascular disease score was associated with worse cognitive function.  WMHV was 
associated with global deficits, and cerebral microbleeds were associated with domain-specific deficits.  
In the Leukoaraiosis and Disability study,76 among 633 older individuals over 2.4 years of follow-up, 
29.5% of those with severe WMHV transitioned to death or disability, compared to 10% with mild WMHV.  
Also, cognitive decline was seen among those who had increase in WMHV over time.  In a prior analysis 
using the MRI cohort of the Northern Manhattan Study (NOMAS),77 in an adjusted model, WMHV was 
associated with poorer episodic memory, processing speed, and semantic memory.  Among those above 
the median age, WMHV was associated with poorer episodic and semantic memory.  Hence, several 
studies have demonstrated a consistent association between subclinical cerebrovascular disease and 
functional and cognitive impairment.   
The risk of recurrence of clinical events such as stroke and MI is high soon after an event, and 
the period of risk may remain elevated for an extended period.78 It is similarly conceivable that the risk of 
subclinical cerebrovascular disease may be elevated for a period of time after a clinical event.  However, 
future research on the trajectories of these changes is required to better characterize whether such a risk 
window exists.  In summary, prior studies show a strong relationship between imaging markers of silent 
brain infarcts and white matter disease and stroke risk factors, and emerging evidence suggests a link 
between such markers and disability and cognitive dysfunction.    
 
Newer structural markers of cerebrovascular dysfunction 
Newer imaging and analytic approaches have been able to identify brain structural changes and other 
evidence of cerebrovascular dysfunction that cause progressive cognitive and functional decline.  For 
example, among 241 initially stroke- and dementia-free participants in the Swedish National Study on 
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Aging and Care in Kungsholmen, diffusion tensor imaging was performed and WMHV was estimated.79 
Vascular risk factors and APOE-epsilon-4 status were associated with impaired white matter integrity and 
cognitive decline.  Among 232 individuals with cognitive impairment, graph theory was applied to diffusion 
tensor imaging data.  WMHV was associated with reduced nodal efficiency, decreased cortical thickness, 
and impaired executive and memory function.80  
In another example, thirty-two participants in the Determinants of Dementia After Stroke study 
had MRI at the time of stroke and 6 months later.81 Probabilistic tractography was used to identify the 
cortical regions associated with acute infarct, and “change in focal cortical thickness” was calculated as 
change exceeding change in the reference regions.  The authors summarized the results as follows: “(1) 
acute infarcts induced focal degenerative changes in cortical regions connected to the infarct; (2) this was 
paralleled by a degeneration of connecting fiber tracts; (3) the degree of cortical thinning correlated with 
the loss of microstructural integrity in connecting white matter tracts; and (4) remote effects were seen 
regardless of the fate of the acute infarct, i.e., whether the infarct turned into a cavitating or noncavitating 
lesion. These findings highlight secondary neurodegeneration as an important feature of brain infarcts 
and may have implications for the understanding of structural and functional reorganization after stroke.”  
These findings highlight the likely role of secondary neurodegeneration in tracts affected by stroke, which 
likely has a long-term effect on disability.   
In a cross-sectional analysis among 1906 non-demented participants in the ARIC study,82  
WMHV and infarcts were associated with lower cognitive performance, and these associations were 
partially mediated by regional cerebral cortical volume, thought to be a marker of structural integrity.  
Specifically, the posterior region of interest included: “hippocampus, parahippocampal gyrus, entorhinal 
cortex, inferior parietal lobule, precuneus and cuneus”; and the frontal region of interest included: 
“rostral/caudal anterior cingulate, rostral/caudal midfrontal, lateral orbital frontal, medial orbital frontal, 
paracentral, pars opercularis, pars triangularis, precentral, superior frontal, and frontal pole.”82 The 
authors suggest that the occurrence of microinfarcts may be the process that links WMHV, infarcts, 
regional cerebral cortical volume, and cognition.   
In a cross-sectional analysis among 426 individuals with cerebral small vessel disease but no 
dementia in the Nijmegen Diffusion tensor and MRI Cohort,83 relationships among WMHV, cortical 
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thickness, network measures, and cognition were examined.  WMHV was associated with thinner cortex 
in frontotemporal regions but thicker cortex in paracentral regions.  Network disruption, measured using 
graph theory, was associated with WMHV and cognition.  When tested together, cortical thickness but not 
WMHV was associated with cognitive function, and cortical thickness mediated the relationship between 
WMHV and cognitive function.   
 In summary, newer imaging and analytic techniques may be able to detect previously 
undetectable structural and functional brain dysfunction that could underlie the progressive disability and 
cognitive changes seen in epidemiological studies.   
 
Traumatic brain injury 
Traumatic brain injury (TBI) may provide a useful neurological condition, analogous to stroke, that could 
illuminate the progressive nature of cerebrovascular disease.  The course of TBI has traditionally been 
conceptualized similarly as stroke: an acute event causes a decrement in function, followed by a period of 
recovery with progressive functional improvement, after which functional ability plateaus.84  Several 
studies, however, have shown a progressive decline in cognitive function in the long term after TBI, in the 
intermediate follow-up period of 1-2 years as well as up to 30 years of follow-up.84 Even after mild TBI, 
recovery of mood, cognition, and concussion symptoms extends beyond 1 year, and a significant 
proportion of individuals (16% of 260) had impairments in complex attention at 1 year from injury.85 
Among 478 individuals in the TBI Model Systems National Database followed up 10 years after TBI, age 
was a major predictor of functional decline over time.86 In another analysis in this cohort using a sample 
size of 3870 individuals,87 trajectories of Glasgow Outcome Scale-Extended scores increased after TBI, 
reached a maximum at 10 years of follow-up, then decreased thereafter.   
These declines have been paralleled by structural changes in the brain, manifested by expansion 
of the original lesion size, regional and diffuse atrophy, and loss of integrity of white matter tracts.  Protein 
deposition and inflammation have been implicated as pathophysiological processes for this decline and 
associated structural change.  The concept of “negative plasticity” has been introduced to explain this 
process.84 Specifically, this view describes a “self-reinforcing, downward spiral of negative brain plasticity 
whereby declining brain function is attributable to a combination of disuse (called ‘reduced schedules of 
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activity’), reduced quality of sensory-perceptual processing, and weakened neuromodulatory control. In 
combination, these factors increase reliance on simplified cognitive processing at the expense of more 
complex processing capacity (called ‘negative learning’). These processing changes result in brain 
changes, which in turn result in further disuse, perceptual compromise and reduced neuromodulatory 
control.”84 With TBI, an initial injury would lead to impairments that reduce functional ability and social 
interaction, which may “foster brain adaptations to simpler and more habitual cognitive processes at the 
expense of complex processing.”84 
Cognitive decline is common after TBI.  Cognitive change after recovery from TBI was tested 
among 33 patients with moderate to severe TBI.88 Comprehensive neuropsychological testing was 
compared between 1 year post-TBI and 2-5 years after injury.  There was heterogeneity in the patterns of 
change in cognition, and there was decline on at least 2 neuropsychological measures in 27.3% of the 
cohort.  
One underlying mechanism of long-term decline after TBI is progressive atrophy.  Fifty-six 
moderate-severe traumatic brain injury patients were compared to 12 healthy controls on 2 MRIs, one 
done 5 months after injury and one 20 months after injury.89 Those with TBI had progressive atrophy 
during this period, 96% in at least one brain region, and 75% in at least 3 of 4 regions (whole brain, 
corpus callosum, and right and left hippocampi). The authors suggest that the chronic atrophy may be 
due to “tissue shrinkage—the result of lost neuropil, protein and/or fluids—or to cell death, with 
disconnection and disuse, inflammation and delayed apoptosis contributing independently or 
interactively.”89 
Microstructural disruption may also play a role in progressive dysfunction after TBI.  Among 12 
patients with TBI, repeated diffusion tensor imaging was performed at 1 week, 7 months, and 21 months 
from injury (on average), and neuropsychological testing was performed concomitantly with imaging.90 
There was continual change in structural volumes, fractional anisotropy, and mean diffusivity in the 
chronic phase, with some patients experiencing long-term decline in neuropsychological function 
corresponding to these imaging changes. 
Inflammatory processes may also be involved in the long-term decline seen after TBI.  A recent 
review article summarized the various inflammatory processes involved after TBI.91 An early inflammatory 
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response after injury involves several cell types, including astrocytes, microglia, macrophages, 
neutrophils, and T cells.  However, this response may become maladaptive if sustained and cause 
ongoing tissue damage.  Specifically, neutrophils may promote neuronal cell death and destruction of 
surrounding cell types.  Also, reactive oxygen species have been implicated in ongoing brain tissue 
damage after TBI, and early trials have suggested a protective effect of anti-oxidant therapies (e.g. N-
actyl cysteine) during the early recovery period.  Amantadine has also been proven to be effective when 
administered for 4 weeks in the subacute phase of recovery after TBI (4-16 weeks after injury), but the 
mechanism of effect is not certain.    
 There may also be chronic effects of injury that does not involve head trauma, and emerging 
research is examining the long-term effects of non-head trauma and falls.  For example, in the Health and 
Retirement Survey (HRS), disability trajectories after accident injury, not only involving head trauma, were 
examined over 10 years of follow-up in 591 individuals.92 Functional data were examined 2 years before 
injury and 8 years post-injury.  Five distinct trajectories were identified (Figure ii).  Sex, number of health 
conditions, and insurance status were associated with individual trajectories.  Among 754 individuals 
followed with monthly disability assessments over 12 years, there were 4 trajectories of change in 
disability after a fall that were highly influenced by pre-fall functional status.93 
 In summary, the pathophysiological processes involved in TBI may overlap with those involved in 
cerebrovascular dysfunction, and the epidemiological study of TBI may inform studies of the long-term 
cognitive and functional effect of stroke and vascular disease.    
 
Neurodegenerative disease 
Neurodegenerative diseases such as Alzheimer’s dementia have traditionally been conceived of as 
progressive conditions with cumulative negative effects on cognitive performance, functional status, and 
social participation.  Recent research has begun to show that neurodegenerative diseases share 
pathophysiological processes with cerebrovascular disease.  Among experts in stroke and 
neurodegenerative disease, there has been a recent recognition of the vascular components of dementia, 
and a call for further research to elucidate the relationships and mechanisms by which stroke and 
vascular dysfunction cause progressive cognitive and functional decline.94 For many years, the entity of 
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vascular dementia was conceived as a condition in which focal infarcts caused cognitive impairment and 
a step-wise dementia.  However, currently there has been a growing recognition that both 
neurodegenerative dementia and vascular dysfunction often co-exist, and that they share 
pathophysiological mechanisms and risk factors.   
 Often, neurodegenerative dementia and cerebrovascular disease coexist.  Among 393 cognitively 
unimpaired elderly individuals in the Mayo Clinic Study of Aging, those with imaging evidence of 
increased cortical amyloid as well as those with evidence of subclinical brain ischemic vascular disease 
had increased cognitive decline, and the presence of both showed additive and not synergistic effects.95 
Genetic overlap among Alzheimer’s disease, CRP, and plasma lipids was found in a study that examined 
data from multiple genome-wide association studies with a total of >200,000 individuals, suggesting 
overlapping pathophysiologies among neurodegenerative, inflammatory, and vascular conditions.96 
Subclinical cerebrovascular injury has been associated with subsequent cognitive deficits and 
decline.  WMHV are associated with cognitive decline and, along with infarcts and cerebral microbleeds, 
cause vascular dementia.  Sensitive MRI techniques can identify white matter tracts through diffusion 
tensor imaging, which may be able to detect disruption of white matter tracts even before WMHs 
manifest.  Progression of periventricular WMHV was seen in the Rotterdam Scan Study between 2 MRIs 
spaced 3 years apart and was associated with declines in information processing speed and cognition.97  
Even in the absence of clinical cognitive impairment, a stroke can cause delayed cognitive deficits.  
Fifteen months after stroke, among 115 stroke survivors without baseline dementia, 31% had a drop in 
cognitive function as measured by the MMSE, and 9% developed incident dementia.98 Over 
approximately 20 years of follow-up among 6514 participants in the Rotterdam Study who were free of 
dementia at baseline, atrial fibrillation was associated with higher risk of incident dementia, independently 
of clinical stroke and vascular risk factors.99 Subclinical cerebrovascular disease was thought to be a 
possible cause.  Among 3117 individuals with mild cognitive impairment and 6603 individuals with normal 
cognitive function, the Framingham Stroke Risk Profile score was associated with baseline cognition as 
well as decline in cognitive scores over time.100 
The direction of causation can also occur in the opposite direction, in which cognitive deficits 
predate and may cause clinical stroke events.  Subjective memory complaints have been associated with 
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risk of subsequent stroke among 9152 participants in the Rotterdam Study, with a hazard ratio of 1.20, 
and authors suggested that “subjective memory complaints may be a marker of cerebral microvascular 
injuries.”101 The cerebral cortex has reduced perfusion in Alzheimer’s disease, and this is thought to 
involve several processes: small vessel disease, amyloid angiopathy, abnormal vascular contractility, and 
secondary upregulation of vascular endothelial growth factor.102  Although there has traditionally been a 
focus on the pathological effects of Alzheimer’s disease on the arterial system, there is growing evidence 
in animal models that this dementia also affects the structure and function of the venous system, resulting 
in abnormal venules that potentiate the arterial abnormalities seen in this disease.103 Among 72 patients 
with stroke or transient ischemic attack (TIA) with cognitive impairment, a carbon-11-labeled Pittsburgh 
compound B positron emission tomography (PET) scan was performed, and cognitive assessments were 
performed at 3-6 months and annually thereafter for 3 years.104 There was a significant decline in mini-
mental state examination (MMSE) scores over follow-up among those with Alzheimer’s disease–like Aβ 
deposition but not those without, and there was a steeper decline in MMSE and Montreal Cognitive 
Assessment scores among those with this pattern of Aβ deposition.   
In addition to pathological evidence of neurodegenerative disease and cerebrovascular disease, 
processes that do not manifest during routine pathological analysis seem to effect long-term cognitive 
changes.  In an in-depth longitudinal study of 856 individuals with pathological analysis of brain tissue, the 
majority of variance in cognitive decline was not explained by traditional pathological evidence of 
Alzheimer’s disease, Lewy body dementia, and cerebrovascular disease.105 
 In summary, there are several points of connection between neurodegenerative dementia and 
cerebrovascular disease, with overlapping risk factors, shared pathophysiological processes, and 
bidirectional patterns of influence between the 2 conditions.  However, more research is needed to clarify 
these shared relationships.   
 
Inflammatory processes 
Another line of evidence suggests that serum biomarkers of inflammation may be able to detect 
subclinical risk of vascular disease, and hence may be able to link stroke pathophysiology with ongoing, 
continuous changes in function.  Prior research has identified a significant role of inflammation in 
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atherosclerosis and stroke106, 107 as well as significant associations between stroke and inflammatory 
biomarkers, such as leukocyte count108 and high-sensitivity C-reactive protein (hsCRP).109-113 Some 
studies have suggested that hsCRP also predicts prognosis after stroke.110, 114 Prior research in NOMAS 
has identified a link between inflammatory markers and MI, mortality, and carotid plaque thickness.115, 116 
In CHS, interleukin-6 (IL6) and CRP have been associated with white matter lesions,117 and other studies 
have found associations between CRP and stroke severity and mortality.118 Other markers of immune 
activity have also been implicated.  For example, it appears that B-lymphocyte activation is linked to 
delayed cognitive decline after stroke in a mouse model as well as in pathological analysis of post-
mortem specimens.119  In the Framingham Offspring study, a cross-sectional analysis was performed 
among stroke-free individuals testing associations among biomarkers (systemic and vascular 
inflammatory biomarkers and markers of oxidative stress) and MRI findings (WMHV, SBI, and cerebral 
microbleeds).120 Cerebral microbleeds were associated with higher levels of tumor necrosis factor 
receptor-2 (TNFR2) and myeloperoxidase, and WMHV and SBI were associated with higher levels of 
osteoprotegerin, intercellular adhesion molecule 1, lipoprotein-associated phospholipase A2 mass, and 
lower myeloperoxidase levels.  Neutrophil counts and neutrophil-to-lymphocyte ratios were independently 
associated with 3-month outcomes among 846 intravenous thrombolysis-treated patients, suggesting the 
importance of inflammatory states in outcome after acute stroke treatment.121 
 Interactions have also been found between vascular risk factors and inflammatory states.  Forty 
individuals, 19 with diabetes, had comprehensive neuropsychological measurements, physical 
examinations, MRI, and inflammatory marker analysis twice over 2 years.122 Cerebral autoregulation was 
associated with functional status.  Also, those with diabetes had worse cerebral vasoregulation and 
cognitive function over time, and higher cortisol and CRP levels were associated with decline in 
vasoregulation.   
A single ischemic stroke may cause changes in inflammatory profiles123 that may have an 
ongoing deleterious effect on brain structure and function124 that may persist years after stroke.125 Beyond 
the association with vascular outcomes, inflammation has been associated with quality of life (QOL) in a 
limited number of studies,126-129 but the association of inflammatory markers with disability has not been 
well-studied, particularly among minority populations.   
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 Inflammatory processes have been implicated not only in cerebrovascular disease but in other 
neurological diseases as well.  In a large pathological study of individuals who had had TBI, there was 
increased microglial activity peaking 3 months after TBI but remaining elevated for several years.130 It is 
well-known that Alzheimer’s dementia pathogenesis involves inflammatory processes.131 The 
accumulation of amyloid-β activates microglia, which cause an acute inflammatory response to attempt to 
clear the abnormal protein.  However, a persistent inflammatory response ensues, causing retraction of 
microglial processes and resulting in functional and structural changes.  Implicated in this process are the 
cytokines tumor necrosis factor-alpha, IL6, interleukin-1α, and GM-CS.  More recent research suggests 
that inflammatory processes may be the primary drivers of the structural and functional brain changes 
seen in the disease, and not just responses to abnormal buildup of proteins.132 These immunological and 
inflammatory processes may promote neurodegenerative disease independently of the buildup of amyloid 
proteins.  These inflammatory processes may originate from within the central nervous system or be tied 
to systemic inflammatory states or conditions.  A distinction that may be useful in understanding these 
processes may be between adaptive and innate neuro-inflammatory processes.132 Studies in animal 
models have also suggested that neutrophil invasion of the central nervous system plays a key role in the 
development of Alzheimer’s dementia, begins before the onset of cognitive decline and peaks at the time 
of first detection of memory loss.  Studies in mice even suggest that depleting circulating neutrophils 
restores cognitive functioning.133 Finally, in a mouse model, exogenously applied beta-2-microglobulin 
caused cognitive impairment and reduced neurogenesis.134 In summary, inflammatory processes have 
been found to play a significant role in vascular disease and progressive neurodegenerative disease, but 
more research is needed to clarify the effects of inflammatory states on long-term functional trajectories.   
 
Limitations of previous research  
The proposed research seeks to fill 2 major areas of deficiency in the existing literature.  The first area is 
a lack of quality data delineating the long-term course of disability in relation to vascular disease, 
particularly stroke.135 Several studies on predictors of functional outcomes pre-date important shifts in 
paradigms of treatment (of cholesterol and blood pressure, for example), obesity prevalence, and 
population patterns of aging.  Also, in many prior studies, vascular disease and vascular events are not 
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reliably ascertained, precluding accurate causal inference about the relationship between vascular 
disease and functional outcomes.  Several studies have examined disability in various cohorts, including 
the Asset and Health Dynamics Among the Oldest Old cohort,136 the Health and Retirement Survey,137 
the Baltimore Longitudinal Study of Aging,138 the National Health and Nutrition Examination Survey,139 the 
National Health Interview Survey,140 National Long-Term Care Survey,141 and the Panel Study of Income 
Dynamics.142 However, there are significant limitations of these studies: some of these are not 
longitudinal cohorts with repeated measures of functional status; none of these cohorts has examined 
inflammatory and imaging markers as exposures; and reliable and thorough validation and subtyping of 
vascular events are lacking.   
The second understudied area that would be addressed by the proposed research involves 
trajectory analysis of functional outcomes in relation to stroke.  Specifically, trajectory analysis requires 
multiple repeated measures over time within an individual to allow the estimation of the initial level, slope, 
and shape of the curve representing change of the outcome over time (Figure iii).  In other fields, 
including multiple sclerosis and critical care, there has been an explicit interest in modeling the course 
and trajectory of functional status before and after discrete clinical events.  For example, in multiple 
sclerosis there are clinically distinct syndromes defined by different trajectories of change in functional 
status, and diagnostic and treatment approaches are tailored to the particular syndrome (Figure iv).  In 
critical care medicine, there has been an interest in modeling different trajectories of function before and 
after admission to an intensive care unit (Figure v), with implications for trial design and understanding 
the biological effects of critical illness.143, 144 However, to our knowledge, such a conceptual approach has 
not yet been applied to stroke trials, perhaps because of a conceptualization of stroke in prior research as 
a discrete event with time-limited effects on function, as well as a focus of clinical trials on acute stroke 
treatments and interventions, which prioritize short-term outcomes and adverse events.   
Historically, most studies of disability and stroke have examined the course of functional change 
only after stroke and have not examined the course of functional status before the event.26-33 Most of 
these studies had short-term follow-up and measured disability once, reducing precision and precluding 
detailed modeling of the trajectories of outcomes over time.  Also, most studies of disability after stroke 
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have included only hospitalized patients with limited follow-up, and relatively few population-based 
studies have examined predictors of functional status with long-term follow-up.145  
 
My previous research 
In order to address this deficiency in the literature, we examined, in the stroke-free, population-based 
cohort of NOMAS (please see below for further details of the NOMAS study design),146 vascular 
predictors of functional status as measured by the Barthel Index (BI).  Using models adjusted for 
demographic, medical, and social risk factors, we found an annual decline of 1.02 BI points (p<0.0001).  
Predictors of change in BI over time included: age (-0.08 BI points per year; p<0.0001), male sex (0.32 
per year, compared to female; p<0.0001), diabetes (-0.37 per year, compared to non-diabetics; 
p=0.0003), and hypercholesterolemia (0.20 per year, compared to no hypercholesterolemia; p=0.006). 
Using validated and specialist-adjudicated data on the vascular events of stroke and myocardial infarction 
(MI), we found that results did not change when stroke and MI were censored.  The magnitude and 
significance of predictors of BI were similar for motor and non-motor domains.  Hence, diabetes but not 
hypertension was a strong predictor of long-term function, even when vascular events occurring during 
follow-up were censored.  The research proposed here was designed to clarify the role of inflammatory 
and imaging markers in predicting long-term disability.   
We also examined predictors of long-term functional status and the slope of decline over 5 years 
of annual follow-up in a cohort of stroke patients (n=525), who are distinct from the subjects in the 
prospective NOMAS cohort of initially stroke-free participants described above (please see below for 
further details of the NOMAS study design).147 In this stroke patient cohort, mean age was 68.6+12.4 
years, 45.5% were male, 54.7% Hispanic, 54.7% had Medicaid/no insurance, and 35.1% had moderate 
stroke. The proportion with BI>95 declined over time (OR 0.91, 95% CI 0.84-0.99). Predictors of 
functional status included increasing age, stroke severity, urinary incontinence, diabetes, marital status, 
and left-sided stroke.  Changes in BI by insurance status were confirmed by a significant interaction term 
(β for interaction = -0.167, p=0.034); those with Medicaid / no insurance declined (OR 0.84, p=0.003), 
whereas those with Medicare/private insurance did not (OR 0.99, p=0.92).  An important unresolved 
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question was whether the observed decline in this study was due to the stroke (or related factors) or 
simply a result of the aging process.   
Another analysis in the NOMAS prospective cohort of initially stroke-free participants addressed 
this question.148 We examined 210 participants who experienced an ischemic stroke during follow-up and 
lived more than 6 months after stroke.  There was no difference in the rate of functional decline over time 
before and after stroke (p=0.51), with a decline of 0.96 BI points per year before stroke (p<.0001) and 
1.24 after stroke (p=0.001).  However, when stratified by insurance status, among those with Medicaid or 
no insurance, in a fully adjusted model, there was a difference in slope before and after stroke (p=0.04), 
with a decline of 0.58 BI points per year before stroke (p=0.02) and 1.94 after stroke (p=0.001) (Figure vi).   
 
Research on patient-centered outcome trajectories surrounding vascular events 
I performed a systematic review on studies of trajectories of patient-centered outcomes surrounding 
vascular events.  Using MEDLINE, PubMed, and Google Scholar, I included all possible combinations of 
the following search terms: “stroke,” “trajectory,” “trajectories,” “cerebrovascular,” “myocardial infarction,” 
“disability,” “curve,” “growth,” “cognition,” “cognitive,” “functional,” and “function.” Publication time included 
all studies published from 1950 to December 1, 2015.  All studies were reviewed in full for relevance, and 
reference lists were reviewed for potentially relevant studies.  Due to the heterogeneity in the study 
designs and outcomes of studies, no strict exclusion criteria were used, and studies are summarized in 
narrative form.   
 
Studies examining disability 
Several studies examined the long-term course of disability surrounding vascular events.  Among over 
64,000 individuals who had stroke from 2008-2010 in the Swedish Stroke Register, functional 
dependence was seen in 16.2% of survivors at 3 months, but this proportion increased to 28.3% at 12 
months.149  
In another analysis in HRS among 9237 individuals >65 years of age,150 the joint trajectories of 
physical, emotional, and cognitive function were analyzed with biennial assessments over 12 years of 
follow-up.  Individuals were almost equally divided into one of 4 distinct trajectories of change over time: 
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1) minimal impairment, 2) moderate impairment with increasing cognitive deficit, 3) moderate impairment 
with increasing physical and emotional deficit, and 4) significant and increasing impairment.  Also, worse 
trajectories were predicted by lower education, income, and net worth.   
In a prospective study in the Collaborative Evaluation of Rehabilitation in Stroke Across Europe 
project, 4 rehabilitation centers in Europe assessed 532 stroke patients at 5 years from stroke who had at 
least a minimal initial impairment.151 As shown in Figure vii, there was a decline between 6 months and 5 
years in BI and motor performance (measured by the Rivermead Motor Assessment), but no differences 
when the 2-month and 5-year time points were compared.   
Among 3186 older individuals in Taiwan followed over 4 waves over 11 years,152 latent class 
growth curve modeling identified 3 trajectories of function: 1) maintained function (85% of the cohort), 2) 
progressive disability (11%), and 3) consistent disability (4%).  Male sex, higher education, less 
comorbidity burden, and fewer depressive symptoms were associated with the maintained function 
trajectory.   
In another study among 810 Taiwanese individuals followed biennially over 10 years,153 
hypertension and depression predicted increased disability among the cohort as a whole whereas 
diabetes was predictive only among those who died during follow-up.    
Finally, in the Whitehall II study, among 5376 participants, comprehensive motor function was 
assessed and vascular risk was summarized at several time-points over 16 years with the Framingham 
general cardiovascular disease risk score.154 The development of mobility limitations was associated with 
worse cardiovascular risk profiles, independently of cognitive status and SES. 
 
Studies examining cognition 
Several studies examined cognitive function related to vascular events.  The authors of a study examining 
repeated measures of MMSE after 167 cases of intracerebral hemorrhage claimed that “prognostic 
factors for cognitive decline after ICH are already present when ICH occurs, suggesting a process of 
ongoing cognitive impairment instead of new-onset decline induced by the ICH itself.”155 However, the 
basis for this claim is tenuous, since pre-ICH cognitive status was estimated by a different measure than 
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the outcome and was assessed retrospectively, raising questions about bias in the estimation of pre-ICH 
cognition.  Prospective follow-up began only after ICH.   
 Among 538 individuals free of overt stroke, neurological disease, and cardiac disease,156 there 
were on average 2.3 assessments of cognitive function spaced 2.1 years apart.  Baseline carotid intima 
thickness was associated with accelerated cognitive decline on multiple tests of verbal, nonverbal, and 
executive function.   
Among 6476 elderly individuals, cognitive function was assessed 5 times over 9 years.157 
Baseline depressive symptoms, functional status, and stroke were associated with lower cognitive 
function but not accelerated decline over time, perhaps due to the advanced age of the cohort.   
 
Other outcomes 
Predominantly male (98%) veterans with ischemic stroke in 2007 (n=3811) were followed for 1-year 
trajectories of 3 outcomes: nursing home care, home care, and mortality.158 Latent class growth analysis 
was used to identify 5 different trajectories, as summarized by the authors as follows: “Members of the 
cohort had one of the following 5 trajectories: 49% had a Rapid Recovery trajectory with little or no use of 
care during the 12 months, 15% had a Steady Recovery trajectory with initially high nursing or home care 
that tapered off during a 1- to 3-month period; 9% had a Long-Term Home Care trajectory with 
consistently high home care use during the 12 months, 13% had a Long-Term Nursing Home trajectory 
with consistently high nursing home use during the 12 months, and 14% had an Unstable trajectory with 
multiple transitions between nursing home, home care, and acute care.”158 
 
Studies comparing trajectories before and after vascular events 
Several recent studies have compared trajectories of outcomes before and after vascular events.  In an 
analysis in the Health and Retirement Survey (HRS), cognitive function as measured by the modified 
telephone interview for cognitive status (TICS-m) scale was assessed every 2 years over a mean of 4.1 
years of follow-up.159 Compared to Whites, Blacks had greater cognitive decline in adjusted models.  
Incident stroke caused reduced cognitive function that did not differ by race, and there were no significant 
differences in slope of change over time post-stroke.  In another analysis in HRS, the course of functional 
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and cognitive impairment was compared before and after stroke (with 432 hospitalizations) and MI (with 
450 hospitalizations).160 Using a combined measure of ADLs and IADLs, there was a greater increase in 
disability at the time of stroke compared to MI.  Difference in pre- and post-stroke slopes of change 
depended on initial impairment levels.  Stroke but not MI was associated with higher odds of cognitive 
impairment.  
In the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, the course of 
cognitive function was compared before and after stroke among 515 individuals who had stroke, and 
23057 who remained stroke-free, during a mean follow-up of 6.1 years.161 There was a significantly 
steeper decline in cognitive function after stroke in the areas of global cognition and executive function.  
The risk of cognitive impairment was higher after stroke compared to before stroke, with an odds ratio of 
1.23 per year (95% CI 1.10-1.38).   
In HRS, trajectories of biennially measured memory performance were analyzed before and after 
nonfatal stroke (n=1189), before fatal stroke (n=385), and among 15,766 individuals who did not 
experience stroke over 10 years of follow-up.162 Among stroke survivors, the pre-stroke decline in 
memory performance was greater than among those who remained stroke-free, and those who died of 
stroke had even greater declines.  There was no significant difference in slope of change in memory 
performance before and after stroke.  Limitations of this analysis were the long intervals between memory 
assessments, the self-report of stroke, and the large amount of missing data regarding stroke timing.   
Among 17341 participants in HRS,163 there were biennial assessments of a composite memory 
score over 10 years of follow-up.  There were 3 types of individuals: stroke survivors (n=1169), stroke 
decedents (n=405), and those who did not experience stroke during follow-up (n=15767).  Stroke was 
defined by self-report or report of a proxy but not confirmed by specialist review, and there was a 
significant amount of missing data on month (8.3%) and year (10.5%) of stroke.  Also, there was a 
significant amount of loss to follow-up (37%).  Overall, pre-stroke decline in memory performance was 
greater in older individuals compared to younger individuals.  Females had slightly steeper declines in 
memory performance pre-stroke compared to males, but there were no significant differences among the 
stroke-free cohort.  For those in the older age stratum, there was a steeper decline in memory 
performance after stroke compared to before (-0.15 vs. -0.07 points/year, p = 0.003).   
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In the ARIC study,164 a change score in 3 cognitive measures was calculated over approximately 
14 years, and 2 MRIs were performed over a similar time interval (10 years) and scored for presence of 
infarcts, WMHV, and ventricular size.  There was ongoing surveillance for hospitalizations, and type of 
hospitalization was categorized using ICD-9 codes.  For those who were hospitalized during follow-up, 
there was a decline in performance on the Digit Symbol Substitution Test.  When trajectories of change in 
cognitive performance were compared pre- and post-hospitalization, there was accelerated decline in the 
Digit Symbol Substitution test after hospitalization, with an additional 0.20 digit-symbol pairs/year (95% CI 
0.12–0.27), and accelerated decline in the Word Fluency Test after hospitalization, with an additional 0.09 
words/year (95% CI 0.02–0.17).  Hospitalized patients had greater development of atrophy.  Overall, 
critical illness and major surgical hospitalizations were associated with greater cognitive decline and MRI 
changes.   
In ARIC, trajectories of self-rated health were examined over a median of 17.6 years in 11,188 
individuals who remained disease-free, 1071 individuals who developed MI, and 809 who developed 
stroke.165 Higher neighborhood income was strongly associated with better self-rated health and less 
prevalent comorbidities.  There was no difference in the slope of change in self-rated health over time 
before and after stroke in this analysis.   
Among 687 community-dwelling elderly individuals assessed for life space mobility, those with 
surgical hospitalizations had greater drop in mobility at the time of hospitalization compared to those with 
non-surgical admissions, who had no significant recovery over time.166 
 
Functional trajectories immediately before death 
Among 213 individuals >70 years of age who entered hospice care over a 13-year period, 5 functional 
trajectories in the last year of life were identified with monthly telephone assessments, and the 21% with 
neurodegenerative disease had the worst trajectory.167 In the last year of life, 6 distinct trajectories of 
disability were identified among 552 decedents, and hospital admissions were common, with 71% with at 






The recent epidemiological studies reviewed here suggest areas of further research to clarify the 
relationships between vascular disease, particularly stroke and MI, and the long-term course of functional 
status.  Most studies that have compared the course of outcomes before and after vascular events have 
focused on cognition and not functional status.  Furthermore, the precision and identification of events 
during follow-up have not always been reliable.  Also, the mechanisms and pathophysiological processes 
underlying the patterns of decline seen in previous literature are not known and need to be examined.  
Due to these gaps in the literature, several important questions remain unanswered.  First, what is the 
impact of vascular disease on disability in the absence of recurrent clinical events?  It is unclear whether 
intensive preventive efforts, similar to those used to prevent clinical vascular events, would have an 
impact on subclinical events, progression of white matter disease, and disability.169  
There is an underlying assumption behind the current choice of outcome and timing in clinical 
trials: that the functional outcomes (for example, modified Rankin scale [MRS]) are stable and well-
represented at 3, 6, or 12 months after stroke.  But these are untested assumptions that, according to the 
research presented here, may not be plausible.  Rather, post-stroke patients with different recovery 
trajectories may represent different disease or recovery states, and may respond differently to 
interventions, just as the different subtypes of ischemic stroke may be considered different disease 
entities, since the mechanisms of vessel blockage are distinct in each.   
An explicit focus on the trajectories of disability as an outcome in observational studies and 
treatment trials would be required to address these unresolved questions.  Also, the optimal means to 
detect the severity or risk of subclinical events is not certain.   The associations among strokes 
discovered on imaging, white matter microvascular disease, and long-term functional status are not well 
delineated.  Social support and socioeconomic status affect access to care, control of risk factors, and 
vascular outcomes after stroke,170, 171 but the effect of these factors on functional status after stroke is not 
known.  Finally, the mechanisms influencing long-term disability trajectories, including subclinical vascular 





Stroke is the leading cause of disability17 and a significant cause of cognitive impairment and depression 
in the immediate post-stroke period.172-174 Stroke is traditionally seen as a discrete event, and it is 
assumed that, following the 3-6 month recovery period after stroke, functional status would more or less 
stabilize unless recurrent events occur.  Indeed, the short-term effects of stroke on disability are well-
described, but the long-term course of functional status before and after stroke is less clear.175, 176 In 
contrast to this traditional view of stroke, there is growing evidence that a paradigm may be more 
appropriate in which the effect of cerebrovascular disease on disability is viewed in a continuous, ongoing 
manner.  In other words, stroke may be more effectively considered as an ongoing, chronic condition with 
effects on function, instead of just a discrete event.  For example, stroke is caused by conditions that may 
have an ongoing and cumulative effect on vessel dysfunction, including vascular risk factors and 
inflammatory states.  In addition to causing recurrent strokes, such processes cause subclinical infarcts 
and white matter disease that may reduce functional status over the long term.50, 70 It is also possible that 
individual strokes cause injury to the brain that lead to a chronic and degenerative process with 
progressive damage, dysfunction, and functional decline. 
 The proposed etiologic model for the current analyses is presented in Figure viii (note that this is not 
intended to be a directed acyclic graph).  Vascular risk factors have a direct impact on vessel dysfunction 
(including subclinical infarcts and clinical strokes) as well as an indirect effect, mediated through systemic 
inflammation.  Systemic inflammatory states cause elevations in serum biomarkers, which are measured 
in order to quantify the degree of inflammation present.  Other factors, indicated by ‘U1’ and not 
measured in this analysis, also influence systemic inflammation.  A different set of unmeasured factors, 
U2, influence vascular dysfunction and stroke.  Vessel dysfunction is detected, in part, by structural brain 
changes measured on brain MRI as subclinical brain infarcts and white matter disease.  Vascular 
dysfunction causes impairment in blood flow and structural damage to the brain, which causes cognitive 
and physical impairments.  These impairments cause impaired functional status by affecting an 
individual’s performance in ADLs and IADLs.   
 In analysis ‘A,’ several groups of variables are considered confounders of the relationship between 
inflammatory markers and functional status, and were adjusted for sequentially in groups: demographic 
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variables. vascular risk factors. social variables, and mood and cognitive variables.  Also, in final models 
there was adjustment for stroke and MI occurring during follow-up in order to determine whether the 
associations between inflammatory biomarkers and functional status were independent of these events.  
The adjustment plan was similar for analysis ‘B.’  In addition, as described below, a basic mediation 
analysis was performed in analysis B, using all functional data before and after the time of MRI.  The 
unique timing of the MRI during follow-up allows a test of whether MRI findings mediate the relationship 
between certain factors (described below) and functional status.   
 The objective of this research is to identify individuals at risk of steep decline in functional status, and 
to describe the long-term trajectory of these outcomes before and after major vascular events.  Our 
central hypotheses are that stroke can cause a decline in function over the long term even in the absence 
of recurrent clinical vascular events, and that vascular risk factors and inflammatory and imaging markers 
predict an accelerated decline. We further hypothesize that this effect will be specific to stroke and brain 
injury, rather than to vascular events, such as myocardial infarction (MI), more generally, and we will test 
this by comparing effects of stroke to those of MI. We will study two large observational cohorts, the 
Northern Manhattan Study (NOMAS) and the Cardiovascular Health Study (CHS) to enhance the validity 
of these hypotheses.  The hypotheses and aims for this proposal are:   
 
Hypothesis #1: Serum inflammatory biomarkers and cerebral white matter disease independently predict 
worse functional status in NOMAS in those free of stroke at baseline. 
Specific Aim #1:   a) [Analysis A] To determine whether levels of serum inflammatory biomarkers 
measured at the time of enrollment (interleukin-6, tumor necrosis factor alpha receptor-1, C-reactive 
protein, lipoprotein-associated phospholipase-A2) are associated with lower Barthel index (BI) scores and 
a steeper slope of decline in a multiethnic cohort, using multivariable regression and adjusting for 
baseline demographic characteristics (age, sex), vascular risk factors (diabetes, hypertension, 
hypercholesterolemia), behavioral factors (smoking and alcohol use), social variables (marital status, 
insurance status, number of friends), and cognitive factors (depressed mood, performance on mini-mental 
state examination).   
28 
 
b)  [Analysis B] In a subset of the cohort in which study brain MRI was performed, to determine whether 
volumes of cerebral white matter disease and subclinical brain infarcts are associated with BI, using the 
same approach as (a). 
Analyses A and B will use repeated measures of functional status with the BI to estimate the trajectories 
of BI over time, and will describe how the primary predictors affect the intercept and slope of the 
estimated trajectories (Figure iii).  Figure ix graphically displays the effect on the estimated trajectory of a 
change in intercept, and Figure x displays the effect of a change in slope.   
 
Hypothesis #2: In order to delineate the unique effect of stroke on functional change that results 
particularly from vascular disease, we will use myocardial infarction (MI) as a comparison or control 
group.  We hypothesize that the slope of decline in functional status over the long term is steeper after 
stroke than before stroke.  The slopes of decline before and after MI are similar.   
Specific Aim #2:  [Analysis C] To determine, in CHS, using multivariable regression, censoring for 
recurrent stroke and adjusting for demographic, vascular, behavioral, social, and cognitive factors, 
whether the slope of functional status (measured by the National Center for Health Statistic Supplement 
on Aging IADL score) is different before and after stroke.  A similar model will be applied to functional 
status before and after MI. 










Figure ii.  Trajectories of functional limitations after injury in the Health and Retirement 







































Figure v. Trajectories of function in relation to admission to intensive care units. Figure 






Figure vi. Conceptual depiction of the course of functional status before and after stroke among 






Figure vii. Reproduced from Meyer et al.151 
 
“Recovery patterns of (A) the Barthel Index (BI), (B) Rivermead Motor Assessment of Gross 
Function (RMA-GF), (C) RMA of Leg and Trunk function (RMA-LT), and (D) RMA of Arm 
function (RMA-A) from admission to the rehabilitation center up to 5 years after stroke. ICH 






















































Background: Inflammatory biomarkers have been previously associated with stroke and mortality, but 
inflammation may also have detrimental effects beyond acute events.  The association of these 
biomarkers with functional status is not well defined.  We hypothesized that serum levels of high-
sensitivity C-reactive protein (CRP), interleukin-6 (IL6), lipoprotein-associated phospholipase A2 
(LpPLA2), and tumor necrosis factor receptor-1 (TNFR1) predict long-term functional status 
independently of vascular risk factors and stroke and myocardial infarction (MI) occurring during follow-
up. 
Methods:  In the prospective, multiethnic Northern Manhattan Study, stroke-free individuals in northern 
Manhattan aged >40 years had annual assessments of disability with the Barthel index (BI), for a median 
of 13 years.  BI was analyzed as a continuous variable (range 0-100).  Baseline demographics, risk 
factors, and laboratory studies were collected, including CRP (n=2240), IL6 (n=1679), LpPLA2 mass and 
activity (n=1912), and TNFR1 (n=1863).  Separate generalized estimating equation models estimated 
standardized associations between each biomarker and 1) baseline functional status and 2) change in 
function over time, adjusting for demographics, vascular risk factors, social variables, cognition, and 
depression measured at baseline, and stroke and MI occurring during follow-up.   
Results: Mean age was 69 (SD 10) years, 36% were male, 54% Hispanic, 74% had hypertension, 22% 
diabetes; 337 MIs and 369 first strokes occurred during follow-up.  CRP (-0.41, 95% CI -0.82 to 0.002) 
and LpPLA2 (-0.40, 95% CI -0.75 to -0.04) were associated with baseline BI but not change over time.  
TNFR1 was associated with baseline BI (-0.93, 95% CI -1.59 to -0.26) and change over time (-0.36 BI 
points per year, 95% CI -0.69 to -0.03).   
Conclusions: In this large population-based study, higher serum inflammatory biomarker levels were 
associated with disability, even when adjusting for baseline covariates and stroke and MI occurring during 
follow-up.  Elevated TNFR1 predicted greater disability over time, suggesting that systemic inflammation 





Serum biomarkers of inflammation may be able to detect subclinical risk of vascular disease, and hence 
may be able to link stroke pathophysiology with ongoing, continuous changes in function.  Prior research 
has identified a significant role of inflammation in atherosclerosis and stroke106, 107 as well as significant 
associations between stroke and inflammatory biomarkers, such as leukocyte count108 and high-
sensitivity C-reactive protein (hsCRP).109-113 Some studies have suggested that hsCRP also predicts 
prognosis after stroke.110, 114  
Prior research in the Northern Manhattan Study (NOMAS) has identified associations between 
inflammatory markers and MI, mortality, and carotid plaque thickness.115, 116 In the Cardiovascular Health 
Study (CHS), interleukin-6 (IL6) and CRP have been associated with white matter lesions,117 and other 
studies have found associations between CRP and stroke severity and mortality.118 It appears that B-
lymphocyte activation is linked to delayed cognitive decline after stroke in a mouse model as well as in 
pathological analysis of post-mortem specimens.119   
 Interactions have also been found between vascular risk factors and inflammatory states.  Forty 
individuals, 19 with diabetes, had comprehensive neuropsychological measurements, physical 
examinations, MRI, and inflammatory marker analysis twice over 2 years.122 Cerebral autoregulation was 
associated with functional status.  Also, those with diabetes had worse cerebral vasoregulation and 
cognitive function over time, and higher cortisol and CRP levels were associated with decline in 
vasoregulation.   
A single ischemic stroke may cause changes in inflammatory profiles123 that may have an 
ongoing deleterious effect on brain structure and function124 that may persist years after stroke.125 Beyond 
the association with vascular outcomes, inflammation has been associated with quality of life (QOL) in a 
limited number of studies,126-129 but the association of inflammatory markers with disability has not been 
well-studied, particularly among minority populations.   
  We hypothesized that elevated levels of serum inflammatory biomarkers independently predict 
worse functional status in those free of stroke at baseline.  We studied this hypothesis in NOMAS in those 
who have data on serum biomarkers.  Four biomarkers were studied: CRP, IL6, tumor necrosis factor 
receptor-1 (TNFR1), and lipoprotein-associated phospholipase-A2 (LpPLA2).  CRP is an acute phase 
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reactant that reflects acute inflammatory states and tissue injury.177 In addition, it may be directly 
implicated in pro-atherogenic processes, and several large epidemiologic studies have shown 
associations between higher CRP levels and vascular events and mortality.  IL6 is an inflammatory 
cytokine that is also elevated with brain injury, predominantly expressed in brain white matter, and may 
be involved with recovery in traumatic brain injury and neuropathy.178 Elevated IL6 has been associated 
with various types of dementia and stroke.  TNFR1 is one of the 2 major receptors to which TNF binds, 
and binding to TNFR1 causes enhancement of inflammation and engages pathways meant to clear 
pathogens, including cytotoxic effects.179 Elevated serum TNFR1 levels have been associated with 
autoimmune diseases and vascular conditions including stroke.  LpPLA2 is an inflammatory biomarker 
secreted by immune cells in the walls of arteries and is involved in the inflammatory processes occurring 
in atherosclerotic plaque.180 Elevated LpPLA2 has been associated with coronary heart disease and 
vascular events in previous studies.  No known studies have tested the associations of the above 
biomarkers with trajectories of functional status.   
 
Methods 
Historically, NOMAS developed over time as a series of distinct studies with disparate designs.  Initially, 
patients who experienced a first ischemic stroke were enrolled in a stroke incidence study and were 
followed over time as part of a stroke case follow-up study.  A case-control study was then developed 
with individuals free of stroke who were identified by random-digit dialing serving as the controls.  Finally, 
a prospective cohort study enrolled individuals free of stroke at baseline and is currently following up 
living subjects.    
The cohort that was the focus of this analysis is the NOMAS population-based prospective cohort 
of those free of stroke at baseline, which was originally designed to evaluate the effects of medical, socio-
economic, serum, and imaging risk factors for incident vascular disease and other outcomes in a multi-
ethnic community. A total of 3298 participants were recruited by random digit dialing of both published 
and unpublished telephone numbers between 1993 and 2001. Subjects were enrolled if they: 1) were at 
least 40 years of age; 2) lived in a pre-defined geographic area of northern Manhattan for at least 3 
months in a household with a telephone; and 3) did not have a history of stroke. The study was approved 
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by the institutional review boards of Columbia University and the University of Miami, and informed 
consent was obtained from all participants.  Further characteristics of the cohort have been outlined in 
prior publications.181-183  
 
Baseline Evaluation   
Trained bilingual research assistants interviewed participants and collected data using standardized 
questions regarding the following conditions: hypertension, diabetes, hypercholesterolemia, cigarette 
smoking, alcohol use, and cardiac conditions.184 All participants underwent a thorough baseline 
examination including comprehensive medical history, physical examination, review of medical records, 
functional status assessed by the BI, quality of life (QOL) assessed by the Spitzer QOL index (QLI), and 
fasting blood samples.   
 
Follow-up  
All participants are followed annually via phone screening to detect change in vital status, new 
neurological or cardiac symptoms and events, interval hospitalizations, cognitive function, and functional 
status via the Barthel index (BI). Only two subjects have been completely lost to follow-up after their 
baseline examination, and the average annual contact rate is 99%. 
A positive screen for any potential cardiac or neurological event is followed by an in-person 
assessment to determine whether a vascular outcome has occurred. In addition, all admissions and 
discharges are screened for hospitalizations and outcomes that may not have been captured by 
telephone interview. Nearly 70% of vascular events lead to hospitalizations at Columbia-Presbyterian 
Hospital.  Hospital records are reviewed to classify outcomes as previously reported.183 Stroke includes 
ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage, but not transient ischemic 
attack or venous sinus thrombosis.  At least 2 stroke neurologists verify and classify all stroke cases.  MI 
is defined by criteria adapted from the Cardiac Arrhythmia Suppression trial185 and the Lipid Research 
Clinics Coronary Primary Prevention trial186 requiring at least 2 of the 3 following criteria: (a) ischemic 
cardiac pain determined to be typical angina; (b) cardiac marker abnormalities defined as abnormal CK-
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MB fraction or troponin I values; and (c) ischemic EKG abnormalities.  Diagnosis of MI is adjudicated by 
cardiologists independently after review of all clinical data.   
There were 435 MIs occurring during follow-up, 225 (51.72%) definite, 112 (25.75%) probable, 
and 98 (22.53%) possible.  For this analysis, only definite and probable MI were included (n=337).  Out of 
first MIs occurring during follow-up (n=333), 184 (55.3%) were definite, 81 (24.3%) were probable, and 68 
(20.4%) were possible.  There were 369 first strokes occurring during follow-up, 322 (87.26%) infarcts, 35 
(9.49%) intracerebral hemorrhages (ICH), 8 (2.17%) subarachnoid hemorrhages (SAH), and 4 (1.08%) 
unknown.  All were included in this analysis. 
 
Study outcome   
The BI, developed in 1965187 and later modified,188 measures an individual’s performance in 10 ADLs and 
has been extensively used in stroke observational studies and clinical trials as a measure of post-stroke 
disability.189 The scale ranges from 0 to 100 in 5-point increments, with 100 indicating normal physical 
functioning.  Previous research has demonstrated the reliability of phone assessments of function using 
the BI.190 Although it is an ordinal scale, recent research has advocated analyzing the scale as a 
continuous variable due to increased power to detect associations, ability to describe the course of 
change over time in linear form, and avoidance of potential misclassification due to crude 
categorization.191-193  
 One limit of the BI is that it is subject to ceiling effects, because the difficulty of ADL performance 
is relatively low compared to more complex tasks such as IADLs, or more complicated cognitive tasks.  
Hence, in a population that is not expected to have significant disability, such as the stroke-free, 
population-based NOMAS cohort, the BI may not capture subtle or early deficits in functional status.  
Estimation of a ceiling effect of a measure should ideally be performed in the cohort under analysis, and 
the estimate in one population does not necessarily translate to the cohort under analysis.194 There are 
several ways to estimate ceiling effects, the most effective of which involve comparisons of the properties 
of the scale to other scales measuring related constructs.195 The following metrics can be calculated for 
each scale and compared among the scales: effect size196, standardized response mean,197 paired t-
statistic,198 or relative efficiency.199 Also, the distribution of maximum scores on each scale can be 
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compared to estimate the ceiling effect.  There is a plan to perform these analyses using functional and 
quality of life measures that began to be assessed on follow-up visits in NOMAS approximately 2 years 
ago.   These analyses would estimate not only ceiling effects but also responsiveness and statistical 
estimates of meaningful clinical change.  However, at the time of this analysis there was not sufficient 
data to complete these analyses.   
 
Explanatory variables: Inflammatory biomarkers 
In 2240 participants, blood samples were collected at baseline and the following were measured using 
immunoassays: hsCRP (using enzyme-linked immunosorbence), IL6, TNFR1, and LpPLA2 mass and 
activity (PLAC assay; diaDexus Inc, South San Francisco, CA).  Laboratory personnel were blinded to 
patient clinical data and markers were run in the same participants. Serum samples for IL6 and CRP were 
drawn into EDTA tubes at baseline, spun immediately at 3,000 g at 4°C for 20 min, and frozen at –70°C 
for later analysis. Inflammatory marker levels were then measured in batched samples by enzyme-linked 
immunosorbent assay using monoclonal antibodies to IL6 with a lower limit of detection of 0.1 pg/ml 
(Biosource International, Camarillo, Calif., USA) and hsCRP with a lower limit of detection of 0.1 mg/l 
(BioCheck Inc., Foster City, Calif., USA).  Each participant had a maximum of only one measurement of 
each inflammatory biomarker.   
The distributions of all 4 biomarkers (IL6, TNFR1, CRP, and LpPLA2—mass assay and activity 
assay) were determined (Table A2).  The pattern of missing inflammatory labs was examined, and the 
most common missing pattern was missing values for LpPLA2 mass and activity, reflecting the fact that 
these labs were added to the inflammatory laboratory panel later in time.  For non-normally distributed 
biomarkers, log transformations were performed (Table A2 and Figure A2).  Although not required to 
satisfy model assumptions, log transformations were performed in order to approximate a normal 
distribution of the variable to be consistent with prior analyses.  There were 67 “0” values for IL6.  The 
next highest value, above 0, was 0.005.  These “0” values were assigned a value of 0.0025 for the log 
transformed analyses.  There were 2 “0” values for TNFR1.  The next highest value, above 0, was 0.09.  
These “0” values were assigned a value of 0.045 for the log transformed analyses.  In secondary 
analysis, a value of 0.000001 was assigned to the “0” values for each of IL6 and TNFR1.  For IL6, there 
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were 36 values that were >2000, including 35 values of 5000, which were determined to be due to coding 
error of high values; these were excluded for the non-quartile analyses of IL6.  Inflammatory biomarker 
values were centered to the mean of all values.  Quartiles of each biomarker were also used as 
categorical variables using the lowest quartile as the referent group.  Additionally, CRP was categorized 
according to the three CDC/AHA risk stratification levels:  <1 mg/L; 1-3 mg/L; and >3 mg/L (Appendix 
A2).200  In secondary analysis, we explored CRP-dominant versus IL-6-dominant profiles, as outlined in 
Appendix A2, as primary predictors, as previously described.201   
 
Covariates  
All analytic models were adjusted for the following variables: age, sex, race-ethnicity, body mass index 
(weight in kilograms divided by the square of height in meters), self-reported hypercholesterolemia, 
diabetes mellitus (defined by self-report, fasting blood glucose level >126 mg/dL, or insulin/oral 
hypoglycemic use), hypertension (defined as a systolic blood pressure recording >140 mmHg or a 
diastolic blood pressure recording >90 mm Hg based on the average of two blood pressure 
measurements or the patient's self-report of a history of hypertension or antihypertensive use), smoking 
(defined as either nonsmoker or smoker within the last year), alcohol use (with moderate alcohol use 
classified as 1 drink/month to 2 drinks/day), social variables (marital status, insurance status [classified as 
uninsured, Medicaid, Medicare, or private insurance], number of friends [individuals whom the participant 
knows well enough to visit in their homes], years living in the community), and cognitive factors 
(depressed mood, and performance on mini-mental state examination [analyzed as a continuous 
variable]).  Of note, there was no evidence of over-reporting of hypertension by self-report.  Specifically, 
1729 individuals (52.4%) self-reported hypertension, and 2067 (62.7%) had a systolic blood pressure 
recording >140 mmHg or a diastolic blood pressure recording >90 mm Hg based on the average of two 
blood pressure measurements.  There were 700 (21.2%) who did not self-report hypertension and had 
elevated blood pressure readings as defined above,  There were 1357 (41.2%) who did self-report 
hypertension and had elevated blood pressure readings at the time of evaluation.  The definitive way to 
identify over- or under-diagnosis of hypertension by self-report would be to perform ambulatory blood 
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pressure monitoring in all participants.  However, the composite definition of hypertension seems to be an 
accurate method of identifying cases of hypertension in this population.   
 
Statistical analysis  
The goal of this analysis was to determine whether levels of serum inflammatory biomarkers (IL6, TNFR1, 
CRP, and LpPLA2) were associated with baseline BI and a steeper slope of decline over time (Figure iii).  
We first calculated the distribution of main explanatory variables, baseline covariates, and BI, and we 
compared the distributions of variables based on availability of inflammatory lab data to detect differences 
in the inflammatory lab cohort compared to the prospective cohort.  Then, each biomarker exposure was 
analyzed separately.  Due to correlations among repeated measures of outcomes in the same individual, 
regression models based upon generalized estimating equations (GEE) with an identity link function were 
used to assess the association between main explanatory variables and repeated measurements of BI, 
adjusting for baseline demographic variables (age, sex, race-ethnicity), medical risk factors (BMI, 
diabetes, hypertension, hypercholesterolemia), smoking and alcohol use, social variables (marital status, 
insurance status, number of friends, number of years in the community), and cognitive factors (depressed 
mood, performance on mini-mental state examination).  In model building, we sequentially added groups 
of variables in a pre-specified manner based upon the standards of the field.  Specifically, the first model 
included no covariates, and successive models included demographic variables, vascular risk factors, 
social variables, and cognitive and mood factors.   
In order to assess whether the main explanatory variables were associated with the slope of 
change in outcomes over time, we included interaction terms between time of follow-up assessment and 
the variable.  All significant interactions with time were included in the final model.  We used QIC for GEE 
models and AIC for mixed models as the model selection criteria after considering candidate final models. 
Various model diagnostics including tests of linearity, residual plots, and goodness of fit measures were 
used to evaluate the final model.  There was no evidence to suggest lack of linearity in the final models.  
As a working correlation structure for the GEE models we chose the exchangeable (intraclass) structure 
and compared the QIC obtained with this model with one using the unstructured working correlation 
structure.  We chose the exchangeable model, with the lower QIC, as the final model.  In order to assess 
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whether interval vascular events such as clinical stroke and MI were implicated in the trajectory of 
functional status, we ran a second set of models in which stroke and MI were included as time-varying 
covariates.  MI was defined as definite and probable MI (not including possible MI).  A sensitivity analysis 
was performed in which possible MI was added to the definition of MI, and models did not significantly 
differ and are not presented here.  We also performed a sensitivity analysis in which those with baseline 
coronary artery disease were excluded, and models did not significantly differ and are not presented here.  
In a separate analysis, we assessed whether interval non-stroke and non-MI hospitalizations were related 
to changes in functional status, using a similar strategy as above. 
We also pursued an alternative modeling strategy using mixed models.  For the mixed models 
approach, we first calculated intraclass correlation coefficients using an ‘empty’ or ‘random intercept only’ 
model to determine the proportion of variance that is due to between-person variation.  This model was 
used as a baseline for comparison for subsequent models.  We then determined whether there was an 
effect of time on average on the outcome of functional status by determining whether there was a fixed 
effect of time.  We also determined whether the average effect of time varies across individuals by 
determining the random effect of time.  We added covariates in a similar manner as for the analyses 
described above.   
There are several differences in the way that mixed models and GEE models analyze correlated 
data, and in the results that are generated from each.  GEE is a population-average model that estimates 
an overall population effect, whereas mixed models estimate an overall population effect (fixed effect) but 
also allow for individual variation around this average (random effects).202, 203 GEE models use a working 
correlation structure, which can be specified among several possibilities, and the fit of each structure can 
be compared using the QIC, as outlined above.  Although the standard errors that are estimated from this 
method are robust, the population correlation structure is assumed and not directly specified, as it must 
be with mixed models.  Hence, mixed models may be more prone to erroneous results as a result of 
misspecification.  However, the advantage of using mixed models to analyze time trends in outcomes is 
that repeated measures over time have an inherent order or sequence, and mixed models can explicitly 
specify this structure, as opposed to GEE models.  Also, different findings when using mixed models 
compared to GEE models may be related to different handling of missing data and the greater 
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preservation of data in the mixed models (because there is no need to delete case-wise if selected 
outcome data for an individual are missing).  Hence, although results from both analyses will be 
presented here, the mixed model results should be considered the “primary” model results.   
A basic analysis of the mediation effect of each biomarker was performed, in which adjusted 
models incorporating each biomarker were compared to an adjusted model without any biomarker, and 
the magnitude and direction of the time trend was compared between models.  Also, the QIC was 
compared between models. 
 We examined the effect of hospitalization on functional status in several ways, and determined 
whether loss to follow-up was related to hospitalization, which may have introduced bias in the estimation 
of functional trajectories.  We also examined the impact of loss to follow-up in several ways.  We first 
calculated the time between last functional assessment and death.  For those with the longest amount of 
time between last assessment and death, records were examined individually to assess for the reason for 
loss to follow-up.  Secondly, the distribution was determined of the last ADL score measured among 
those who died.  We also calculated the distribution of maximum follow-up times among survivors and 
examined records for individuals who had maximum follow-up time <10 years to identify possible reasons 
for loss to follow-up.   
 
Results 
Table A1 shows distributions of variables in the cohort, stratified by availability of inflammatory labs.  The 
inflammatory lab cohort consisted of 2551 participants.  There were significant differences in the 
distributions of several variables based on availability of inflammatory lab data, including: age, sex, race-
ethnicity, health insurance, physical activity, hypercholesterolemia, and social support.  Those who had 
inflammatory lab data were slightly younger, less often Hispanic, more often married, and more often 
covered by Medicaid or had no insurance. However, there were no differences in major vascular risk 
factors.   
Appendix A1 and Figure A1 show the distributions of the Barthel index score in the entire 
prospective cohort.  There were a total of 38110 assessments among the 3298 participants in the 
prospective cohort.  Table A2 and Figure A2 show the distributions of biomarkers in the inflammatory lab 
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cohort, including raw variables and log-transformed variables.  Appendix A2 (A) shows the distributions of 
CRP according to AHA/CDC categories; the majority of individuals had levels >3 mg/L.  Appendix A2 (B) 
shows the conceptual framework of IL6- and CRP-dominant profiles, and (C) shows frequencies of the 
reference level as well as IL6- and CRP-dominant profiles.   
Table A3 shows associations between standardized CRP levels and trajectories of functional 
status, in unadjusted and adjusted models.   In all models, there was a significant annual decline in 
functional status of around one BI point per year in most models, and of 0.39 points per year in a model 
adjusted for stroke and MI occurring during follow-up.  In addition, in most models, including the fully 
adjusted model, higher CRP levels were associated with a lower overall mean functional score.  Finally, 
CRP levels were not significantly associated with change in functional status over time.  Patterns of 
association were similar when log of CRP levels was tested as the main predictor – namely, a significant 
overall annual decline in function, a lower mean overall functional level with higher log of CRP levels, and 
no significant association between log of CRP levels and change in functional status over time (Table 
A4).  When the AHA/CDC categorization of CRP levels was used (Table A5), similar trends were seen but 
with reduced significance, possibly due to reduced power from the use of categorical instead of 
continuous variables.   
 As shown in Table A6, higher standardized TNFR1 levels were associated with lower overall 
functional status as well as accelerated decline over time.  In the fully adjusted model including 
adjustment for stroke and MI occurring during follow-up, each SD increase in TNFR1 level was 
associated with a mean of -0.93 (95% CI -1.59, -0.26) lower BI points overall as well as an additional -
0.36 points per year of decline over time (95% CI -0.69, -0.03), over and above the -0.52 points per year 
of BI decline (95% CI -0.73, -0.31) in the entire cohort.  There was a similar pattern when log of TNFR1 
levels were examined as primary predictor, though in most models except for the final model, the estimate 
for the association between log of TNFR1 levels and functional status was not significant (Table A7) 
(results for unstandardized log of TNFR1 levels are shown in Appendix A3).  In a sensitivity analysis in 
which TNFR1 levels of 0 were set to missing (Appendix A4), in the fully adjusted model, increasing levels 
of log of TNFR1 were associated with -1.12 BI points overall (95% CI -1.97, -0.27) and -0.34 additional BI 
points per year (95% CI -0.67, -0.01).   
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When quartiles of TNFR1 were examined (Appendix A5), higher quartiles of TNFR1 were 
associated with lower overall BI values as well as additional decline in function over time.  In the fully 
adjusted model, the highest quartile of TNFR1 was associated with an additional -0.72 BI points of 
decline per year (95% CI -1.34, -0.10) compared to the lowest TNFR1 quartile.  Using a dichotomous 
variable of the highest quartile of TNFR1 versus all other quartiles (Appendix A6), the highest quartile was 
associated with reduced overall function as well accelerated decline over time in an unadjusted model, 
but in a fully adjusted model, the highest quartile was only associated with an additional -0.64 BI points of 
decline per year (95% CI, -1.25, -0.04).   
  In adjusted models, log of IL6 levels was not associated with either overall mean BI or change in 
BI over time (Table A8).  Results were not meaningfully different in a sensitivity analysis with 0 values set 
to missing (Appendix A7).  When IL6 was dichotomized at the median (Appendix A8), IL6 scores above 
the median were associated with reduced function overall (-1.10, 95% CI -2.18, -0.02) and decline in 
function over time (-0.20 BI points per year, 95% CI -0.38, -0.01) in an unadjusted model but not after 
adjustment.   
In adjusted models (Table A9), higher LpPLA2 mass levels were associated with lower mean BI 
score (-0.40, 95% CI -0.75, -0.04) but not associated with change of BI over time.  LpPLA2 activity levels 
were not associated with either overall mean BI or change in BI over time (Table A10).  Neither CRP- nor 
IL6-dominant profiles were associated with overall mean BI or change in BI over time (Table A11), in 
unadjusted or adjusted models. 
Table A12 shows results using mixed models without covariate adjustment.  Model 1 (Table A12 
[A]) shows that the between-person variance was 134.91 and within-person variance was 172.18.  
Hence, the intraclass correlation coefficient was 134.91 / (134.91 + 172.18) = 0.43932.  According to this 
calculation, 43.9% of the variance in BI scores was due to between-person differences and 56.1% was 
due to within-person variation.  The mean BI score was 91.2782.  According to the p-value (<0.0001) of 
the standard error of this intercept (under “solution for fixed effects”), the sample varies significantly in the 
intercept.  Examining model 2 (Table A12 [B]), the AIC was lower (better) when time was added to the 
model, signifying a better fit with time in the model (Tables A12 [C] and [D]).   
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Two adjusted linear mixed models were fit in order to evaluate the change of functional status 
over time in the cohort: one with a linear time trend (Table A13), and one that evaluated change in BI per 
year of age (Table A14).  Both showed a significant decline in functional status over time.  Other 
significant predictors of functional status included: race-ethnicity, diabetes, physical activity, marital 
status, insurance coverage, depression, cognition measured by the MMSE, and QOL.  Unexpectedly, 
depression was associated with better overall functional status.   
Table A15 shows adjusted mixed models individually testing the association between a single 
biomarker and trajectories of functional status. Similarly to the GEE models, increasing log of CRP and 
LpPLA2 mass levels were associated with lower overall functional status but not change in function over 
time; also, LpPLA2 activity levels were not associated with function.  Also similar to the GEE models, 
increasing log of TNFR1 levels were associated with lower overall BI score (-1.05, 95% CI -1.40, -0.70) as 
well as accelerated decline in function over time (-0.43 additional points per year per unit increase in log 
of TNFR1 levels, 95% CI -0.62, -0.23).  In contrast to the GEE models, increasing log of IL6 levels were 
significantly associated with accelerated decline in function over time (-0.13 point per year, 95% CI -0.24, 
-0.02), and there was a trend for lower overall functional status (-0.20, 95% CI -0.41, 0.004).   
Table A16 shows an analysis of the mediating effect of each biomarker, comparing adjusted 
models incorporating each biomarker to an adjusted model without any biomarker.  In each case, addition 
of a biomarker reduced the QIC, indicating better explanatory power with the biomarker included.  
However, there was no consistent pattern of effect on the annual change in BI score overall.   
 The effect of hospitalization on functional status was assessed in Appendix A9.  In 20.2% of study 
visits, there was a hospitalization since the last contact (A).  Only 24.5% of individuals had no 
hospitalization during follow-up, and the majority of those who were hospitalized (21.6%) had 1 
hospitalization, with a range up to 17 hospitalizations (B).  Comparing the number of hospitalizations to 
the number of study visits (C), the mean of the ratio of number of hospitalizations to number of follow-up 
visits was 0.20 (D), suggesting on average that there was one hospitalization for every 5 follow-up visits.  
For a non-stroke/MI hospitalization, the amount of time between pre-hospitalization assessment and post-
hospitalization assessment was on average 1.09 years, with an upper quartile of only 1.11 years (E).  For 
all hospitalizations, the corresponding interval was on average 1.05 years, with an upper quartile of 1.11 
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years (F). These results suggest that hospitalization did not cause selective loss to follow-up or introduce 
bias into the timing of BI assessments.   
 The impact of loss to follow-up and death was assessed in Appendix A10.  The average time 
between last functional assessment and death was 0.74 years, with an upper quartile of 0.93 years (A). 
The distribution of the last BI score assessed before death is summarized in (B) and (C); although there 
are low scores, the majority of scores (37.2%) are 95 or 100, signifying normal functional status.  Those 
with last BI score before death of <60 more often had a shorter interval between last functional 
assessment and death (61.2% with interval <0.5 years) compared to those with BI of 60-90 (37.0%) or 
95-100 (33.8%).  Among survivors, there was a greater proportion with higher BI scores (E) compared to 
those who died.  The average follow-up time among survivors was 15.2 years, with a median of 15.1 
years (F).   
 
Conclusions for Analysis A 
NOMAS is a large, population-based study with frequent, regular measurements of functional status, 
numbering over 38,000 overall.  Hence, it is well-suited to estimate trajectories of functional status over 
time and identify factors that influence these trajectories.  In the sub-study of NOMAS analyzed here, 
accurate measurement of inflammatory biomarkers allowed us to elucidate the influence of these 
biomarkers, and by extension systemic inflammatory states, on trajectories of function over time.  Also, 
adjustment for potentially confounding factors allowed us to estimate the independent effect of these 
variables on function.  Among those with inflammatory biomarker data at baseline, the prevalence of 
increased biomarker levels was high.  When trajectories of functional status were examined, there was an 
overall decline in functional status over time in the entire cohort.  Increasing CRP levels, examined using 
different cutoffs and variable definitions, were associated with lower overall mean functional score but not 
with change in slope of function over time.  Results were similar for LpPLA2 mass levels.  However, for 
TNFR1, increasing levels were associated not only with overall reduced functional status, but also 
additional annual decline in function over time.  This association was consistent using different cutoffs 
and transformations of TNFR1.   
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 In addition to GEE models, we also used mixed models to estimate associations, which in most 
cases confirmed the significance and magnitude of effects seen with GEE models.  Although IL6 was not 
a significant predictor in GEE models, increasing IL6 levels were associated with accelerated decline in 
function over time using the mixed model approach.  Due to improved handling of missing data, with 
greater preservation of data in the mixed models, as well as a more accurate specification of the time 
trend with mixed models compared to GEE models, the mixed model results should be considered the 
primary model results.  We also tested whether the annual change in functional status was altered by 
adding each biomarker in models, but there was no consistent pattern of effect.    
 For models testing CRP, TNFR1, IL6, LpPLA2, we observed that the estimate for annual change 
in BI score was significantly reduced after adjusting for depression, cognitive status, and QOL.  This is not 
surprising considering the well-known association between inflammatory processes and depression.204 
However, the effect of inflammatory markers discussed above remained even after adjusting for these 
factors, suggesting that inflammatory processes have an effect on functional status that is independent of 
depression.     
The data quality in this study was high, and there was no evidence of bias on the timing of follow-
up assessments or loss to follow-up.  Specifically, we tested the potential effect of hospitalization on data 
ascertainment and found no evidence of any effect of hospitalization on timing or regularity of follow-up 
assessments.  Also, there was no evidence that there was loss to follow-up in the last functional 
assessments before death, and overall the average length of follow-up among survivors was an 
impressive 15.2 years.   
Strengths of this analysis include a large, population-based cohort with repeated, regular 
measurements of functional status with a validated scale.  There was also regular surveillance for 
vascular events and hospitalization and expert adjudication of events.  Biomarkers were measured 
according to standard procedures, and confounders were adjusted for in models.  One limitation of the 
proposed study involves deficiencies in the primary measure.  The BI is subject to ceiling effects and is 
insensitive to small changes in disability.205 However, the ceiling effects seen with the BI would likely lead 
to an underestimation of the effect and would be unlikely to result in false positive associations.  Hence, if 
the BI did not have a ceiling effect, the estimated associations would likely be even larger than those 
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seen in this analysis.  Analyzing the BI as a continuous variable is advantageous since this approach can 
capture and quantify the variance and course of change over time, which would likely not be captured by 
using a categorical or dichotomous variable.192, 193  One advantage of the BI is that it is widely used in 
stroke research, which allows comparison with prior studies, and it is also not a stroke-specific scale, 
which allows its use in a stroke-free population.   
Further discussion of the findings of this analysis will be found in the concluding chapter. 
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Table A1. Baseline characteristics of the cohort, by availability of labs: 






Number of participants, No. (%) 2551 (77.4) 747 (22.7) -- 
Biological characteristics:    
Age, mean (SD), y 69.3 (10.2) 71.3 (10.7) <0.0001 
Body mass index, mean (SD), kg/m2 27.9 (5.5) 27.5 (5.7) 0.09 
    
Demographics:    
Male, No. (%) 923 (36.2) 304 (40.7) 0.02 
Race-ethnicity: 
  Non-Hispanic white, No. (%) 
  Non-Hispanic black, No. (%) 
  Hispanic, No. (%) 












Received at least high school education, No. (%) 1154 (45.3) 357 (47.8) 0.2 
Highest education achieved, No. (%)  
  Eighth grade or less  
  Some high school  
  Completed high school 
  Some college  














Marital status, No. (%) married 826 (32.4) 216 (28.9) 0.07 
Health insurance, No. (%)  
   Medicaid or no insurance 








Medicaid health insurance, No. (%)  886 (34.7) 230 (30.8) 0.045 
Medicare health insurance, No. (%)  1573 (61.7) 525 (70.3) <0.0001 
Private insurance, No. (%) 1052 (41.3) 334 (44.7) 0.09 
    
Vascular risk factors, No. (%)    
Hypertension  1886 (73.9) 543 (72.7) 0.5 
History of hypertension 1345 (52.7) 384 (51.4) 0.5 
Systolic BP, mean (SD) 143.6 (21.0) 144.0 (21.1) 0.6 
Diastolic BP, mean (SD) 83.4 (11.1) 82.0 (11.8) 0.003 
Alcohol consumption: 
   Never Drank  
   Past Drinker  
   Light Drinker  
   Moderate Drinker  
   Intermediate Drinker  

















   None 
   Light 










Diabetes mellitus  557 (21.9) 159 (21.3) 0.7 
Smoking: 
   Never 
   Former 










Hypercholesterolemia 1628 (63.8) 422 (56.5) 0.0003 
Total cholesterol, mean (SD), mg/dL  202.9 (39.7) 202.4 (42.1) 0.7 
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High-density lipoprotein, mean (SD), mg/dL  46.6 (14.3) 47.5 (15.8) 0.2 
Low-density lipoprotein, mean (SD), mg/dL  129.9 (35.9) 126.3 (34.9) 0.02 
History of atrial fibrillation 111 (4.4) 32 (4.3) 0.9 
History of coronary heart disease  540 (21.2) 164 (22.0) 0.6 
    
Other medical conditions, No. (%)    
Hamilton depression scale score, mean (SD) 3.26 (3.89) 2.85 (3.68) 0.01 
Hamilton depression score >12 108 (4.3) 31 (4.3) 0.9 
Chronic bronchitis, asthma, or emphysema 310 (12.2) 96 (12.9) 0.6 
Mini mental state score, mean (SD) 26.0 (3.74) 26.0 (3.82) 0.9 
History of migraine headaches  447 (17.6) 100 (13.4) 0.008 
Spitzer quality of life index score  9.15 (1.26) 9.08 (1.42) 0.2 
Quality of well-being scale score:  
   Overall 
   Physical activities 
   Social activities 
   Mobility 



















    
Social variables, No. (%)    
Number of people known well enough to visit with in 
their homes:  
   None 
   1 or 2 
   3 or 4 














Number of times talked to someone on telephone in 
past week:  
   Not at all  
   Once  
   Two to six times  














Number of times in past week spent with someone 
who does not live with you:  
   Not at all  
   Once  
   Two to six times  














Have someone you can trust and confide in  2358 (92.6) 681 (91.3) 0.2 
Feeling lonely:  
   Quite often  
   Sometimes  










See relatives and friends:  
   As often as want 
1557 (61.1) 430 (57.7) 0.09 
Is there someone who would give you help if sick:  2093 (82.2) 606 (81.8) 0.8 





Table A2. Distributions of biomarkers 




Std Dev Min Max N 
missing 
N 
C-reactive protein, mg/L 5.24 2.55 1.10 5.92 8.86 0.04 120.00 311 2240 
Interleukin-6, pg/mL 109.72 1.56 0.80 2.88 723.80 0 5000.00 872 1679 
Tumor necrosis factor receptor-1, mg/L 2.57 2.28 1.75 2.97 1.72 0 33.22 688 1863 
Lipoprotein-associated phospholipase A2 mass 117.00 115.50 96.52 135.89 29.57 12.12 220.94 639 1912 
Lipoprotein-associated phospholipase A2 activity 308.65 306.71 245.34 365.54 88.29 28.12 972.59 614 1937 
Log transformed variables:          
Log of C-reactive protein levels 0.92 0.93 0.10 1.78 1.23 -3.08 4.79 311 2240 
Log of interleukin-6 levels 0.32 0.44 -0.22 1.06 2.00 -5.99 8.52 872 1679 
Log of tumor necrosis factor receptor-1 levels 0.81 0.82 0.56 1.09 0.53 -3.10 3.50 688 1863 
    Without substitutions for 0 values:          
Log of interleukin-6 levels 0.58 0.50 -0.11 1.09 1.57 -5.30 8.52 939 1612 





Table A3. Associations between standardized C-reactive protein levels and trajectories of 
functional status  
Variable Change in 
BI score 
95% CI p-value
Unadjusted model:    
Annual change in BI score -1.02 -1.10, -0.93 <.0001 
Change in BI score per SD increase in CRP levels -0.83 -1.54, -0.12 0.02 
Additional annual change in BI score per SD increase in CRP 
levels 
-0.08 -0.21, 0.06 0.3 
Adjusted for demographics:*    
Annual change in BI score -1.03 -1.11, -0.94 <.0001 
Change in BI score per SD increase in CRP levels -0.76 -1.53, 0.01 0.054 
Additional annual change in BI score per SD increase in CRP 
levels 
-0.10 -0.24, 0.04 0.17 
Adjusted for vascular risk factors:**    
Annual change in BI score -1.03 -1.11, -0.95 <.0001 
Change in BI score per SD increase in CRP levels -0.44 -1.16, 0.27 0.2 
Additional annual change in BI score per SD increase in CRP 
levels 
-0.11 -0.25, 0.04 0.15 
Adjusted for social variables:†    
Annual change in BI score -1.02 -1.10, -0.94 <.0001 
Change in BI score per SD increase in CRP levels -0.38 -1.07, 0.32 0.3 
Additional annual change in BI score per SD increase in CRP 
levels 
-0.11 -0.25, 0.03 0.14 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.57 -0.71, -0.43 <.0001 
Change in BI score per SD increase in CRP levels -0.36 -0.76, 0.04 0.07 
Additional annual change in BI score per SD increase in CRP 
levels 
0.07 -0.04, 0.17 0.2 
Adjusted for stroke and MI:π    
Annual change in BI score -0.39 -0.52, -0.25 <.0001 
Change in BI score per SD increase in CRP levels -0.41 -0.83, -0.002 0.049 
Additional annual change in BI score per SD increase in CRP 
levels 
0.04 -0.06, 0.15 0.4 
CRP=C-reactive protein; BI=Barthel index; MI=myocardial infarction 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 








Table A4. Associations between log of C-reactive protein levels and trajectories of functional 
status  




Unadjusted model:    
Annual change in BI score -1.01 -1.09, -0.93 <.0001
Change in BI score per unit increase in log of CRP levels -0.72 -1.13, -0.31 0.0006
Additional annual change in BI score per unit increase in log of 
CRP levels 
-0.03 -0.10, 0.05 0.5 
Adjusted for demographics:*    
Annual change in BI score -1.02 -1.10, -0.94 <.0001
Change in BI score per unit increase in log of CRP levels -0.79 -1.22, -0.36 0.0003
Additional annual change in BI score per unit increase in log of 
CRP levels 
-0.03 -0.10, 0.04 0.4 
Adjusted for vascular risk factors:**    
Annual change in BI score -1.03 -1.11, -0.94 <.0001
Change in BI score per unit increase in log of CRP levels -0.40 -0.85, 0.05 0.08 
Additional annual change in BI score per unit increase in log of 
CRP levels 
-0.03 -0.11, 0.04 0.4 
Adjusted for social variables:†    
Annual change in BI score -1.01 -1.09, -0.93 <.0001
Change in BI score per unit increase in log of CRP levels -0.33 -0.78, 0.11 0.14 
Additional annual change in BI score per unit increase in log of 
CRP levels 
-0.03 -0.11, 0.04 0.4 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.57 -0.72, -0.43 <.0001
Change in BI score per unit increase in log of CRP levels -0.30 -0.58, -0.02 0.04 
Additional annual change in BI score per unit increase in log of 
CRP levels 
0.00 -0.12, 0.13 0.96 
Adjusted for stroke and MI:π    
Annual change in BI score -0.39 -0.53, -0.26 <.0001
Change in BI score per unit increase in log of CRP levels -0.34 -0.62, -0.06 0.02 
Additional annual change in BI score per unit increase in log of 
CRP levels 
0.02 -0.11, 0.14 0.8 
CRP=C-reactive protein; BI=Barthel index; MI=myocardial infarction 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 







Table A5. Associations between C-reactive protein levels, according to AHA/CDC categorization, 
and trajectories of functional status  




Unadjusted model:    
Annual change in BI score -1.01 -1.17, -0.84 <.0001
Change in BI score with 1-3 mg/L CRP, compared to <1 mg/L 0.28 -0.79, 1.35 0.6 
Change in BI score with >3 mg/L CRP, compared to <1 mg/L -1.89 -3.00, -0.77 0.0009
Additional annual change in BI score with 1-3 mg/L CRP, compared 
to <1 mg/L 
0.04 -0.17, 0.26 0.7 
Additional annual change in BI score with >3 mg/L CRP, compared 
to <1 mg/L 
-0.05 -0.26, 0.16 0.6 
Adjusted for demographics:*    
Annual change in BI score -1.01 -1.17, -0.85 <.0001
Change in BI score with 1-3 mg/L CRP, compared to <1 mg/L 0.61 -0.62, 1.83 0.3 
Change in BI score with >3 mg/L CRP, compared to <1 mg/L -1.83 -3.06, -0.61 0.0034
Additional annual change in BI score with 1-3 mg/L CRP, compared 
to <1 mg/L 
0.03 -0.18, 0.25 0.8 
Additional annual change in BI score with >3 mg/L CRP, compared 
to <1 mg/L 
-0.05 -0.26, 0.15 0.6 
Adjusted for vascular risk factors:**    
Annual change in BI score -1.01 -1.18, -0.85 <.0001
Change in BI score with 1-3 mg/L CRP, compared to <1 mg/L 0.95 -0.31, 2.22 0.1 
Change in BI score with >3 mg/L CRP, compared to <1 mg/L -0.76 -2.08, 0.56 0.3 
Additional annual change in BI score with 1-3 mg/L CRP, compared 
to <1 mg/L 
0.04 -0.17, 0.25 0.7 
Additional annual change in BI score with >3 mg/L CRP, compared 
to <1 mg/L 
-0.05 -0.26, 0.15 0.6 
Adjusted for social variables:†    
Annual change in BI score -1.00 -1.16, -0.84 <.0001
Change in BI score with 1-3 mg/L CRP, compared to <1 mg/L 0.86 -0.41, 2.12 0.2 
Change in BI score with >3 mg/L CRP, compared to <1 mg/L -0.62 -1.94, 0.70 0.4 
Additional annual change in BI score with 1-3 mg/L CRP, compared 
to <1 mg/L 
0.04 -0.16, 0.25 0.7 
Additional annual change in BI score with >3 mg/L CRP, compared 
to <1 mg/L 
-0.06 -0.26, 0.15 0.6 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.34 -0.64, -0.05 0.02 
Change in BI score with 1-3 mg/L CRP, compared to <1 mg/L 0.77 0.04, 1.50 0.04 
Change in BI score with >3 mg/L CRP, compared to <1 mg/L -0.36 -1.11, 0.39 0.3 
Additional annual change in BI score with 1-3 mg/L CRP, compared 
to <1 mg/L 
-0.41 -0.88, 0.06 0.086 
Additional annual change in BI score with >3 mg/L CRP, compared 
to <1 mg/L 
-0.21 -0.59, 0.16 0.3 
Adjusted for stroke and MI:π    
Annual change in BI score -0.23 -0.52, 0.06 0.1 
Change in BI score with 1-3 mg/L CRP, compared to <1 mg/L 0.61 -0.08, 1.31 0.08 
Change in BI score with >3 mg/L CRP, compared to <1 mg/L -0.49 -1.22, 0.24 0.2 
Additional annual change in BI score with 1-3 mg/L CRP, compared 
to <1 mg/L 
-0.28 -0.73, 0.16 0.2 
Additional annual change in BI score with >3 mg/L CRP, compared 
to <1 mg/L 
-0.14 -0.50, 0.23 0.5 
CRP=C-reactive protein; BI=Barthel index; MI=myocardial infarction 






**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 









Table A6. Associations between standardized tumor necrosis factor receptor-1 protein levels and 
trajectories of functional status  
Variable Change in 
BI score 
95% CI p-value
Unadjusted model:    
Annual change in BI score -1.07 -1.17, -0.97 <.0001 
Change in BI score per SD increase in TNFR1 levels -2.78 -3.65, -1.91 <.0001 
Additional annual change in BI score per SD increase in TNFR1 
levels 
-0.26 -0.46, -0.06 0.01 
Adjusted for demographics:*    
Annual change in BI score -1.06 -1.16, -0.96 <.0001 
Change in BI score per SD increase in TNFR1 levels -1.78 -2.58, -0.98 <.0001 
Additional annual change in BI score per SD increase in TNFR1 
levels 
-0.21 -0.41, -0.02 0.03 
Adjusted for vascular risk factors:**    
Annual change in BI score -1.08 -1.18, -0.98 <.0001 
Change in BI score per SD increase in TNFR1 levels -1.46 -2.45, -0.47 0.004 
Additional annual change in BI score per SD increase in TNFR1 
levels 
-0.29 -0.47, -0.11 0.002 
Adjusted for social variables:†    
Annual change in BI score -1.08 -1.17, -0.98 <.0001 
Change in BI score per SD increase in TNFR1 levels -1.47 -2.49, -0.45 0.005 
Additional annual change in BI score per SD increase in TNFR1 
levels 
-0.30 -0.48, -0.12 0.001 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.66 -0.86, -0.45 <.0001 
Change in BI score per SD increase in TNFR1 levels -0.78 -1.44, -0.12 0.02 
Additional annual change in BI score per SD increase in TNFR1 
levels 
-0.32 -0.67, 0.02 0.07 
Adjusted for stroke and MI:π    
Annual change in BI score -0.52 -0.73, -0.31 <.0001 
Change in BI score per SD increase in TNFR1 levels -0.93 -1.59, -0.26 0.006 
Additional annual change in BI score per SD increase in TNFR1 
levels 
-0.36 -0.69, -0.03 0.03 
TNFR1=tumor necrosis factor receptor-1; BI=Barthel index; MI=myocardial infarction 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 








Table A7. Associations between standardized log of tumor necrosis factor receptor-1 protein 
levels and trajectories of functional status 
Variable Change in BI 
score 
95% CI p-value
Unadjusted model:    
Annual change in BI score -1.03 -1.12, -0.94 <.0001 
Change in BI score per SD increase in log of TNFR1 levels -2.36 -3.25, -1.48 <.0001 
Additional annual change in BI score per SD increase in log of 
TNFR1 levels 
-0.08 -0.21, 0.04 0.2 
Adjusted for demographics:*    
Annual change in BI score -1.02 -1.11, -0.93 <.0001 
Change in BI score per SD increase in log of TNFR1 levels -1.36 -2.20, -0.53 0.001 
Additional annual change in BI score per SD increase in log of 
TNFR1 levels 
-0.06 -0.18, 0.07 0.4 
Adjusted for vascular risk factors:**    
Annual change in BI score -1.03 -1.12, -0.94 <.0001 
Change in BI score per SD increase in log of TNFR1 levels -0.93 -1.76, -0.09 0.03 
Additional annual change in BI score per SD increase in log of 
TNFR1 levels 
-0.06 -0.19, 0.07 0.3 
Adjusted for social variables:†    
Annual change in BI score -1.02 -1.11, -0.93 <.0001 
Change in BI score per SD increase in log of TNFR1 levels -0.79 -1.64, 0.05 0.066 
Additional annual change in BI score per SD increase in log of 
TNFR1 levels 
-0.07 -0.19, 0.06 0.3 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.51 -0.73, -0.28 <.0001 
Change in BI score per SD increase in log of TNFR1 levels -0.56 -0.98, -0.13 0.01 
Additional annual change in BI score per SD increase in log of 
TNFR1 levels 
0.03 -0.26, 0.32 0.8 
Adjusted for stroke and MI:π    
Annual change in BI score -0.47 -0.67, -0.27 <.0001 
Change in BI score per SD increase in log of TNFR1 levels -0.63 -1.07, -0.18 0.006 
Additional annual change in BI score per SD increase in log of 
TNFR1 levels 
-0.18 -0.35, -0.002 0.047 
TNFR1=tumor necrosis factor receptor-1; BI=Barthel index; MI=myocardial infarction; SD=standard 
deviation 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 










Table A8. Associations between log of interleukin-6 levels and trajectories of functional status 
Variable Change in 
BI score 
95% CI p-value 
Unadjusted model:    
Annual change in BI score -0.98 -1.08, -0.89 <.0001 
Change in BI score per unit increase in log of IL6 levels -0.30 -0.61, 0.01 0.057 
Additional annual change in BI score per unit increase in log of 
IL6 levels 
-0.04 -0.11, 0.02 0.2 
Adjusted for demographics:*    
Annual change in BI score -0.99 -1.08, -0.90 <.0001 
Change in BI score per unit increase in log of IL6 levels -0.20 -0.51, 0.11 0.2 
Additional annual change in BI score per unit increase in log of 
IL6 levels 
-0.04 -0.11, 0.02 0.2 
Adjusted for vascular risk factors:**    
Annual change in BI score -0.99 -1.09, -0.90 <.0001 
Change in BI score per unit increase in log of IL6 levels -0.13 -0.44, 0.19 0.4 
Additional annual change in BI score per unit increase in log of 
IL6 levels 
-0.05 -0.11, 0.02 0.2 
Adjusted for social variables:†    
Annual change in BI score -0.98 -1.07, -0.89 <.0001 
Change in BI score per unit increase in log of IL6 levels -0.12 -0.44, 0.20 0.5 
Additional annual change in BI score per unit increase in log of 
IL6 levels 
-0.04 -0.11, 0.03 0.2 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.46 -0.61, -0.31 <.0001 
Change in BI score per unit increase in log of IL6 levels -0.09 -0.28, 0.10 0.3 
Additional annual change in BI score per unit increase in log of 
IL6 levels 
0.00 -0.09, 0.08 0.9 
Adjusted for stroke and MI:π    
Annual change in BI score -0.26 -0.42, -0.11 0.0009 
Change in BI score per unit increase in log of IL6 levels -0.16 -0.42, 0.11 0.2 
Additional annual change in BI score per unit increase in log of 
IL6 levels 
-0.09 -0.21, 0.02 0.11 
IL6=interleukin-6; BI=Barthel index; MI=myocardial infarction 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 










Table A9. Associations between standardized lipoprotein phospholipase-A2 mass levels and 
trajectories of functional status 
Variable Change in 
BI score 
95% CI p-value 
Unadjusted model:    
Annual change in BI score -0.98 -1.07, -0.89 <.0001 
Change in BI score per SD increase in LpPLA2 levels 0.18 -0.33, 0.69 0.5 
Additional annual change in BI score per SD increase in 
LpPLA2 levels 
-0.01 -0.10, 0.09 0.9 
Adjusted for demographics:*    
Annual change in BI score -0.98 -1.07, -0.89 <.0001 
Change in BI score per SD increase in LpPLA2 levels 0.10 -0.46, 0.66 0.7 
Additional annual change in BI score per SD increase in 
LpPLA2 levels 
-0.02 -0.11, 0.07 0.7 
Adjusted for vascular risk factors:**    
Annual change in BI score -0.98 -1.07, -0.90 <.0001 
Change in BI score per SD increase in LpPLA2 levels 0.01 -0.56, 0.59 0.96 
Additional annual change in BI score per SD increase in 
LpPLA2 levels 
-0.01 -0.11, 0.08 0.8 
Adjusted for social variables:†    
Annual change in BI score -0.97 -1.05, -0.88 <.0001 
Change in BI score per SD increase in LpPLA2 levels -0.07 -0.65, 0.50 0.8 
Additional annual change in BI score per SD increase in 
LpPLA2 levels 
0.00 -0.10, 0.09 0.9 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.54 -0.71, -0.38 <.0001 
Change in BI score per SD increase in LpPLA2 levels -0.35 -0.71, 0.00 0.052 
Additional annual change in BI score per SD increase in 
LpPLA2 levels 
0.07 -0.12, 0.27 0.4 
Adjusted for stroke and MI:π    
Annual change in BI score -0.43 -0.59, -0.27 <.0001 
Change in BI score per SD increase in LpPLA2 levels -0.40 -0.75, -0.04 0.03 
Additional annual change in BI score per SD increase in 
LpPLA2 levels 
0.08 -0.12, 0.28 0.4 
LpPLA2=lipoprotein phospholipase-A2; BI=Barthel index; MI=myocardial infarction; SD=standard 
deviation 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 







Table A10. Associations between lipoprotein phospholipase-A2 activity levels and trajectories of 
functional status 
Variable Change in 
BI score 
95% CI p-value 
Unadjusted model:    
Annual change in BI score -0.99 -1.07, -0.90 <.0001 
Change in BI score per unit increase in LpPLA2 levels 0.003 -0.003, 0.008 0.4 
Additional annual change in BI score per unit increase in 
LpPLA2 levels 
0.0002 -0.001, 0.0008 0.7 
Adjusted for demographics:*    
Annual change in BI score -0.99 -1.07, -0.90 <.0001 
Change in BI score per unit increase in LpPLA2 levels 0.004 -0.002, 0.01 0.2 
Additional annual change in BI score per unit increase in 
LpPLA2 levels 
-0.0003 -0.001, 0.0008 0.6 
Adjusted for vascular risk factors:**    
Annual change in BI score -0.99 -1.08, -0.90 <.0001 
Change in BI score per unit increase in LpPLA2 levels 0.002 -0.004, 0.01 0.5 
Additional annual change in BI score per unit increase in 
LpPLA2 levels 
-0.0002 -0.001, 0.0008 0.7 
Adjusted for social variables:†    
Annual change in BI score -0.98 -1.07, -0.90 <.0001 
Change in BI score per unit increase in LpPLA2 levels 0.002 -0.004, 0.01 0.5 
Additional annual change in BI score per unit increase in 
LpPLA2 levels 
-0.0003 -0.001, 0.0007 0.6 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.52 -0.68, -0.37 <.0001 
Change in BI score per unit increase in LpPLA2 levels 0.001 -0.003, 0.005 0.6 
Additional annual change in BI score per unit increase in 
LpPLA2 levels 
-0.0004 -0.002, 0.001 0.7 
Adjusted for stroke and MI:π    
Annual change in BI score -0.41 -0.56, -0.26 <.0001 
Change in BI score per unit increase in LpPLA2 levels 0.0006 -0.003, 0.004 0.7 
Additional annual change in BI score per unit increase in 
LpPLA2 levels 
-0.0003 -0.002, 0.001 0.7 
LpPLA2=lipoprotein phospholipase-A2; BI=Barthel index; MI=myocardial infarction 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 







Table A11. Associations between C-reactive protein and interleukin-6 dominant profiles and 
trajectories of functional status 
Variable Change in 
BI score 
95% CI p-value 
Unadjusted model:    
Annual change in BI score -1.03 -1.19, -0.86 <.0001 
Change in BI score with IL6-dominant profile€ -0.31 -1.63, 1.02 0.6 
Change in BI score with CRP-dominant profile€ -0.71 -2.02, 0.60 0.3 
Additional annual change in BI score with IL6-dominant 
profile€ 
0.00 -0.23, 0.23 0.98 
Additional annual change in BI score with CRP-dominant 
profile€ 
0.16 -0.06, 0.38 0.16 
Adjusted for demographics:*    
Annual change in BI score -1.04 -1.20, -0.87 <.0001 
Change in BI score with IL6-dominant profile€ 0.64 -0.75, 2.03 0.4 
Change in BI score with CRP-dominant profile€ -0.93 -2.32, 0.45 0.2 
Additional annual change in BI score with IL6-dominant 
profile€ 
0.02 -0.21, 0.24 0.9 
Additional annual change in BI score with CRP-dominant 
profile€ 
0.16 -0.07, 0.38 0.2 
Adjusted for vascular risk factors:**    
Annual change in BI score -1.04 -1.21, -0.88 <.0001 
Change in BI score with IL6-dominant profile€ 0.07 -1.33, 1.47 0.9 
Change in BI score with CRP-dominant profile€ -0.79 -2.16, 0.57 0.3 
Additional annual change in BI score with IL6-dominant 
profile€ 
0.03 -0.20, 0.25 0.8 
Additional annual change in BI score with CRP-dominant 
profile€ 
0.15 -0.07, 0.38 0.2 
Adjusted for social variables:†    
Annual change in BI score -1.04 -1.21, -0.88 <.0001 
Change in BI score with IL6-dominant profile€ 0.02 -1.35, 1.40 0.97 
Change in BI score with CRP-dominant profile€ -0.77 -2.13, 0.59 0.3 
Additional annual change in BI score with IL6-dominant 
profile€ 
0.06 -0.16, 0.28 0.6 
Additional annual change in BI score with CRP-dominant 
profile€ 
0.15 -0.08, 0.38 0.2 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.48 -0.72, -0.23 0.0001 
Change in BI score with IL6-dominant profile€ -0.35 -1.23, 0.52 0.4 
Change in BI score with CRP-dominant profile€ -0.01 -0.82, 0.80 0.98 
Additional annual change in BI score with IL6-dominant 
profile€ 
0.13 -0.27, 0.53 0.5 
Additional annual change in BI score with CRP-dominant 
profile€ 
-0.21 -0.69, 0.26 0.4 
Adjusted for stroke and MI:π    
Annual change in BI score -0.35 -0.60, -0.10 0.006 
Change in BI score with IL6-dominant profile€ -0.32 -1.20, 0.56 0.5 
Change in BI score with CRP-dominant profile€ 0.00 -0.80, 0.81 0.99 
Additional annual change in BI score with IL6-dominant 
profile€ 
0.04 -0.36, 0.44 0.8 
Additional annual change in BI score with CRP-dominant 
profile€ 
0.02 -0.40, 0.43 0.9 
CRP=C-reactive protein; IL6=interleukin-6; BI=Barthel index; MI=myocardial infarction 






*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 






Table A12. Mixed models results 
A) Model 1: ‘empty’ or ‘random intercept only’ model 
Covariance Parameter Estimates 
Cov Parm Subject Estimate Standard Error Z Value Pr > Z Alpha Lower Upper 
Intercept ID 134.91 3.9066 34.53 <.0001 0.05 127.57 142.90 
Residual   172.18 1.3071 131.73 <.0001 0.05 169.65 174.77 
 
Solution for Fixed Effects 
Effect Estimate Standard Error DF t Value Pr > |t|
Intercept 91.2782 0.2175 3297 419.65 <.0001
 
Fit Statistics 
-2 Res Log Likelihood 311566.7 
AIC (Smaller is Better) 311570.7 
AICC (Smaller is Better) 311570.7 
BIC (Smaller is Better) 311582.9 
 
B) Model 2: assessing fixed effect of time 
Solution for Fixed Effects 
Effect Estimate Standard Error DF t Value Pr > |t|
Intercept 99.3657 0.1650 3297 602.36 <.0001
FUF -1.6889 0.04769 3187 -35.41 <.0001
 
Fit Statistics 
-2 Res Log Likelihood 290708.1 
AIC (Smaller is Better) 290716.1 
AICC (Smaller is Better) 290716.1 
BIC (Smaller is Better) 290740.5 
 
C) Model 3: with time 
Fit Statistics 
-2 Res Log Likelihood 84898.5 
AIC (Smaller is Better) 84906.5 
AICC (Smaller is Better) 84906.5 
BIC (Smaller is Better) 84930.7 
 

















-2 Res Log Likelihood 85013.2 
AIC (Smaller is Better) 85021.2 
AICC (Smaller is Better) 85021.2 






Table A13. Linear adjusted mixed model with fixed linear time, random intercept, and covariates 
Variable Change in 
BI score 
95% CI p-value 
Intercept 64.38 60.95, 67.81 <.0001 
Annual change in BI score -0.62 -0.74, -0.51 <.0001 
Age at baseline, years -0.14 -0.17, -0.12 <.0001 
Male sex 0.32 -0.17, 0.80 0.2 
Black, compared to non-Hispanic White -0.80 -1.44, -0.17 0.014 
Hispanic, compared to non-Hispanic White 0.55 -0.09, 1.19 0.09 
Diabetes -0.68 -1.20, -0.16 0.01 
Hypertension 0.29 -0.21, 0.78 0.3 
Coronary artery disease 0.35 -0.18, 0.87 0.2 
Hypercholesterolemia 0.28 -0.16, 0.73 0.2 
Any physical activity 0.80 0.36, 1.24 0.0003 
Moderate alcohol use  -0.08 -0.55, 0.39 0.7 
Former smoker, compared to never -0.13 -0.60, 0.34 0.6 
Current smoker, compared to never 0.11 -0.53, 0.75 0.7 
Body mass index -0.03 -0.07, 0.01 0.17 
Married -0.50 -0.98, -0.02 0.04 
Medicaid or no insurance, compared to Medicare or private 
insurance 
-0.65 -1.15, -0.15 0.01 
Number of friends 0.15 -0.45, 0.74 0.6 
Depression 2.15 1.11, 3.19 <.0001 
Mini-mental state score 0.17 0.11, 0.24 <.0001 
Spitzer quality of life index score 4.20 4.09, 4.30 <.0001 







Table A14. Linear adjusted mixed model with fixed linear time, random intercept, and covariates, 
with aging variable as time trend 
Variable Change in 
BI score 
95% CI p-value 
Intercept 66.04 62.63, 69.44 <.0001 
Annual change in BI score, per year of age -0.16 -0.19, -0.14 <.0001 
Male sex 0.29 -0.20, 0.78 0.2 
Black, compared to non-Hispanic White -0.87 -1.51, -0.23 0.007 
Hispanic, compared to non-Hispanic White 0.40 -0.23, 1.04 0.2 
Diabetes -0.68 -1.20, -0.16 0.01 
Hypertension 0.36 -0.14, 0.85 0.16 
Coronary artery disease 0.41 -0.11, 0.93 0.12 
Hypercholesterolemia 0.27 -0.17, 0.71 0.2 
Any physical activity 0.74 0.31, 1.18 0.0008 
Moderate alcohol use  -0.11 -0.57, 0.36 0.7 
Former smoker, compared to never -0.13 -0.61, 0.34 0.6 
Current smoker, compared to never 0.02 -0.62, 0.66 0.9 
Body mass index -0.04 -0.08, 0.005 0.08 
Married -0.54 -1.03, -0.06 0.03 
Medicaid or no insurance, compared to Medicare or private 
insurance 
-0.69 -1.19, -0.19 0.007 
Number of friends 0.08 -0.51, 0.68 0.8 
Depression 2.11 1.07, 3.15 <.0001 
Mini-mental state score 0.15 0.09, 0.22 <.0001 
Spitzer quality of life index score 4.23 4.13, 4.34 <.0001 







Table A15. Adjusted linear mixed models testing associations between levels of inflammatory 
biomarkers and trajectories of functional status* 
Variable Change in BI 
score 
95% CI p-value 
CRP model:    
Annual change in BI score -0.47 -0.62, -0.31 <.0001 
Change in BI score per unit increase in log of CRP levels -0.42 -0.71, -0.14 0.004 
Additional annual change in BI score per unit increase in 
log of CRP levels 
-0.01 -0.15, 0.14 0.9 
TNFR1 model:    
Annual change in BI score -0.54 -0.70, -0.37 <.0001 
Change in BI score per unit increase in log of TNFR1 levels -1.05 -1.40, -0.70 <.0001 
Additional annual change in BI score per unit increase in 
log of TNFR1 levels 
-0.43 -0.62, -0.23 <.0001 
IL6 model:    
Annual change in BI score -0.35 -0.54, -0.16 0.0004 
Change in BI score per unit increase in log of IL6 levels -0.20 -0.41, 0.004 0.055 
Additional annual change in BI score per unit increase in 
log of IL6 levels 
-0.13 -0.24, -0.02 0.02 
LpPLA2 mass model:    
Annual change in BI score -0.48 -0.64, -0.32 <.0001 
Change in BI score per unit increase in LpPLA2 mass 
levels 
-0.36 -0.68, -0.04 0.03 
Additional annual change in BI score per unit increase in 
LpPLA2 mass levels 
0.10 -0.05, 0.26 0.2 
LpPLA2 activity model:    
Annual change in BI score -0.43 -0.99, 0.13 0.13 
Change in BI score per unit increase in LpPLA2 activity 
levels 
0.0007 -0.003, 0.004 0.7 
Additional annual change in BI score per unit increase in 
LpPLA2 activity levels 
-0.0001 -0.002, 0.002 0.9 
CRP=C-reactive protein; TNFR1=tumor necrosis factor receptor-1; IL6=interleukin-6; LpPLA2=lipoprotein 
phospholipase-A2; BI=Barthel index; MI=myocardial infarction 
*All models are adjusted for: baseline age, sex, race-ethnicity, diabetes, hypertension, coronary artery 
disease, hypercholesterolemia, physical activity, alcohol use, smoking, body mass index, marital status, 
insurance, number of friends, depression, mini-mental state score, Spitzer quality of life index, and stroke 







Table A16. Analysis of inflammatory biomarkers as mediating factors* 
Variable Change in 
BI score 
95% CI p-value 
Model without any biomarker:    
Annual change in BI score -0.42 -0.51, -0.32 <.0001 
QIC value 12433 
CRP model:    
Annual change in BI score -0.39 -0.53, -0.26 <.0001 
Change in BI score per unit increase in log of CRP 
levels 
-0.41 -0.82, 0.002 0.051 
Additional annual change in BI score per unit increase 
in log of CRP levels 
0.05 -0.06, 0.16 0.4 
QIC value 7625.7 
TNFR1 model:    
Annual change in BI score -0.52 -0.73, -0.31 <.0001 
Change in BI score per unit increase in TNFR1 levels -0.93 -1.60, -0.26 0.007 
Additional annual change in BI score per unit increase 
in TNFR1 levels 
-0.36 -0.69, -0.03 0.03 
QIC value 6351.9 
IL6 model:    
Annual change in BI score -0.26 -0.42, -0.11 0.0009 
Change in BI score per unit increase in log of IL6 levels -0.16 -0.42, 0.11 0.2 
Additional annual change in BI score per unit increase 
in log of IL6 levels 
-0.09 -0.21, 0.02 0.11 
QIC value 5498.2 
LpPLA2 mass model:    
Annual change in BI score -0.43 -0.59, -0.27 <.0001 
Change in BI score per unit increase in LpPLA2 mass 
levels 
-0.40 -0.76, -0.04 0.03 
Additional annual change in BI score per unit increase 
in LpPLA2 mass levels 
0.08 -0.12, 0.28 0.4 
QIC value 6410 
LpPLA2 activity model:    
Annual change in BI score -0.32 -0.93, 0.29 0.3 
Change in BI score per unit increase in LpPLA2 activity 
levels 
0.006 -0.003, 0.004 0.7 
Additional annual change in BI score per unit increase 
in LpPLA2 activity levels 
-0.0003 -0.002, 0.001 0.7 
QIC value 6507.6 
CRP=C-reactive protein; TNFR1=tumor necrosis factor receptor-1; IL6=interleukin-6; LpPLA2=lipoprotein 
phospholipase-A2; BI=Barthel index; MI=myocardial infarction 
*All models are adjusted for: baseline age, sex, race-ethnicity, diabetes, hypertension, coronary artery 
disease, hypercholesterolemia, physical activity, alcohol use, smoking, body mass index, marital status, 
insurance, number of friends, depression, mini-mental state score, Spitzer quality of life index, and stroke 
















Figure A2. Distributions of raw and transformed inflammatory biomarkers 
A) C-reactive protein 
 
 











D) Interleukin-6: the graph is truncated, with only IL-6 levels <50 shown 
 
 








F) Tumor necrosis factor receptor-1 
 
 
G) log of tumor necrosis factor receptor 
 
 










































Background: Stroke is associated with chronic functional decline, but it is unclear whether subclinical 
brain infarcts (SBI) and white matter hyperintensities (WMH) predict functional decline independently of 
vascular events.   
Methods:  In the Northern Manhattan Study, 1290 stroke-free individuals underwent brain MRI and a 
median of 11 years annual functional assessments with Barthel index (BI; range 0-100) and vascular 
event surveillance.  WMH volume (% total cranial volume) was treated continuously.  Generalized 
estimating equation models tested associations between WMH and SBI, and BI, adjusting for 
demographic, vascular, cognitive, and social risk factors, and stroke and myocardial infarction during 
follow-up. 
Results: Mean age was 70.6 (SD 9.0) years, 40% of participants were male, 66% Hispanic; 193 (16%) 
had SBI; and mean WMH was 0.68 (SD 0.84).  Functional change was -0.85 BI points per year (95%CI -
1.01 to -0.69); among those with SBI there were -0.88 additional points annually (-1.44 to -0.32).  In WMH 
models, annual functional change was -1.04 points (-1.2 to -0.88), with -0.74 additional points annually 
per SD WMH increase (-0.99 to -0.49).   
Conclusions: Subclinical ischemic brain injury predicts doubling of decline in function over time, 








Subclinical infarcts are discrete brain infarcts that by definition are not associated with discrete events but 
are rather detectable only by brain imaging.  Similarly, white matter disease generally refers to areas of 
white matter structural damage in the brain due to vessel dysfunction, which are only detectable by brain 
imaging.  Strikingly, subclinical infarcts have been found to be at least 5 times as prevalent as clinical 
strokes, suggesting that a focus on discrete clinical stroke events reveals only the tip of the iceberg of the 
burden of cerebrovascular disease.50 White matter hyperintensities (WMHs) were present in 96% of 
individuals older than 60 years of age in CHS and in 95% in the Rotterdam Scan Study.53 Silent acute 
infarcts have also been detected in up to 4.2% of individuals with dementia in previous studies.54  
Traditional vascular risk factors and inflammatory states cause subclinical infarcts and WMH in 
addition to recurrent clinically evident strokes.  The vascular causes of worsening white matter grade 
have been shown to have a differential impact depending upon initial grade.57 In the Rush Memory and 
Aging Project, there was an association between greater WMH volume (WMHV) and lower motor function 
among those with average and low physical activity.58 The progression of white matter lesions over time 
has not been found to have a significant genetic component, and it is likely that behavioral and 
environmental factors, as well as medical conditions, have a more causative role.59 
Subclinical infarcts and WMHs have been associated with the occurrence of “hard” vascular 
outcomes and mortality in multiple studies, including stroke.60, 61, 65, 66 and longevity.62 Subclinical infarcts 
and WMHs have also been associated with cognitive impairment68, 69 and reduced functional status over 
the long term.50, 70 White matter disease may mediate the relationship between hypertension and 
disability.71 Even in younger individuals free of cardiovascular disease but at risk due to a family history of 
early cardiac disease, white matter lesion burden was inversely associated with manual dexterity (as 
measured by the Grooved Pegboard test).72 When regional WMHV was tested separately in adjusted 
models, this association was also seen for WMHV in each brain lobe except for the temporal and occipital 
lobes.  Asymptomatic brain MRI abnormalities, including WMHs and infarcts, have been associated with 
functional impairment cross-sectionally,73 at 3 months,74 and over 4 years of follow-up.70 In a case-control 
study performed in Singapore, the burden of small vessel disease and large vessel disease was 






impairment and 94 controls.75 A higher cerebrovascular disease score was associated with worse 
cognitive function.  WMHV was associated with global deficits and cerebral microbleeds were associated 
with domain-specific deficits.  In the Leukoaraiosis and Disability study,76 among 633 older individuals 
over 2.4 years of follow-up, 29.5% of those with severe WMHV transitioned to death or disability, 
compared to 10% with mild WMHV.  Also, cognitive decline was seen among those who had increase in 
WMHV over time.  In a prior analysis using the MRI cohort of NOMAS,77 in an adjusted model, WMHV 
was associated with poorer episodic memory, processing speed, and semantic memory.  Among those 
above the median age, WMHV was associated with poorer episodic and semantic memory. 
  Despite these prior studies, the influence of SBI and WMHV on longitudinal trajectories of 
functional status is not well delineated.  We hypothesized that SBI and increasing volumes of cerebral 
white matter disease independently predicted worse baseline functional status and slope of change over 
time in those free of stroke at baseline.  We studied these hypotheses in the Northern Manhattan Study 
(NOMAS) in an MRI substudy.   
 
Methods 
The NOMAS MRI study is a substudy of the prospective cohort that began in 2003 and included 
individuals: 1) older than age 50 years, 2) without contraindications to MRI, 3) without clinical stroke and 
4) able to provide signed informed consent. Baseline characteristics of the MRI cohort (n=1290) are 
similar to the overall NOMAS prospective study.  Each participant received a comprehensive battery of 
standardized neuropsychological tests at entry. Imaging was performed on a 1.5T MRI system (Philips 
Medical Systems, Best, Netherlands), including the following sequences: axial T1, axial T2, axial proton 
density, dual-spin echo, diffusion weighted imaging, and FLAIR. After image acquisition, data were 
transferred to the University of California at Davis for morphometric analysis of TCV and WMHV using T1 
and fluid-attenuated inversion recovery sequences.77 The images are now stored at Columbia and at the 
University of Miami and have been further processed by Dr. Clinton Wright for more advanced 
categorization of WMH and silent brain infarcts (SBI). An operator traced dura mater, and non-brain 
structures were manually removed from images. Total cranial volume (TCV) constituted the sum of whole 






≥3.5 standard deviations above the mean image intensity multiplied by pixel dimensions and section 
thickness.”77  
The FreeSurfer image analysis software (version 5.1) was used to perform volumetric 
segmentation of lobar gray matter (GM) volumes and hippocampal volumes.  As previously described, “all 
T1-weighted MRIs underwent motion correction, skull stripping, and transformations into Talaraich space 
before segmentation, identification of gray/white matter boundaries, automated topology correction, and 
surface deformation. Through 3-dimensional segmentation methods, neuroanatomic labels for regional 
white matter and cortical GM parcellations were assigned to each voxel using a probabilistic atlas and 
Bayesian classification rule. FreeSurfer provides an estimate of hippocampal volume, and 68 cortical GM 




Two datasets were used in this analysis, the “original” dataset and “new” dataset.  In the original dataset, 
total WMH volumes were calculated after correcting for TCV and were treated as a continuous (log 
transformed) and categorical variable (quartiles) consistent with previous analyses in NOMAS.206-208 SBIs 
were defined as lesions greater than 3 mm in size, distinct from the circle of Willis in the basal ganglia, 
and of similar intensity as cerebrospinal fluid. The location and size of SBIs were recorded.209 In the new 
dataset, according to personal communication from Jose Gutierrez, MD, who read the images: “All T1 
axial sequences were analyzed systematically. First, we rated small voids (i.e. parenchymal 
hypodensities) of < 5 mm in axial diameter without associated FLAIR hyperintensities as small 
perivascular spaces (SPVS). Due to the high number of SPVS observed and the inability to accurately 
count each of them, a semi-quantitative score was created. The extent of SPVS by anatomical brain 
region was rated as 0=No SPVS voids, 1=1-3 voids, 2=4 or more voids in each of 12 anatomical brain 
regions. The total SPVS score was created by adding the subscores for each of the 12 anatomical 
regions. This method has good to excellent reliability.  Parenchymal voids observed in 3D T1 and FLAIR 
sequences with a diameter of > 5 mm were individually characterized for the purpose of classifying them 






putamen and anterior perforating substance, upper two thirds of putamen, anterior limb of internal 
capsule, thalamus, head of the caudate, globus pallidus, subinsular cortex, the frontal, parietal, temporal 
(including the hippocampus) and occipital white matter. Brainstem areas included the midbrain, pons, 
medulla, middle cerebellar peduncle and the cerebellum. Each hypodensity was measured in its longest 
axial diameter and perpendicularly to it. The number of axial images in which the same void was 
observed was used to calculate the vertical diameter (# slices x slice thickness). The void volume was 
calculated with the abc/2 formula used to obtain the volume of ellipsoid bodies.  Using a cutoff of 5 mm in 
axial images yielded a minimum effective diameter of 3 mm typically used to differentiate small from large 
perivascular spaces or infarcts.  We also noted the appearance of large hypointensities on the FLAIR 
sequence, such as cavitation (defined by a corresponding FLAIR hypointensity as compared to the brain 
parenchyma intensity), lack of cavitation (defined by isointensity), and white matter hyperintensity (WMH, 
defined by a hyperintense lesion) as well as the presence and extent of a hyperintense rim around each 
cavitated void (thick, equivocal or absent). Finally, we rated the intensity of each void on proton density 
images as hypointense, isointense or hyperintense in respect to the lateral ventricle CSF. The collection 
of these data was performed blindly to demographic or clinical information, and the rater did not define 
whether the hypointensities were compatible with a LPVS or a LI at the time of the readings.”  
 Location of SBI was recorded according to specific brain region, and then recoded according to 
cortical or subcortical location.  Lacunar infarct location was categorized into cortical, subcortical, and 
brainstem.   
 
Covariates  
All analytic models were adjusted for the following variables: age, sex, body mass index (body weight in 
kilograms divided by the square of height in meters), self-reported hypercholesterolemia, diabetes 
mellitus (defined by self-report, fasting blood glucose level >126 mg/dL, or insulin/oral hypoglycemic use), 
hypertension (defined as a systolic blood pressure recording >140 mmHg or a diastolic blood pressure 
recording >90 mm Hg based on the average of two blood pressure measurements or the patient's self-
report of a history of hypertension or antihypertensive use), smoking (defined as either nonsmoker or 






drinks/day), social variables (marital status, insurance status [classified as uninsured, Medicaid, 
Medicare, or private insurance], number of friends [individuals whom the participant knows well enough to 
visit in their homes], years living in the community), and cognitive factors (depressed mood, and 
performance on mini-mental state examination [analyzed as a continuous variable]).   
 
Statistical analysis 
The goal of this analysis was to determine whether increasing volumes of cerebral white matter disease 
and SBI are associated with BI and a steeper slope of decline.  Each outcome was analyzed in separate 
models, using an approach similar to that outlined under Statistical Analysis in Analysis A above.   
A sensitivity analysis was performed among those with BI 95 or 100 at ‘baseline’: for 1087 
individuals, this is the ADL measurement closest to and prior to the MRI date.  For 193 others (largely 
Household Members, those enrolled at a later date and identified as members of the household of 
subjects already enrolled), this was the ADL measurement at the time of MRI.  The number of those with 
BI 95 or 100 at ‘baseline’ was 267 + 869 = 1136 (see Appendix B7 for distribution of baseline BI scores). 
A basic mediation analysis was performed, testing whether imaging findings mediated the effect 
of diabetes and insurance status.  For this analysis, all functional measures, before and after MRI, were 
included.  There were 9210 (53.2%) BI assessments performed before MRI and 8089 (46.8%) performed 
after MRI.  Changes in the magnitude of the effect estimates for diabetes and insurance were calculated 
when each MRI variable was included in fully adjusted models.  A change in magnitude of 10% was 
deemed to represent meaningful mediation.   
The association between location of SBI (cortical, subcortical, and both) and trajectories of 
functional status was examined in separate models as well as with a multi-level categorical location 
variable in a single model.   
Among those with inflammatory biomarker data in the MRI cohort, a basic mediation analysis was 
performed testing whether MRI evidence of ischemic injury mediated the association between 
inflammatory biomarkers and functional status.  First, the distributions of inflammatory biomarkers in the 
MRI cohort were examined.  Then, the magnitude of the effect estimates for each biomarker was 






The influence of cognition, measured by the MMSE, on functional status was examined in several 
ways.  The association between MMSE and overall functional status was examined, as well as the 
association with change in functional status over time.  Next, interaction with education was examined by 
including interaction terms between MMSE and education in the model.  Two-way interactions between 
MRI variables and MMSE were examined as well as 3-way interactions among these variables and time.   
Due to potential mismeasurement in the hypercholesterolemia variable related to inclusion of 
statin treatment in the variable definition, the levels of cholesterol subtypes were used in place of the 
hypercholesterolemia variable in secondary analyses.  Apolipoprotein E (APOE) status was adjusted for, 
and APOE status was not associated with change in BI or slope of change in BI over time (results not 
shown).   
 
Results 
Table B1 compares the distributions of baseline variables among those in the MRI cohort to those in the 
prospective cohort who were not in the MRI cohort.  Those in the MRI cohort were younger, more often 
male, Hispanic, married, and covered by Medicare, and had more social support.  Those in the MRI 
cohort also had a more favorable vascular risk profile, with lower prevalence of hypertension, diabetes, 
and coronary artery disease, and had overall lower levels of inflammatory biomarkers.  There was a mean 
of 6.1 (SD 3.4) years between baseline enrollment into NOMAS and time of MRI (Appendix B4).  
Appendix B7 shows the distribution of baseline BI score (soonest BI measurement at or after MRI) in the 
MRI cohort; there were 1136 (88.8%) with a score of 95 or 100 at baseline.  In the original dataset, 
among 1238 individuals with data on SBI, there were 193 (15.6%) with SBI and 1045 (84.4%) without.  
Table B2 shows the distribution of number of SBI per individual, showing a skewed distribution with most 
individuals having no SBI.  According to the new dataset (Appendix B2), 244 (20.2%) had SBI (A), 508 
(42.1%) had at least one large perivascular space (B and C), 215 (17.8%) had at least one lacunar infarct 
(D and E), and most individuals had a total perivascular space score of 4 (193, 16.0%), with a range of 0-
22 (F).   
Appendix B1 shows the distributions of brain locations for SBIs in the original dataset, first by 






individuals, 83 (6.7%) had cortical/superficial SBI location, 88 (7.1%) had subcortical SBI, and 22 (1.8%) 
had both.   Appendix B3 summarizes the location of lacunar infarcts in the new dataset.  There were 109 
subcortical, 255 cortical, and 13 brainstem lacunar infarcts (C).  Out of the entire MRI cohort, there were 
117 (9.1%) with cortical SBI, 53 (4.1%) with subcortical SBI, and 44 (3.4%) with both (D).   
Table B3 and Figure B1 show the distributions of white matter hyperintensity volume, shown as 
raw volumes as well as adjusted for total cranial volume.  The adjusted volume (WMHV as % of total 
cranial volume) was used in all analyses presented here.  The mean of the maximum follow-up time per 
person, from time of MRI to last follow-up assessment, was 7.30 years (SD 2.06, median 7.42 years).   
 As shown in Table B4, the presence of SBI was strongly and consistently associated with 
accelerated decline in function over time, with the magnitude of the association varying little between the 
unadjusted model (-1.10 BI points per year, 95% CI -1.64, -0.56) and the full adjusted model (-0.88, 95% 
CI -1.43, -0.32).  SBI was not associated with change in overall functional status.  SBI had a similar effect 
on mobility and non-mobility domains of the BI (Appendix B9), proportional to the portion of the BI 
comprising each domain.   
Similarly, adjusted WMHV was associated with accelerated functional decline, with -0.82 
additional BI points per year (95% CI -1.06, -0.57) per unit increase in WMHV in an unadjusted model and 
-0.74 additional points per year (95% CI -0.99, -0.49) in a fully adjusted model (Table B5).  Adjusted 
WMHV had a similar effect on mobility and non-mobility domains of the BI (Appendix B10), proportional to 
the portion of the BI comprising each domain.   
Using the recent re-definition of SBI (‘new’ dataset), results were similar (Table B6), with -1.00 
additional BI points per year (95% CI -1.49, -0.51) with SBI in an unadjusted model, and -0.89 additional 
points per year (95% CI -1.42, -0.36) in a fully adjusted model.  SBI had a similar effect on mobility and 
non-mobility domains of the BI (Appendix B11), proportional to the portion of the BI comprising each 
domain.   
In contrast, there were no significant associations between overall BI, change in BI over time, and 
large perivascular spaces (LPVS) in unadjusted or adjusted models, either with a dichotomous definition 
of LPVS (Table B7) or one that incorporated the number of LPVS per individual (Table B8).  Similarly, 






overall BI score or change in BI over time, in unadjusted or adjusted models, and when mobility and non-
mobility domains of the BI were tested separately (Appendix B14).     
There was a significant and consistent association between presence of lacunar infarcts and 
accelerated decline in functional status over time (Table B10), with a change of -1.20 BI additional points 
per year (95% CI -1.74, -0.66) with lacunar infarcts in an unadjusted model, and -1.11 points per year 
(95% CI -1.69, -0.53) in a fully adjusted model.  Results were similar when the number of lacunar infarcts 
was tested (Table B11 and Appendix B8), with an additional decline of -0.40 points per year (95% CI -
0.72, -0.08) with each additional lacunar infarct.  Presence of lacunar infarct had a similar effect on 
mobility and non-mobility domains of the BI (Appendix B12), and the number of lacunar infarcts had a 
similar effect (Appendix B13), proportional to the portion of the BI comprising each domain.   
 Sensitivity analysis was performed among those with BI score of 95 or 100 at baseline (n=1136, 
Appendix B15).  Although the magnitude of overall decline and the magnitude of additional decline with 
MRI variables were both slightly reduced in most models, there were still highly significant associations 
paralleling the findings in models among the entire cohort.  For example, SBI as defined in the original 
dataset was associated with additional decline of -0.88 points per year (95% CI -1.44, -0.32) in the entire 
cohort and -0.79 points per year (95% CI -1.34, -0.24) among those with BI of 95 or 100 at baseline.   
Table B12 shows results from an analysis testing whether MRI findings mediate the effect of 2 
variables on functional status: diabetes and insurance status.  For SBI (original and new definitions), 
WMHV, and lacunar infarct, addition of the MRI variable reduced the effect estimate for diabetes by about 
4%.  SPVS did not reduce the effect for diabetes.  For all variables except WMHV, adding the MRI 
variable reduced the effect estimate for Medicaid or insurance (versus Medicare or private insurance) by 
around 15%, and adding WMHV reduced the effect estimate by 25%.   
Table B13 shows models testing the association between location of SBI and functional status.  
The original dataset was examined first.  When tested in separate models, superficial (or cortical) SBI 
location (-0.79 points per year, 95% CI -1.63, 0.06) and subcortical location (-1.11, 95% CI -1.81, -0.41) 
were both associated with accelerated decline in functional status over time, but not with overall BI score.  
When tested in the same model, subcortical location was associated with accelerated decline over time (-






0.38), and neither was associated with overall BI score.  Individuals with both cortical and subcortical SBI 
had more than double the additional decline in functional status than those with subcortical SBI alone (-
2.68 points per year, 95% CI -5.03, -0.32).  When the new dataset was examined, cortical (-0.95 points 
per year, 95% CI -1.72, -0.17) and subcortical (-1.35, 95% CI -2.37, -0.33) SBI were individually 
associated with accelerated decline in functional status over time, and there was a trend for an 
association of similar magnitude with both cortical and subcortical SBI (-1.23, 95% CI -2.63, 0.17).   
A series of models tested whether MRI evidence of ischemic injury mediated the association 
between inflammatory biomarkers and functional status.  Appendix B5 summarizes the distributions of 
inflammatory biomarkers (CRP, TNFR1, IL6, and LpPLA2 mass and activity) among those with biomarker 
data in the MRI cohort (ranging from 610 individuals with IL6 values to 792 with CRP values).  Appendix 
B6 compares the distributions of baseline characteristics between those in the MRI cohort with at least 
one inflammatory biomarker result (911 [70.6%]) to those without any biomarker result (368 [29.4%]).  
The only substantive difference in vascular risk factor profile was a higher prevalence of 
hypercholesterolemia among those with biomarker data compared to those without (64.5% vs. 55.2%).  
As shown in Table B14, CRP was not associated with overall function or change in functional status over 
time, but log of CRP levels was associated with accelerated decline in functional status over time.  
However, adding either SBI or WMHV to the model did not appreciably change this estimate, suggesting 
no significant mediation effect.  There was a similar pattern when the new definition of SBI was examined 
(Table B18).  IL6 and log of IL6 levels were not significantly associated with overall function or change in 
functional status over time in unadjusted or adjusted models, limiting the evaluation of mediation by MRI 
variables (Tables B15 and B19).  TNFR1 levels were associated with additional decline in BI over time in 
unadjusted and adjusted models (Table B16), but the addition of SBI or WMHV did not appreciably 
change the effect estimate for this association.  There was a similar pattern when the new definition of 
SBI was used (Table B20).  LpPLA2 mass and activity levels were not associated with overall function or 
change in function over time in unadjusted or adjusted models, limiting the evaluation of mediation by 
MRI variables (Table B17).  When the association between inflammatory biomarkers and MRI variables 
was examined (Table B21), no significant associations were found for any of the examined biomarkers as 






Next, the influence of cognition -- as measured by the mini-mental state examination score 
(MMSE) -- on functional status was examined (Table B22).  Higher MMSE was associated with better 
functional status (0.22 BI points per point of MMSE in the MRI cohort, 95% CI 0.08, 0.35), and when 
effect of MMSE on slope of functional change was examined, MMSE was associated with a more 
favorable slope of decline over time (0.04 BI points per year, 95% CI 0.02, 0.06) but not overall function.  
In the entire cohort but not the MRI cohort, MMSE was associated with more favorable slope of functional 
decline in those with high school education, compared to those without (0.06 BI points per year, 95% CI 
0.01, 0.11).   
Sensitivity analysis was also done without BMI in models, due to possible correlation between 
BMI and hypercholesterolemia, which found no substantive differences in results (results not shown).  
Also, in secondary analysis, the levels of cholesterol subtypes were examined in place of the 
hypercholesterolemia variable, and there were no substantive changes in the estimates for the main 
predictors (results not shown).   
The interactions among SBI, cognition, and functional status were further examined in the original 
dataset in fully adjusted models (Table B23).  In a model without interaction terms with time, SBI was 
associated with lower function (-2.63 BI points, 95% CI -4.87, -0.39) and higher MMSE scores were 
associated with higher functional status (0.28, 95% CI 0.06, 0.51).  When interaction with time was 
examined, SBI was associated with an additional -0.88 points of decline (95% CI -1.44, -0.32) over time, 
and MMSE was associated with 0.05 BI points per year (95% CI -0.01, 0.10) per point of MMSE.  There 
was no significant interaction between SBI and MMSE.  However, when 3-way interactions with time were 
examined, there was an annual decline in function overall (-0.89 BI points per year, 95% CI -1.06, -0.71), 
an additional -0.77 points of decline (95% CI -1.31, -0.24) per year in those with SBI, a reduced slope of 
decline with highest MMSE scores (0.07 BI points per year, 95% CI 0.02, 0.13), and a steeper decline in 
functional status per point of MMSE in those with SBI (-0.18 BI points per year, 95% CI -0.32, -0.04).  
When interactions among WMHV, cognition, and functional status were examined (Table B24), 2-way 
and 3-way interactions among time, MMSE, and WMHV were not significant in final models.   
Interactions among cognition, SBI, and functional status were also examined in the new dataset 






with 0.24 BI points (95% CI 0.04, 0.45) on average.  When interactions with time were examined, SBI was 
associated with an additional -0.90 BI points per year (95% CI -1.43, -0.36) and MMSE was associated 
with 0.05 additional BI points per year (95% CI -0.004, 0.11).  In the final model testing 3-way 
interactions, SBI was associated with accelerated functional decline (-0.80 BI points per year, 95% CI -
1.32, -0.29), MMSE was associated with reduced decline (0.07 BI points per year, 95% CI 0.01, 0.13), 
and there was a steeper decline in functional status per point of MMSE in those with SBI (-0.15 BI points 
per year, 95% CI -0.28, -0.02).   
A similar pattern of associations was seen when lacunar infarcts (LI) were tested (Table B26).  In 
the final model testing 3-way interactions, presence of lacunar infarct was associated with accelerated 
functional decline of -1.03 BI points per year (95% CI -1.60, -0.46), MMSE was associated with reduced 
decline (0.07 BI points per year, 95% CI 0.01, 0.13), and there was a steeper decline in functional status 
per point of MMSE in those with LI (-0.15 BI points per year, 95% CI -0.29, -0.01).   
 
Conclusions for Analysis B 
The MRI sub-study of NOMAS is a large sub-cohort with unique MRI imaging data on participants.  Since 
individuals from the prospective cohort of NOMAS were enrolled into the MRI sub-study on average 6.1 
years from enrollment into NOMAS, the MRI sub-study participants were comparatively younger and 
healthier, and 88.8% were functionally normal (BI score of 95 or 100) at the time of MRI.  Despite healthy 
risk factor profiles and good functional status, 15.6-20.2% had SBI on imaging, depending on the 
classification system used.  According to the original classification system, SBI location was evenly 
divided between subcortical (7.1%) and cortical (6.7%) location, whereas with the new classification 
system there were more cortical (9.1%) than subcortical (4.1%) SBI, and more with both (3.4%) compared 
to the original system (1.8%).  Due to these discrepancies, we present data using both classification 
systems.  For WMHV, the mean value was 0.7% of TCV, with a range up to 6.2%.  Although less than the 
entire prospective cohort, the mean follow-up time in the MRI sub-study was 7.3 years, which allowed 
robust estimation of long-term trajectories of functional status after MRI.   
 Using different measures of SBI, we found a strong, consistent, independent, and significant 






annual decline in function due to aging.  This was seen with both the original and new classification 
system, with WMHV (per unit increase), and when mobility and non-mobility domains of the BI were 
examined as separate outcomes.  This pattern of association was seen with MRI imaging markers 
believed to be caused by vascular impairment (SBI, lacunar infarcts, and WMHV) but not with other MRI 
structural findings, such as LPVS, which are not believed to be caused directly by a primary vascular 
pathology.  There was a greater decline in functional status with increasing number of SBIs and lacunar 
infarcts, reflecting a dose-response relationship that supports biological plausibility of the association.  
Also, these associations were seen even among those with no disability at baseline (BI of 95 or 100), 
which emphasizes the “silent” or “subclinical” nature of these predictors, and yet their strong predictive 
power on trajectories of functional status.   
 The causal relationship between MRI findings of subclinical ischemic brain injury and functional 
decline must be further elucidated.  We began to test this relationship by assessing the mediating effect 
of MRI findings (measured on average 6.1 years after baseline assessment) with baseline diabetes and 
insurance status, two factors that have been demonstrated to be strong predictors of functional decline in 
this cohort.  Indeed, the addition of MRI markers of subclinical ischemic damage (SBI, lacunar infarct, and 
WMHV) reduced the effect size for diabetes by about 4%, and reduced the effect size for insurance status 
by 15-25%.  Hence, part of the effects of diabetes and insurance status on functional status may be to 
cause subclinical ischemic brain injury, which would only be apparent if an MRI were done to image this 
injury.   
 We found evidence for a relationship between location of SBI and accelerated functional decline 
over time, but patterns were not consistent with different measurements of SBI.  Using the original 
classification of SBI, subcortical but not cortical location was associated with accelerated decline over 
time, and presence of SBI in both locations was associated with the most decline.  With the new 
classification system, the magnitude of additional decline over time with cortical and subcortical SBI was 
similar, and presence of SBI in both locations was not associated with any incremental decline over time.  
 We examined the interrelationships among inflammatory biomarkers, MRI imaging findings, and 
trajectories of functional status.  Inflammatory biomarkers were measured at study enrollment, and MRI 






subclinical brain ischemic injury on the association between inflammatory states and functional status.  
However, no significant mediating effect was seen for any of the inflammatory biomarkers or MRI 
measures.   
 There are well-known associations among cognitive status, education level, and functional status, 
and we examined these relationships in this analysis as well.  We found a significant association between 
higher cognitive level and improved function, even when adjusting for SBI.  Higher cognitive performance 
was also associated with reduced slope of decline over time in functional status, but when 3-way 
interactions with time were tested, among those with SBI, there was an inverse relationship between 
cognition and decline in functional status.  This was true in the original dataset as well as the new 
dataset, and with lacunar infarcts as well as SBI.     
 Strengths of this study include the large population-based cohort, the accurate assessment of 
events during follow-up, minimal loss to follow-up, the use of state-of-the-art imaging and measurement of 
subclinical brain vascular disease, and the repeated measures of functional outcomes that allow 
trajectory analysis.  A limitation of this analysis is that, in the MRI substudy, participants were recruited 
from the prospective cohort and most often obtained MRI imaging during follow-up instead of at baseline.  
The MRI cohort selects individuals who will be able to return for follow up and imaging and may reflect a 
healthy survivor bias, which may reduce power to detect declines in functional status.  







Table B1. Baseline characteristics of the cohort, comparing MRI to non-MRI subjects: 
Variable MRI cohort Non-MRI 
cohort 
p-value 
Number of participants, No. (%) 1290 (36.9) 2208 (63.1) - 
Biological characteristics:    
Age, mean (SD), y 64.5 (8.4) 72.2 (10.3) <0.0001 
Body mass index, mean (SD), kg/m2 28.0 (4.8) 27.8 (5.9) 0.4 
    
Demographics:    
Male, No. (%) 510 (39.5) 790 (35.8) 0.03 
Race-ethnicity: 
  Non-Hispanic white, No. (%) 
  Non-Hispanic black, No. (%) 
  Hispanic, No. (%) 












Received at least high school education, No. (%) 592 (45.9) 1012 (45.9) 0.9 
Highest education achieved, No. (%)  
  Eighth grade or less  
  Some high school  
  Completed high school 
  Some college  














Marital status, No. (%) married  543 (42.1) 634 (28.8) <0.0001 
Health insurance, No. (%)  
   Medicaid or no insurance 








Medicaid health insurance, No. (%)  418 (32.4) 769 (34.8) 0.1 
Medicare health insurance, No. (%)  597 (46.3) 1595 (72.3) <0.0001 
Private insurance, No. (%) 541 (41.9) 929 (42.1) 0.9 
    
Vascular risk factors, No. (%)    
Hypertension  861 (66.7) 1685 (76.4) <0.0001 
History of hypertension 618 (47.9) 1228 (55.6) <0.0001 
Systolic BP, mean (SD) 140.6 (19.8) 145.2 (21.5) <0.0001 
Diastolic BP, mean (SD) 83.6 (10.6) 82.8 (11.6) 0.04 
Alcohol consumption: 
   Never Drank  
   Past Drinker  
   Light Drinker  
   Moderate Drinker  
   Intermediate Drinker  

















   None 








Diabetes mellitus  245 (19.0) 513 (23.3) 0.003 
Smoking: 
   Never 
   Former 










Hypercholesterolemia 797 (61.8) 1356 (61.4) 0.8 
Total cholesterol, mean (SD), mg/dL  202.4 (38.3) 2097 (41.1) 0.7 
High-density lipoprotein, mean (SD), mg/dL     






History of atrial fibrillation 31 (2.4) 116 (5.3) <0.0001 
History of coronary heart disease  177 (13.7) 547 (24.8) <0.0001 
    
Other medical conditions, No. (%)    
Hamilton depression scale score, mean (SD)  3.1 (3.8) 3.2 (3.9) 0.7 
Chronic bronchitis, asthma, or emphysema 120 (9.3) 302 (13.7) 0.0001 
Mini mental state score, mean (SD)  26.7 (3.3) 25.6 (3.9) <0.0001 
History of migraine headaches  231 (17.9) 346 (15.7) 0.09 
Spitzer quality of life index score  9.3 (1.0) 9.0 (1.4) <0.0001 
    
Social variables, No. (%)    
Number of years living in community 25.3 (14.9) 31.6 (17.0) <0.0001 
Number of people known well enough to visit with in 
their homes:  
   None 
   1 or 2 
   3 or 4 














Number of times talked to someone on telephone in 
past week:  
   Not at all  
   Once  
   Two to six times  














Number of times in past week spent with someone who 
does not live with you:  
   Not at all  
   Once  
   Two to six times  














Have someone you can trust and confide in  1211 (93.9) 2013 (91.4) 0.008 
Feeling lonely:  
   Quite often  
   Sometimes  










See relatives and friends:  
   Not as often as want 








Is there someone who would give you help if sick 1108 (86.0) 1779 (80.9) 0.0001 
    
Inflammatory markers, mean (SD):    
   CRP (n=792 / 1448) 
   logCRP (n=792 / 1448) 
   IL-6 (n=605 / 1037) 
   logIL-6 (n=581 / 994) 
   TNFR1 (n=651 / 1212) 
   mCAM (n=685 / 1227) 





























Table B2. Number of silent brain infarcts per subject, original dataset 




0 1045 84.41 1045 84.41 
1 146 11.79 1191 96.20 
2 32 2.58 1223 98.79 
3 9 0.73 1232 99.52 
4 5 0.40 1237 99.92 







Table B3. Distribution of white matter hyperintensity volume variables, original dataset 








































Table B4. Unadjusted and adjusted models of the association between silent brain infarcts and 
functional status, using the original dataset 
Variable Change in BI 
score 
95% CI p-value 
Unadjusted model:    
Annual change in BI -0.89 -1.04, -0.74 <.0001 
Change in BI with SBI -0.82 -3.00, 1.36 0.5 
Additional annual change with SBI -1.10 -1.64, -0.56 <.0001 
Adjusted for demographics:†    
Annual change in BI -0.91 -1.06, -0.75 <.0001 
Change in BI with SBI 0.97 -1.36, 3.31 0.4 
Additional annual change with SBI -1.11 -1.67, -0.55 <.0001 
Adjusted for vascular risk factors:*    
Annual change in BI -0.91 -1.06, -0.75 <.0001 
Change in BI with SBI 1.08 -1.26, 3.41 0.4 
Additional annual change with SBI -1.11 -1.67, -0.55 <.0001 
Adjusted for social variables:**    
Annual change in BI -0.91 -1.06, -0.75 <.0001 
Change in BI with SBI 1.21 -1.13, 3.54 0.3 
Additional annual change with SBI -1.10 -1.66, -0.55 0.0001 
Adjusted for cognition:π    
Annual change in BI -0.91 -1.06, -0.75 <.0001 
Change in BI with SBI 1.25 -1.09, 3.58 0.3 
Additional annual change with SBI -1.09 -1.64, -0.53 0.0001 
Adjusted for quality of life and depression: ††    
Annual change in BI -0.96 -1.13, -0.80 <.0001 
Change in BI with SBI 0.91 -1.62, 3.44 0.5 
Additional annual change with SBI -1.03 -1.61, -0.45 0.0005 
Adjusted for stroke and MI: ‡    
Annual change in BI -0.85 -1.01, -0.69 <.0001 
Change in BI with SBI 1.11 -1.27, 3.49 0.4 
Additional annual change with SBI -0.88 -1.43, -0.32 0.002 
BI=Barthel index; CI=confidence interval; SBI=silent brain infarct; MI=myocardial infarction 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 







Table B5. Unadjusted and adjusted models of the association between standardized white matter 
hyperintensity volume (WMH/TCV) and functional status, using the original dataset 
Variable Change in 
BI score 
95% CI p-value 
Unadjusted model:    
Annual change in BI -1.12 -1.28, -0.97 <.0001 
Change in BI with 1 unit increase in WMH -1.08 -2.08, -0.09 0.03 
Additional annual change with 1 unit increase in WMH -0.82 -1.06, -0.57 <.0001 
Adjusted for demographics:†    
Annual change in BI -1.14 -1.30, -0.98 <.0001 
Change in BI with 1 unit increase in WMH 0.13 -0.92, 1.18 0.8 
Additional annual change with 1 unit increase in WMH -0.82 -1.07, -0.57 <.0001 
Adjusted for vascular risk factors:*    
Annual change in BI -1.17 -1.34, -1.00 <.0001 
Change in BI with 1 unit increase in WMH 0.30 -0.89, 1.48 0.6 
Additional annual change with 1 unit increase in WMH -0.78 -1.04, -0.52 <.0001 
Adjusted for social variables:**    
Annual change in BI -1.17 -1.34, -1.00 <.0001 
Change in BI with 1 unit increase in WMH 0.34 -0.86, 1.53 0.6 
Additional annual change with 1 unit increase in WMH -0.78 -1.04, -0.52 <.0001 
Adjusted for cognition:π    
Annual change in BI -1.17 -1.34, -1.00 <.0001 
Change in BI with 1 unit increase in WMH 0.31 -0.89, 1.51 0.6 
Additional annual change with 1 unit increase in WMH -0.78 -1.04, -0.52 <.0001 
Adjusted for quality of life and depression: ††    
Annual change in BI -1.18 -1.34, -1.01 <.0001 
Change in BI with 1 unit increase in WMH 0.35 -0.83, 1.52 0.6 
Additional annual change with 1 unit increase in WMH -0.78 -1.04, -0.52 <.0001 
Adjusted for stroke and MI: ‡    
Annual change in BI -1.04 -1.20, -0.88 <.0001 
Change in BI with 1 unit increase in WMH 0.59 -0.50, 1.68 0.3 
Additional annual change with 1 unit increase in WMH -0.74 -0.99, -0.49 <.0001 
BI=Barthel index; CI=confidence interval; WMH=white matter hyperintensity; TCV=total cranial volume; 
MI=myocardial infarction 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 







Table B6. Unadjusted and adjusted models of the association between silent brain infarcts and 
functional status, using the new dataset 
Variable Change in BI 
score 
95% CI p-value 
Unadjusted model:    
Annual change in BI -0.86 -1.02, -0.71 <.0001 
Change in BI with SBI -1.20 -2.97, 0.57 0.2 
Additional annual change with SBI -1.00 -1.49, -0.51 <.0001 
Adjusted for demographics:†    
Annual change in BI -0.88 -1.03, -0.72 <.0001 
Change in BI with SBI 0.37 -1.55, 2.28 0.7 
Additional annual change with SBI -1.00 -1.50, -0.50 <.0001 
Adjusted for vascular risk factors:*    
Annual change in BI -0.92 -1.09, -0.75 <.0001 
Change in BI with SBI 0.47 -1.72, 2.66 0.7 
Additional annual change with SBI -1.00 -1.54, -0.46 0.0003 
Adjusted for social variables:**    
Annual change in BI -0.92 -1.09, -0.75 <.0001 
Change in BI with SBI 0.67 -1.55, 2.88 0.6 
Additional annual change with SBI -1.00 -1.53, -0.46 0.0003 
Adjusted for cognition:π    
Annual change in BI -0.92 -1.09, -0.75 <.0001 
Change in BI with SBI 0.67 -1.55, 2.89 0.6 
Additional annual change with SBI -0.99 -1.53, -0.46 0.0003 
Adjusted for quality of life and depression: ††    
Annual change in BI -0.93 -1.10, -0.76 <.0001 
Change in BI with SBI 0.58 -1.65, 2.81 0.6 
Additional annual change with SBI -0.99 -1.52, -0.45 0.0003 
Adjusted for stroke and MI: ‡    
Annual change in BI -0.82 -0.98, -0.66 <.0001 
Change in BI with SBI 1.07 -1.06, 3.20 0.3 
Additional annual change with SBI -0.89 -1.42, -0.36 0.001 
BI=Barthel index; CI=confidence interval; SBI=silent brain infarct; MI=myocardial infarction 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 







Table B7. Unadjusted and adjusted models of the association between large perivascular spaces 
and functional status, using the new dataset 
Variable Change in BI 
score 
95% CI p-value 
Unadjusted model:    
Annual change in BI -1.01 -1.21, -0.81 <.0001 
Change in BI with LPVS 0.14 -0.96, 1.24 0.8 
Additional annual change with LPVS -0.07 -0.37, 0.24 0.7 
Adjusted for demographics:†    
Annual change in BI -1.03 -1.23, -0.83 <.0001 
Change in BI with LPVS -0.17 -1.37, 1.03 0.8 
Additional annual change with LPVS -0.03 -0.34, 0.28 0.8 
Adjusted for vascular risk factors:*    
Annual change in BI -1.04 -1.25, -0.83 <.0001 
Change in BI with LPVS 0.13 -1.28, 1.54 0.9 
Additional annual change with LPVS -0.13 -0.46, 0.21 0.4 
Adjusted for social variables:**    
Annual change in BI -1.04 -1.25, -0.83 <.0001 
Change in BI with LPVS 0.11 -1.31, 1.53 0.9 
Additional annual change with LPVS -0.13 -0.46, 0.21 0.5 
Adjusted for cognition:π    
Annual change in BI -1.04 -1.25, -0.83 <.0001 
Change in BI with LPVS 0.14 -1.27, 1.55 0.8 
Additional annual change with LPVS -0.13 -0.46, 0.21 0.4 
Adjusted for quality of life and depression: ††    
Annual change in BI -1.04 -1.25, -0.84 <.0001 
Change in BI with LPVS 0.38 -1.02, 1.78 0.6 
Additional annual change with LPVS -0.15 -0.48, 0.19 0.4 
Adjusted for stroke and MI: ‡    
Annual change in BI -0.92 -1.12, -0.72 <.0001 
Change in BI with LPVS 0.74 -0.64, 2.13 0.3 
Additional annual change with LPVS -0.13 -0.46, 0.20 0.4 
BI=Barthel index; CI=confidence interval; LPVS=large perivascular space; MI=myocardial infarction 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 







Table B8. Unadjusted and adjusted models of the association between number of large 
perivascular spaces and functional status, using the new dataset 
Variable Change in 
BI score 
95% CI p-value 
Unadjusted model:    
Annual change in BI -1.05 -1.23, -0.87 <.0001 
Change in BI with 1 additional LPVS -0.03 -0.52, 0.47 0.9 
Additional annual change with 1 additional LPVS 0.03 -0.09, 0.15 0.7 
Adjusted for demographics:†    
Annual change in BI -1.08 -1.26, -0.89 <.0001 
Change in BI with 1 additional LPVS -0.10 -0.63, 0.43 0.7 
Additional annual change with 1 additional LPVS 0.05 -0.07, 0.17 0.4 
Adjusted for vascular risk factors:*    
Annual change in BI -1.11 -1.30, -0.91 <.0001 
Change in BI with 1 additional LPVS 0.0003 -0.61, 0.61 0.99 
Additional annual change with 1 additional LPVS 0.04 -0.08, 0.16 0.5 
Adjusted for social variables:**    
Annual change in BI -1.10 -1.30, -0.91 <.0001 
Change in BI with 1 additional LPVS -0.01 -0.62, 0.59 0.96 
Additional annual change with 1 additional LPVS 0.04 -0.08, 0.16 0.5 
Adjusted for cognition:π    
Annual change in BI -1.11 -1.30, -0.91 <.0001 
Change in BI with 1 additional LPVS -0.02 -0.62, 0.58 0.9 
Additional annual change with 1 additional LPVS 0.04 -0.08, 0.16 0.5 
Adjusted for quality of life and depression: ††    
Annual change in BI -1.11 -1.30, -0.92 <.0001 
Change in BI with 1 additional LPVS 0.08 -0.51, 0.68 0.8 
Additional annual change with 1 additional LPVS 0.03 -0.09, 0.15 0.6 
Adjusted for stroke and MI: ‡    
Annual change in BI -0.99 -1.17, -0.80 <.0001 
Change in BI with 1 additional LPVS 0.20 -0.39, 0.79 0.5 
Additional annual change with 1 additional LPVS 0.04 -0.08, 0.17 0.5 
BI=Barthel index; CI=confidence interval; LPVS=large perivascular space; MI=myocardial infarction 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 







Table B9. Unadjusted and adjusted models of the association between perivascular space score 
and functional status, using the new dataset 
Variable Change in BI 
score 
95% CI p-value 
Unadjusted model:    
Annual change in BI -0.83 -1.10, -0.56 <.0001 
Change in BI with 1 point increase in SPVS -0.09 -0.25, 0.08 0.3 
Additional annual change with 1 point increase in SPVS -0.04 -0.08, 0.005 0.08 
Adjusted for demographics:†    
Annual change in BI -0.84 -1.11, -0.56 <.0001 
Change in BI with 1 point increase in SPVS 0.06 -0.11, 0.24 0.5 
Additional annual change with 1 point increase in SPVS -0.04 -0.08, 0.01 0.08 
Adjusted for vascular risk factors:*    
Annual change in BI -0.90 -1.19, -0.62 <.0001 
Change in BI with 1 point increase in SPVS 0.08 -0.12, 0.27 0.4 
Additional annual change with 1 point increase in SPVS -0.03 -0.08, 0.01 0.14 
Adjusted for social variables:**    
Annual change in BI -0.90 -1.19, -0.62 <.0001 
Change in BI with 1 point increase in SPVS 0.08 -0.12, 0.27 0.4 
Additional annual change with 1 point increase in SPVS -0.03 -0.08, 0.01 0.14 
Adjusted for cognition:π    
Annual change in BI -0.90 -1.19, -0.62 <.0001 
Change in BI with 1 point increase in SPVS 0.08 -0.12, 0.27 0.4 
Additional annual change with 1 point increase in SPVS -0.03 -0.08, 0.01 0.13 
Adjusted for quality of life and depression: ††    
Annual change in BI -0.90 -1.18, -0.61 <.0001 
Change in BI with 1 point increase in SPVS 0.14 -0.06, 0.33 0.17 
Additional annual change with 1 point increase in SPVS -0.04 -0.08, 0.01 0.11 
Adjusted for stroke and MI: ‡    
Annual change in BI -0.82 -1.09, -0.54 <.0001 
Change in BI with 1 point increase in SPVS 0.15 -0.04, 0.34 0.12 
Additional annual change with 1 point increase in SPVS -0.03 -0.07, 0.02 0.2 
BI=Barthel index; CI=confidence interval; SPVS=score of perivascular spaces; MI=myocardial infarction 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 







Table B10. Unadjusted and adjusted models of the association between lacunar infarcts and 
functional status, using the new dataset 
Variable Change in BI 
score 
95% CI p-value 
Unadjusted model:    
Annual change in BI -0.85 -1.01, -0.70 <.0001 
Change in BI with lacunar infarct -0.74 -2.62, 1.14 0.4 
Additional annual change with lacunar infarct -1.20 -1.74, -0.66 <.0001 
Adjusted for demographics:†    
Annual change in BI -0.87 -1.02, -0.72 <.0001 
Change in BI with lacunar infarct 1.05 -0.99, 3.08 0.3 
Additional annual change with lacunar infarct -1.22 -1.77, -0.66 <.0001 
Adjusted for vascular risk factors:*    
Annual change in BI -0.91 -1.08, -0.75 <.0001 
Change in BI with lacunar infarct 1.15 -1.18, 3.48 0.3 
Additional annual change with lacunar infarct -1.20 -1.80, -0.61 <.0001 
Adjusted for social variables:**    
Annual change in BI -0.91 -1.08, -0.75 <.0001 
Change in BI with lacunar infarct 1.31 -1.05, 3.67 0.3 
Additional annual change with lacunar infarct -1.20 -1.80, -0.61 <.0001 
Adjusted for cognition:π    
Annual change in BI -0.91 -1.08, -0.75 <.0001 
Change in BI with lacunar infarct 1.34 -1.01, 3.70 0.3 
Additional annual change with lacunar infarct -1.21 -1.80, -0.61 <.0001 
Adjusted for quality of life and depression: ††    
Annual change in BI -0.92 -1.09, -0.76 <.0001 
Change in BI with lacunar infarct 1.26 -1.12, 3.64 0.3 
Additional annual change with lacunar infarct -1.19 -1.79, -0.60 <.0001 
Adjusted for stroke and MI: ‡    
Annual change in BI -0.81 -0.97, -0.65 <.0001 
Change in BI with lacunar infarct 1.61 -0.65, 3.86 0.16 
Additional annual change with lacunar infarct -1.11 -1.69, -0.53 0.0002 
BI=Barthel index; CI=confidence interval; MI=myocardial infarction 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 







Table B11. Unadjusted and adjusted models of the association between number of lacunar 
infarcts and functional status, using the new dataset 
Variable Change in 
BI score 
95% CI p-value 
Unadjusted model:    
Annual change in BI -0.90 -1.06, -0.75 <.0001 
Change in BI with 1 additional lacunar infarct -1.05 -2.42, 0.32 0.13 
Additional annual change with 1 additional lacunar infarct -0.51 -0.84, -0.19 0.002 
Adjusted for demographics:†    
Annual change in BI -0.92 -1.07, -0.76 <.0001 
Change in BI with 1 additional lacunar infarct -0.24 -1.71, 1.22 0.7 
Additional annual change with 1 additional lacunar infarct -0.52 -0.85, -0.18 0.003 
Adjusted for vascular risk factors:*    
Annual change in BI -0.97 -1.14, -0.81 <.0001 
Change in BI with 1 additional lacunar infarct -0.32 -1.91, 1.26 0.7 
Additional annual change with 1 additional lacunar infarct -0.45 -0.79, -0.11 0.009 
Adjusted for social variables:**    
Annual change in BI -0.97 -1.14, -0.81 <.0001 
Change in BI with 1 additional lacunar infarct -0.29 -1.90, 1.32 0.7 
Additional annual change with 1 additional lacunar infarct -0.45 -0.79, -0.11 0.009 
Adjusted for cognition:π    
Annual change in BI -0.97 -1.14, -0.81 <.0001 
Change in BI with 1 additional lacunar infarct -0.26 -1.87, 1.35 0.7 
Additional annual change with 1 additional lacunar infarct -0.45 -0.79, -0.11 0.009 
Adjusted for quality of life and depression: ††    
Annual change in BI -0.98 -1.15, -0.82 <.0001 
Change in BI with 1 additional lacunar infarct -0.29 -1.91, 1.32 0.7 
Additional annual change with 1 additional lacunar infarct -0.44 -0.78, -0.11 0.01 
Adjusted for stroke and MI: ‡    
Annual change in BI -0.87 -1.03, -0.71 <.0001 
Change in BI with 1 additional lacunar infarct -0.12 -1.56, 1.31 0.9 
Additional annual change with 1 additional lacunar infarct -0.40 -0.72, -0.08 0.014 
BI=Barthel index; CI=confidence interval; MI=myocardial infarction 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 









Table B12. Models testing mediation by MRI variables 











Testing SBI, original dataset:*       
Diabetes -1.57 -2.59, -0.55 0.003 -1.51 -2.55, -0.47 0.004 
Medicaid or no insurance -1.11 -1.81, -0.42 0.002 -0.95 -1.64, -0.27 0.007 
SBI, versus no SBI -- -- -- -1.48 -2.68, -0.27 0.016 
Testing adjusted WMHV, 
original dataset:* 
      
Diabetes -1.57 -2.59, -0.55 0.003 -1.53 -2.57, -0.49 0.004 
Medicaid or no insurance -1.11 -1.81, -0.42 0.002 -0.83 -1.51, -0.14 0.018 
WMHV, per SD  -- -- -- -1.00 -1.53, -0.48 0.0002 
Testing SBI, new dataset:*       
Diabetes -1.57 -2.59, -0.55 0.003 -1.51 -2.55, -0.47 0.004 
Medicaid or no insurance -1.11 -1.81, -0.42 0.002 -0.91 -1.59, -0.23 0.008 
SBI, versus no SBI -- -- -- -1.13 -2.14, -0.11 0.03 
Testing LI, new dataset:*       
Diabetes -1.57 -2.59, -0.55 0.003 -1.51 -2.55, -0.46 0.005 
Medicaid or no insurance -1.11 -1.81, -0.42 0.002 -0.91 -1.59, -0.23 0.009 
LI, versus no LI -- -- -- -1.24 -2.32, -0.16 0.025 
Testing number of LI, new 
dataset:* 
      
Diabetes -1.57 -2.59, -0.55 0.003 -1.46 -2.51, -0.42 0.006 
Medicaid or no insurance -1.11 -1.81, -0.42 0.002 -0.93 -1.60, -0.26 0.007 
LI, per additional LI -- -- -- -0.71 -1.25, -0.16 0.011 
Testing SPVS, new dataset:*       
Diabetes -1.57 -2.59, -0.55 0.003 -1.55 -2.59, -0.51 0.0034 
Medicaid or no insurance -1.11 -1.81, -0.42 0.002 -0.95 -1.63, -0.28 0.006 
SPVS, per additional point -- -- -- 0.01 -0.10, 0.11 0.9 
BI=Barthel index; CI=confidence interval; SBI=silent brain infarct; WMHV=white matter hyperintensity 
volume; SD=standard deviation; LI=lacunar infarct; SPVS=score of perivascular spaces; MI=myocardial 
infarction 
*model additionally adjusted for: time of follow-up, age at time of MRI, sex, race-ethnicity, physical 
activity, alcohol use, body mass index, depression, mini-mental state score, follow-up after MRI, and 














Original dataset, superficial/cortical location:    
Annual change in BI -0.92 -1.08, -0.76 <.0001 
Change in BI with superficial SBI location 0.27 -3.29, 3.83 0.9 
Additional annual change with superficial SBI location -0.79 -1.63, 0.06 0.068 
Original dataset, subcortical location:    
Annual change in BI -0.88 -1.04, -0.72 <.0001 
Change in BI with subcortical SBI location 1.21 -1.87, 4.29 0.4 
Additional annual change with subcortical SBI location -1.11 -1.81, -0.41 0.002 
Original dataset, testing location:    
Annual change in BI -0.85 -1.01, -0.69 <.0001 
Change in BI with cortical SBI location† 0.70 -2.93, 4.34 0.7 
Change in BI with subcortical SBI location† 1.81 -1.14, 4.76 0.2 
Change in BI with both cortical and subcortical SBI location† 0.73 -9.15, 
10.62 
0.9 
Additional annual change with cortical SBI location† -0.49 -1.36, 0.38 0.3 
Additional annual change with subcortical SBI location† -0.90 -1.60, -0.20 0.01 
Additional annual change with both cortical and subcortical SBI 
location† 
-2.68 -5.03, -0.32 0.03 
New dataset, testing location:    
Annual change in BI -0.82 -0.98, -0.66 <.0001 
Change in BI with cortical SBI location† 2.33 -0.31, 4.98 0.084 
Change in BI with subcortical SBI location† 3.54 -0.45, 7.53 0.082 
Change in BI with both cortical and subcortical SBI location† -0.74 -6.84, 5.36 0.8 
Additional annual change with cortical SBI location† -0.95 -1.72, -0.17 0.017 
Additional annual change with subcortical SBI location† -1.35 -2.37, -0.33 0.009 
Additional annual change with both cortical and subcortical SBI 
location† 
-1.23 -2.63, 0.17 0.086 
BI=Barthel index; CI=confidence interval; MI=myocardial infarction 
*models are additionally adjusted for: age at the time of MRI, sex, race-ethnicity, diabetes, hypertension, 
coronary artery disease, hypercholesterolemia, physical activity, alcohol use, smoking, body mass index, 
marital status, insurance status, number of friends, mini-mental state score, and stroke and myocardial 
infarction occurring during follow-up 




Table B14. Models testing mediation of the MRI markers-functional status association by C-reactive protein, original dataset* 




95% CI p-value Change 
in BI 
score 





Unadjusted CRP models:          
Annual change in BI -0.56 -0.66, -0.47 <.0001 -0.56 -0.65, -0.47 <.0001 -0.49 -0.58, -0.39 <.0001 
Change in BI with 1 unit 
increase in CRP 
0.00 -0.05, 0.04 0.9 0.00 -0.04, 0.04 0.99 -0.005 -0.05, 0.04 0.8 
Additional annual BI change 
with 1 unit increase in CRP 
-0.01 -0.02, 0.005 0.2 -0.01 -0.02, 
0.003 
0.12 -0.01 -0.02, 0.005 0.2 
Change in BI score per unit of 
mediator 
-- -- -- 0.75 0.29, 1.21 0.0013 1.15 0.01, 2.30 0.049 
Additional annual BI change per 
unit of mediator 
-- -- -- -0.34 -0.46, -0.22 <.0001 -0.45 -0.72, -0.17 0.0014 
Adjusted CRP models:‡          
Annual change in BI -0.47 -0.57, -0.37 <.0001 -0.48 -0.57, -0.38 <.0001 -0.42 -0.52, -0.32 <.0001 
Change in BI with 1 unit 
increase in CRP 
0.01 -0.05, 0.08 0.6 0.02 -0.04, 0.08 0.5 0.01 -0.05, 0.07 0.7 
Additional annual BI change 
with 1 unit increase in CRP 
-0.01 -0.03, 0.004 0.12 -0.01 -0.03, 
0.002 
0.082 -0.01 -0.03, 0.004 0.13 
Change in BI score per unit of 
mediator 
-- -- -- 1.22 0.71, 1.74 <.0001 1.37 0.09, 2.64 0.035 
Additional annual BI change per 
unit of mediator 
-- -- -- -0.30 -0.42, -0.18 <.0001 -0.34 -0.60, -0.08 0.011 
Unadjusted log of CRP 
models: 
         
Annual change in BI -0.53 -0.63, -0.44 <.0001 -0.54 -0.63, -0.45 <.0001 -0.46 -0.56, -0.36 <.0001 
Change in BI with 1 unit 
increase in log of CRP 
-0.04 -0.33, 0.25 0.8 -0.05 -0.33, 0.24 0.7 -0.05 -0.34, 0.24 0.7 
Additional annual BI change 
with 1 unit increase in log of 
CRP 
-0.09 -0.17, -0.01 0.03 -0.09 -0.16, -0.02 0.02 -0.09 -0.16, -0.01 0.03 
Change in BI score per unit of 
mediator 
-- -- -- 0.74 0.29, 1.20 0.001 1.14 0.0009, 2.28 0.0498 
Additional annual BI change per 
unit of mediator 
-- -- -- -0.34 -0.46, -0.22 <.0001 -0.44 -0.72, -0.17 0.0014 
Adjusted log of CRP 
models:‡ 






Annual change in BI -0.46 -0.55, -0.36 <.0001 -0.46 -0.55, -0.37 <.0001 -0.40 -0.50, -0.30 <.0001 
Change in BI with 1 unit 
increase in log of CRP 
0.29 -0.11, 0.69 0.15 0.31 -0.07, 0.69 0.11 0.29 -0.11, 0.68 0.15 
Additional annual BI change 
with 1 unit increase in log of 
CRP 
-0.09 -0.17, -0.01 0.02 -0.10 -0.17, -0.02 0.011 -0.09 -0.17, -0.01 0.02 
Change in BI score per unit of 
mediator 
-- -- -- 1.21 0.70, 1.73 <.0001 1.37 0.11, 2.63 0.03 
Additional annual BI change per 
unit of mediator 
-- -- -- -0.30 -0.42, -0.18 <.0001 -0.34 -0.60, -0.08 0.01 
* BI=Barthel index score; WMH=white matter hyperintensity volume; SBI=silent brain infarct; CRP=C-reactive protein;  
†per standard deviation change 
‡models are additionally adjusted for: age at the time of MRI, sex, race-ethnicity, diabetes, physical activity, alcohol use, body mass index, 






Table B15. Models testing mediation of the MRI markers-functional status association by interleukin-6, original dataset* 




95% CI p-value Change 
in BI 
score 





Unadjusted IL6 models:          
Annual change in BI -0.53 -0.66, -0.41 <.0001 -0.54 -0.66, -0.42 <.0001 -0.45 -0.58, -0.33 <.0001 
Change in BI with 1 unit 
increase in IL6 
-0.02 -0.10, 0.06 0.7 -0.02 -0.10, 0.06 0.6 -0.01 -0.09, 0.07 0.8 
Additional annual BI change 
with 1 unit increase in IL6 
-0.02 -0.07, 0.02 0.3 -0.02 -0.06, 0.02 0.3 -0.03 -0.07, 0.02 0.2 
Change in BI score per unit of 
mediator 
-- -- -- 0.72 0.20, 1.24 0.007 1.16 -0.11, 2.43 0.074 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.34 -0.48, -0.20 <.0001 -0.45 -0.78, -0.12 0.008 
Adjusted IL6 models:‡          
Annual change in BI -0.45 -0.57, -0.33 <.0001 -0.46 -0.58, -0.34 <.0001 -0.40 -0.52, -0.28 <.0001 
Change in BI with 1 unit 
increase in IL6 
0.07 -0.06, 0.20 0.3 0.07 -0.05, 0.19 0.3 0.07 -0.06, 0.21 0.3 
Additional annual BI change 
with 1 unit increase in IL6 
-0.02 -0.06, 0.02 0.3 -0.02 -0.06, 0.02 0.3 -0.02 -0.07, 0.02 0.3 
Change in BI score per unit of 
mediator 
-- -- -- 1.13 0.54, 1.71 0.0002 0.98 -0.38, 2.35 0.16 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.30 -0.44, -0.16 <.0001 -0.31 -0.61, -0.01 0.046 
Unadjusted log of IL6 
models: 
         
Annual change in BI -0.54 -0.64, -0.44 <.0001 -0.57 -0.67, -0.46 <.0001 -0.45 -0.55, -0.35 <.0001 
Change in BI with 1 unit 
increase in log of IL6 
0.11 -0.30, 0.52 0.6 0.08 -0.34, 0.49 0.7 0.13 -0.29, 0.55 0.5 
Additional annual BI change 
with 1 unit increase in log of 
IL6 
-0.10 -0.20, 0.01 0.07 -0.08 -0.18, 0.03 0.16 -0.10 -0.21, 0.004 0.058 
Change in BI score per unit of 
mediator 
-- -- -- 0.68 0.13, 1.24 0.016 1.32 -0.02, 2.67 0.053 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.35 -0.50, -0.20 <.0001 -0.52 -0.87, -0.17 0.004 
Adjusted log of IL6 
models:‡ 






Annual change in BI -0.45 -0.55, -0.35 <.0001 -0.48 -0.59, -0.38 <.0001 -0.39 -0.50, -0.29 <.0001 
Change in BI with 1 unit 
increase in log of IL6 
0.37 -0.14, 0.89 0.15 0.29 -0.21, 0.80 0.3 0.38 -0.13, 0.90 0.1455 
Additional annual BI change 
with 1 unit increase in log of 
IL6 
-0.10 -0.21, 0.02 0.09 -0.08 -0.19, 0.03 0.2 -0.10 -0.22, 0.01 0.0786 
Change in BI score per unit of 
mediator 
-- -- -- 1.09 0.49, 1.69 0.0004 1.20 -0.24, 2.63 0.10 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.30 -0.43, -0.16 <.0001 -0.38 -0.70, -0.05 0.02 
* BI=Barthel index score; WMH=white matter hyperintensity volume; SBI=silent brain infarct; IL6=interleukin-6;  
†per standard deviation change 
‡models are additionally adjusted for: age at the time of MRI, sex, race-ethnicity, diabetes, physical activity, alcohol use, body mass index, 






Table B16. Models testing mediation of the MRI markers-functional status association by tumor necrosis factor receptor-1, original 
dataset* 




95% CI p-value Change 
in BI 
score 





Unadjusted TNFR1 models:          
Annual change in BI -0.20 -0.56, 0.15 0.3 -0.22 -0.58, 0.13 0.2 -0.14 -0.48, 0.21 0.4 
Change in BI with 1 unit 
increase in TNFR1 
-0.50 -1.11, 0.11 0.11 -0.47 -1.07, 0.13 0.12 -0.50 -1.10, 0.11 0.11 
Additional annual BI change 
with 1 unit increase in TNFR1 
-0.20 -0.37, -0.03 0.02 -0.19 -0.37, -0.02 0.03 -0.20 -0.37, -0.03 0.02 
Change in BI score per unit of 
mediator 
-- -- -- 0.80 0.28, 1.33 0.003 1.01 -0.40, 2.42 0.16 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.35 -0.49, -0.21 <.0001 -0.46 -0.81, -0.12 0.008 
Adjusted TNFR1 models:‡          
Annual change in BI -0.16 -0.52, 0.21 0.4 -0.18 -0.55, 0.19 0.4 -0.11 -0.47, 0.25 0.6 
Change in BI with 1 unit 
increase in TNFR1 
0.21 -0.57, 1.00 0.6 0.17 -0.59, 0.93 0.7 0.19 -0.59, 0.97 0.6 
Additional annual BI change 
with 1 unit increase in TNFR1 
-0.18 -0.36, -0.01 0.04 -0.18 -0.36, -0.005 0.04 -0.18 -0.36, -0.01 0.04 
Change in BI score per unit of 
mediator 
-- -- -- 1.28 0.71, 1.84 <.0001 1.03 -0.51, 2.58 0.2 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.31 -0.44, -0.17 <.0001 -0.35 -0.67, -0.03 0.03 
* BI=Barthel index score; WMH=white matter hyperintensity volume; SBI=silent brain infarct; TNFR1=tumor necrosis factor receptor-1;  
†per standard deviation change 
‡models are additionally adjusted for: age at the time of MRI, sex, race-ethnicity, diabetes, physical activity, alcohol use, body mass index, 








Table B17. Models testing mediation of the MRI markers-functional status association by lipoprotein phospholipase A2, original dataset* 




95% CI p-value Change 
in BI 
score 
95% CI p-value Change 
in BI 
score 
95% CI p-value 
Unadjusted LpPLA2 mass 
models: 
         
Annual change in BI -0.74 -1.12, -0.35 0.0002 -0.79 -1.13, -0.44 <.0001 -0.70 -1.08, -0.32 0.0003 
Change in BI with 1 unit 
increase in LpPLA2 mass 
-0.0007 -0.02, 0.02 0.9 -0.003 -0.02, 0.01 0.8 -0.001 -0.02, 0.01 0.9 
Additional annual BI change 




0.4 0.002 -0.001, 0.005 0.2 0.002 -0.002, 
0.005 
0.3 
Change in BI score per unit of 
mediator 
-- -- -- 1.00 0.48, 1.51 0.0002 1.32 -0.23, 2.87 0.096 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.39 -0.52, -0.26 <.0001 -0.51 -0.87, -0.14 0.007 
Adjusted LpPLA2 mass 
models:‡ 
         
Annual change in BI -0.58 -0.96, -0.21 0.0022 -0.64 -0.99, -0.29 0.0003 -0.57 -0.94, -0.19 0.003 
Change in BI with 1 unit 
increase in LpPLA2 mass 
-0.01 -0.03, 0.01 0.2 -0.01 -0.03, 0.01 0.15 -0.01 -0.03, 0.01 0.2 
Additional annual BI change 




0.7 0.001 -0.002, 0.004 0.4 0.001 -0.002, 
0.004 
0.5 
Change in BI score per unit of 
mediator 
-- -- -- 1.44 0.87, 2.01 <.0001 1.53 -0.16, 3.22 0.076 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.34 -0.48, -0.21 <.0001 -0.36 -0.71, -0.02 0.039 
Unadjusted LpPLA2 activity 
models: 
         
Annual change in BI -0.56 -0.87, -0.26 0.0003 -0.55 -0.84, -0.26 0.0002 -0.50 -0.80, -0.20 0.0011 
Change in BI with 1 unit 
increase in LpPLA2 activity 
0.001 -0.003, 
0.006 
0.5 0.001 -0.003, 0.006 0.5 0.001 -0.003, 
0.005 
0.6 
Additional annual BI change 




0.9 -0.0001 -0.001, 0.001 0.8 0.000 -0.001, 
0.001 
0.98 







Additional annual BI change 
per unit of mediator 
-- -- -- -0.38 -0.51, -0.25 <.0001 -0.51 -0.87, -0.15 0.006 
Adjusted LpPLA2 activity 
models:‡ 
         
Annual change in BI -0.51 -0.83, -0.19 0.002 -0.50 -0.80, -0.19 0.0013 -0.46 -0.77, -0.15 0.004 
Change in BI with 1 unit 
increase in LpPLA2 activity 
-0.0004 -0.006, 
0.005 
0.9 -0.0002 -0.005, 0.005 0.9 -0.001 -0.006, 
0.005 
0.9 
Additional annual BI change 




0.9 0.000 -0.001, 0.001 0.9 0.000 -0.001, 
0.001 
0.9 
Change in BI score per unit of 
mediator 
-- -- -- 1.38 0.81, 1.95 <.0001 1.46 -0.23, 3.15 0.091 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.33 -0.47, -0.20 <.0001 -0.37 -0.71, -0.03 0.03 
* BI=Barthel index score; WMH=white matter hyperintensity volume; SBI=silent brain infarct; LpPLA2=lipoprotein phospholipase-A2;  
†per standard deviation change 
‡models are additionally adjusted for: age at the time of MRI, sex, race-ethnicity, diabetes, physical activity, alcohol use, body mass index, 








Table B18. Models testing mediation of the MRI markers-functional status association by C-reactive protein, new dataset* 
 Model without mediator Model testing mediation with 
number of lacunar infarcts
Model testing SBI mediation 
Variable Change in 
BI score 
95% CI p-value Change 
in BI 
score 
95% CI p-value Change 
in BI 
score 
95% CI p-value 
Unadjusted CRP models:          
Annual change in BI -0.56 -0.65, -0.46 <.0001 -0.49 -0.58, -0.40 <.0001 -0.48 -0.58, -0.39 <.0001 
Change in BI with 1 unit 
increase in CRP 
-0.003 -0.05, 0.04 0.9 -0.003 -0.04, 0.04 0.9 -0.005 -0.05, 0.04 0.8 
Additional annual BI change 
with 1 unit increase in CRP 
-0.01 -0.02, 0.01 0.2 -0.01 -0.02, 0.005 0.2 -0.01 -0.02, 0.01 0.2 
Change in BI score per unit 
of mediator 
-- -- -- 0.52 -0.10, 1.14 0.10 1.13 0.12, 2.14 0.03 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.23 -0.40, -0.06 0.008 -0.42 -0.68, -0.15 0.002 
Adjusted CRP models:‡          
Annual change in BI -0.47 -0.57, -0.37 <.0001 -0.42 -0.51, -0.32 <.0001 -0.42 -0.51, -0.32 <.0001 
Change in BI with 1 unit 
increase in CRP 
0.02 -0.05, 0.08 0.6 0.02 -0.05, 0.08 0.6 0.01 -0.05, 0.07 0.7 
Additional annual BI change 
with 1 unit increase in CRP 
-0.01 -0.03, 
0.004 
0.13 -0.01 -0.03, 0.004 0.13 -0.01 -0.03, 
0.004 
0.15 
Change in BI score per unit 
of mediator 
-- -- -- 0.82 0.13, 1.50 0.02 1.60 0.39, 2.82 0.0098 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.19 -0.35, -0.03 0.02 -0.31 -0.57, -0.05 0.019 
Unadjusted log of CRP 
models: 
         
Annual change in BI -0.53 -0.62, -0.43 <.0001 -0.46 -0.55, -0.37 <.0001 -0.46 -0.55, -0.36 <.0001 
Change in BI with 1 unit 
increase in log of CRP 
-0.02 -0.31, 0.27 0.9 -0.02 -0.31, 0.27 0.9 -0.04 -0.33, 0.25 0.8 
Additional annual BI change 
with 1 unit increase in log of 
CRP 
-0.09 -0.17, -0.01 0.02 -0.09 -0.17, -0.02 0.02 -0.08 -0.16, -0.01 0.03 
Change in BI score per unit 
of mediator 
-- -- -- 0.51 -0.10, 1.12 0.10 1.12 0.11, 2.12 0.03 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.23 -0.40, -0.06 0.008 -0.41 -0.67, -0.14 0.002 







Annual change in BI -0.45 -0.54, -0.36 <.0001 -0.39 -0.48, -0.30 <.0001 -0.40 -0.49, -0.31 <.0001 
Change in BI with 1 unit 
increase in log of CRP 
0.31 -0.09, 0.71 0.13 0.31 -0.08, 0.71 0.12 0.29 -0.11, 0.69 0.16 
Additional annual BI change 
with 1 unit increase in log of 
CRP 
-0.09 -0.17, -0.02 0.015 -0.10 -0.17, -0.02 0.01 -0.09 -0.17, -0.01 0.02 
Change in BI score per unit 
of mediator 
-- -- -- 0.82 0.13, 1.50 0.02 1.56 0.36, 2.77 0.01 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.19 -0.35, -0.04 0.02 -0.31 -0.57, -0.05 0.02 
* BI=Barthel index score; WMH=white matter hyperintensity volume; SBI=silent brain infarct; CRP=C-reactive protein;  
‡models are additionally adjusted for: age at the time of MRI, sex, race-ethnicity, diabetes, physical activity, alcohol use, body mass index, 






Table B19. Models testing mediation of the MRI markers-functional status association by interleukin-6, new dataset* 
 Model without mediator Model testing mediation with 
number of lacunar infarcts









95% CI p-value Change 
in BI 
score 
95% CI p-value 
Unadjusted IL6 models:          
Annual change in BI -0.52 -0.65, -0.39 <.0001 -0.45 -0.58, -0.33 <.0001 -0.43 -0.55, -0.30 <.0001 
Change in BI with 1 unit 
increase in IL6 
-0.01 -0.10, 0.07 0.7 -0.02 -0.10, 0.07 0.7 -0.01 -0.09, 0.07 0.8 
Additional annual BI change 
with 1 unit increase in IL6 
-0.03 -0.07, 0.02 0.3 -0.02 -0.07, 0.02 0.3 -0.03 -0.07, 0.02 0.2 
Change in BI score per unit 
of mediator 
-- -- -- 0.45 -0.25, 1.15 0.2 1.10 -0.07, 2.27 0.065 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.22 -0.42, -0.02 0.03 -0.47 -0.78, -0.16 0.003 
Unadjusted log of IL6 
models: 
         
Annual change in BI -0.53 -0.63, -0.43 <.0001 -0.49 -0.59, -0.38 <.0001 -0.46 -0.56, -0.35 <.0001 
Change in BI with 1 unit 
increase in log of IL6 
0.11 -0.31, 0.53 0.6 0.10 -0.33, 0.52 0.6 0.11 -0.31, 0.53 0.6 
Additional annual BI change 
with 1 unit increase in log of 
IL6 
-0.09 -0.20, 0.01 0.09 -0.09 -0.20, 0.02 0.12 -0.10 -0.20, 0.01 0.078 
Change in BI score per unit 
of mediator 
-- -- -- 0.28 -0.40, 0.95 0.4 0.85 -0.40, 2.10 02 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.18 -0.37, 0.02 0.074 -0.44 -0.77, -0.11 0.0097 
Adjusted log of IL6 
models:‡ 
         
Annual change in BI -0.45 -0.55, -0.35 <.0001 -0.42 -0.52, -0.31 <.0001 -0.39 -0.50, -0.29 <.0001 
Change in BI with 1 unit 
increase in log of IL6 
0.37 -0.15, 0.90 0.16 0.35 -0.17, 0.88 0.2 0.37 -0.15, 0.89 0.16 
Additional annual BI change 
with 1 unit increase in log of 
IL6 
-0.09 -0.21, 0.02 0.11 -0.09 -0.21, 0.03 0.13 -0.10 -0.21, 0.02 0.099 
Change in BI score per unit 
of mediator 
-- -- -- 0.42 -0.25, 1.10 0.2 1.25 -0.12, 2.62 0.07 






per unit of mediator 
* BI=Barthel index score; WMH=white matter hyperintensity volume; SBI=silent brain infarct; IL6=interleukin-6;  
‡models are additionally adjusted for: age at the time of MRI, sex, race-ethnicity, diabetes, physical activity, alcohol use, body mass index, 






Table B20. Models testing mediation of the MRI markers-functional status association by tumor necrosis factor receptor-1, new dataset* 
 Model without mediator Model testing mediation with 
number of lacunar infarcts









95% CI p-value Change 
in BI 
score 
95% CI p-value 
Unadjusted TNFR1 
models: 
         
Annual change in BI -0.20 -0.56, 0.16 0.3 -0.11 -0.46, 0.24 0.5 -0.09 -0.44, 0.26 0.6 
Change in BI with 1 unit 
increase in TNFR1 
-0.50 -1.12, 0.12 0.12 -0.51 -1.12, 0.10 0.099 -0.47 -1.09, 0.14 0.13 
Additional annual BI change 
with 1 unit increase in 
TNFR1 
-0.20 -0.37, -0.03 0.02 -0.20 -0.37, -0.03 0.023 -0.21 -0.38, -0.04 0.018 
Change in BI score per unit 
of mediator 
-- -- -- 0.96 0.26, 1.67 0.007 1.41 0.26, 2.57 0.017 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.35 -0.56, -0.15 0.0007 -0.52 -0.82, -0.21 0.0008 
Adjusted TNFR1 models:‡          
Annual change in BI -0.15 -0.52, 0.22 0.4 -0.08 -0.45, 0.28 0.7 -0.08 -0.44, 0.29 0.7 
Change in BI with 1 unit 
increase in TNFR1 
0.19 -0.60, 0.99 0.6 0.15 -0.62, 0.92 0.7 0.20 -0.58, 0.97 0.6 
Additional annual BI change 




0.046 -0.18 -0.36, -0.01 0.042 -0.19 -0.37, -0.01 0.036 
Change in BI score per unit 
of mediator 
-- -- -- 1.16 0.37, 1.95 0.004 1.75 0.35, 3.15 0.01 
Additional annual BI change 
per unit of mediator 
-- -- -- -0.30 -0.49, -0.10 0.003 -0.39 -0.69, -0.09 0.01 
*BI=Barthel index score; WMH=white matter hyperintensity volume; SBI=silent brain infarct; TNFR1=tumor necrosis factor receptor-1;  
‡models are additionally adjusted for: age at the time of MRI, sex, race-ethnicity, diabetes, physical activity, alcohol use, body mass index, 






Table B21. Unadjusted and adjusted models of the association between inflammatory biomarkers and MRI findings, original dataset* 
 Outcome: SBI Outcome: WMH 




Estimate 95% CI p-value 
CRP, unadjusted model 1.00 0.98, 1.03 0.9 -0.00004 -0.0001, 0.00004 0.3 
CRP, adjusted model† 1.01 0.98, 1.04 0.6 -0.00002 -0.0001, 0.00007 0.6 
TNFR1, unadjusted model 1.14 0.91, 1.44 0.3 0.0006 -0.0001, 0.0014 0.11 
TNFR1, adjusted model† 1.05 0.81, 1.36 0.7 0.00005 -0.0007, 0.0008 0.9 
IL6, unadjusted model 1 1, 1.001 0.5 -0.0000003 -0.000002, 0.000001 0.7 
IL6, adjusted model† 1 1, 1.001 0.6 -0.0000004 -0.000002, 0.000001 0.6 
LpPLA2 mass, unadjusted model 1.01 1.00, 1.01 0.1 0.000008 -0.00001, 0.00003 0.5 
LpPLA2 mass, adjusted model† 1.01 0.999,1.02 0.10 0.00002 -0.000005, 0.00004 0.12 
LpPLA2 activity, unadjusted model 1 0.998, 
1.002 
0.9 0.000002 -0.000005, 0.000009 0.6 
LpPLA2 activity, adjusted model† 1.001 0.998, 
1.003 
0.7 0.000005 -0.000002, 0.00001 0.15 
*SBI=silent brain infarct; WMH=white matter hyperintensity volume; CRP=C-reactive protein; TNFR1=tumor necrosis factor receptor-1; 
LpPLA2=lipoprotein phospholipase-A2 
†models are adjusted for: age, sex, race-ethnicity, diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical activity, 







Table B22. Models assessing the influence of cognition on functional status* 




95% CI p-value Change 
in BI 
score 
95% CI p-value 
Model without interaction terms:†       
Annual change in BI -0.90 -0.97, -0.84 <.0001 -0.55 -0.61, -0.48 <.0001 
Change in BI per point of MMSE 0.57 0.42, 0.71 <.0001 0.22 0.08, 0.35 0.0015 
Model with time interaction:†       
Annual change in BI -2.64 -3.24, -2.04 <.0001 -1.65 -2.27, -1.03 <.0001 
Change in BI per point of MMSE 0.20 0.05, 0.35 0.0102 -0.09 -0.21, 0.03 0.16 
Additional annual change in BI per point of MMSE 0.07 0.04, 0.09 <.0001 0.04 0.02, 0.06 0.0004 
Model with time interaction, with MMSE centered:†       
Annual change in BI -0.94 -1.00, -0.87 <.0001 -0.57 -0.63, -0.50 <.0001 
Change in BI per point of MMSE 0.20 0.05, 0.35 0.0102 -0.09 -0.21, 0.03 0.16 
Additional annual change in BI per point of MMSE 0.07 0.04, 0.09 <.0001 0.04 0.02, 0.06 0.0004 
Model with education term:†       
Annual change in BI -0.90 -0.97, -0.84 <.0001 -0.55 -0.61, -0.48 <.0001 
Change in BI per point of MMSE 0.59 0.44, 0.74 <.0001 0.23 0.09, 0.37 0.001 
High school education, versus less than high school education -0.65 -1.62, 0.33 0.2 -0.47 -1.30, 0.37 0.3 
Model with interaction with education:†       
Annual change in BI -0.90 -0.97, -0.84 <.0001 -0.55 -0.61, -0.48 <.0001 
Change in BI per point of MMSE 0.50 0.33, 0.67 <.0001 0.21 0.07, 0.36 0.004 
High school education, versus less than high school education -11.81 -22.05, -1.57 0.02 -3.15 -14.23, 7.94 0.6 
Change in BI per point of MMSE in those with high school 
education 
0.41 0.04, 0.78 0.028 0.10 -0.30, 0.49 0.6 
Model with interaction with education, with MMSE 
centered:† 
      
Annual change in BI -0.90 -0.97, -0.84 <.0001 -0.55 -0.61, -0.48 <.0001 
Change in BI per point of MMSE 0.50 0.33, 0.67 <.0001 0.21 0.07, 0.36 0.004 
High school education, versus less than high school education -1.02 -2.11, 0.07 0.067 -0.58 -1.60, 0.43 0.3 
Change in BI per point of MMSE in those with high school 
education 
0.41 0.04, 0.78 0.028 0.10 -0.30, 0.49 0.6 
Model with interaction with education and time, with 
MMSE centered:† 
      
Annual change in BI -0.94 -1.00, -0.87 <.0001 -0.57 -0.63, -0.50 <.0001 
Change in BI per point of MMSE 0.13 -0.06, 0.31 0.17 -0.09 -0.23, 0.04 0.2 
Additional annual change in BI per point of MMSE 0.07 0.04, 0.09 <.0001 0.04 0.02, 0.06 0.0004 






Change in BI per point of MMSE in those with high school 
education 
0.44 0.06, 0.82 0.025 0.11 -0.29, 0.51 0.6 
Model with interaction with education and time and 3-way 
interaction, with MMSE centered:† 
      
Annual change in BI -0.98 -1.06, -0.90 <.0001 -0.56 -0.64, -0.48 <.0001 
Change in BI per point of MMSE 0.22 0.04, 0.41 0.016 -0.11 -0.24, 0.02 0.10 
Additional annual change in BI per point of MMSE 0.05 0.02, 0.08 0.0002 0.04 0.02, 0.07 0.0013 
High school education, versus less than high school education -1.26 -2.38, -0.14 0.027 -0.62 -1.65, 0.41 0.2 
Change in BI per point of MMSE in those with high school 
education 
0.14 -0.25, 0.52 0.5 0.17 -0.18, 0.53 0.3 
Additional annual change in BI per point of MMSE in those 
with high school education 
0.06 0.01, 0.11 0.029 -0.01 -0.06, 0.04 0.8 
*BI=Barthel index score; MMSE=mini-mental state examination score 
†Model additionally adjusted for: age, sex, race-ethnicity, diabetes, hypertension, hypercholesterolemia, physical activity, alcohol use, body mass 





Table B23. Models assessing the influence of cognition and silent brain infarct on functional 
status, original dataset* 
Variable Change in 
BI score 
95% CI p-value 
Model without interaction terms:†    
Annual change in BI -0.97 -1.13, -0.82 <.0001 
Change in BI with SBI -2.63 -4.87, -0.39 0.021 
Change in BI per point of MMSE 0.28 0.06, 0.51 0.015 
Model with time interaction, with MMSE centered:†    
Annual change in BI -1.00 -1.16, -0.83 <.0001 
Change in BI with SBI -2.63 -4.88, -0.39 0.021 
Change in BI per point of MMSE 0.08 -0.17, 0.33 0.5 
Additional annual change in BI per point of MMSE 0.05 -0.01, 0.10 0.087 
Model with time interactions, with MMSE centered:†    
Annual change in BI -0.87 -1.04, -0.70 <.0001 
Change in BI with SBI 1.07 -1.32, 3.45 0.4 
Additional annual change in BI with SBI -0.88 -1.44, -0.32 0.002 
Change in BI per point of MMSE 0.08 -0.17, 0.33 0.5 
Additional annual change in BI per point of MMSE 0.05 -0.01, 0.10 0.083 
Model with 2-way SBI interactions, with MMSE centered:†    
Annual change in BI -0.85 -1.01, -0.69 <.0001 
Change in BI with SBI 1.20 -1.24, 3.64 0.3 
Additional annual change in BI with SBI -0.88 -1.43, -0.32 0.002 
Change in BI per point of MMSE 0.35 0.12, 0.59 0.003 
Additional change in BI per point of MMSE in those with SBI -0.48 -1.22, 0.27 0.2 
Model with 3-way interactions with time, with MMSE 
centered:† 
   
Annual change in BI -0.89 -1.06, -0.71 <.0001 
Change in BI with SBI 0.93 -1.44, 3.29 0.4 
Additional annual change in BI with SBI -0.77 -1.31, -0.24 0.0045 
Change in BI per point of MMSE 0.08 -0.17, 0.33 0.5 
Additional annual change in BI per point of MMSE 0.07 0.02, 0.13 0.012 
Additional annual change in BI per point of MMSE in those with 
SBI 
-0.18 -0.32, -0.04 0.011 
*BI=Barthel index score; SBI=silent brain infarct; MMSE=mini-mental state examination score 
†Model additionally adjusted for: age at time of MRI, sex, race-ethnicity, diabetes, hypertension, physical 
activity, alcohol use, body mass index, insurance status, depression, and stroke and myocardial infarction 







Table B24. Models assessing the influence of cognition and white matter hyperintensity volume 
on functional status, original dataset* 
Variable Change in 
BI score 
95% CI p-value 
Model without interaction terms:†    
Annual change in BI -0.98 -1.14, -0.82 <.0001 
Change in BI per SD increase in WMH -2.33 -3.38, -1.27 <.0001 
Change in BI per point of MMSE 0.29 0.06, 0.51 0.013 
Model with time interaction, with MMSE centered:†    
Annual change in BI -1.00 -1.17, -0.84 <.0001 
Change in BI per SD increase in WMH -2.32 -3.38, -1.26 <.0001 
Change in BI per point of MMSE 0.09 -0.16, 0.34 0.5 
Additional annual change in BI per point of MMSE 0.05 -0.01, 0.10 0.09 
Model with time interactions, with MMSE centered:†    
Annual change in BI -1.06 -1.22, -0.89 <.0001 
Change in BI per SD increase in WMH 0.53 -0.58, 1.64 0.3 
Additional annual change in BI per SD increase in WMH -0.73 -0.99, -0.48 <.0001 
Change in BI per point of MMSE 0.11 -0.14, 0.36 0.4 
Additional annual change in BI per point of MMSE 0.04 -0.02, 0.09 0.16 
Model with 2-way SBI interactions, with MMSE centered:†    
Annual change in BI -1.04 -1.20, -0.88 <.0001 
Change in BI per SD increase in WMH 0.55 -0.56, 1.66 0.3 
Additional annual change in BI per SD increase in WMH -0.74 -0.99, -0.49 <.0001 
Change in BI per point of MMSE 0.27 0.05, 0.50 0.018 
Additional change in BI per point of MMSE per SD increase in 
WMH 
0.01 -0.33, 0.35 0.9 
Model with 3-way interactions with time, with MMSE 
centered:† 
   
Annual change in BI -1.06 -1.23, -0.89 <.0001 
Change in BI per SD increase in WMH 0.50 -0.61, 1.61 0.4 
Additional annual change in BI per SD increase in WMH -0.73 -0.98, -0.48 <.0001 
Change in BI per point of MMSE 0.12 -0.13, 0.37 0.3 
Additional annual change in BI per point of MMSE 0.03 -0.02, 0.09 0.2 
Additional annual change in BI per point of MMSE per SD 
increase in WMH 
-0.04 -0.11, 0.03 0.3 
*BI=Barthel index score; SD=standard deviation; WMH=white matter hyperintensity volume; MMSE=mini-
mental state examination score 
†Model additionally adjusted for: age at time of MRI, sex, race-ethnicity, diabetes, hypertension, physical 
activity, alcohol use, body mass index, insurance status, depression, and stroke and myocardial infarction 







Table B25. Models assessing the influence of cognition and silent brain infarct on functional 
status, new dataset* 
Variable Change in 
BI score 
95% CI p-value 
Model without interaction terms:†    
Annual change in BI -0.96 -1.12, -0.81 <.0001 
Change in BI with SBI -2.60 -4.51, -0.69 0.0076 
Change in BI per point of MMSE 0.24 0.04, 0.45 0.022 
Model with time interaction, with MMSE centered:†    
Annual change in BI -0.99 -1.16, -0.83 <.0001 
Change in BI with SBI -2.61 -4.51, -0.70 0.0075 
Change in BI per point of MMSE 0.03 -0.22, 0.27 0.8 
Additional annual change in BI per point of MMSE 0.05 -0.004, 0.11 0.07 
Model with time interactions, with MMSE centered:†    
Annual change in BI -0.84 -1.01, -0.67 <.0001 
Change in BI with SBI 1.11 -0.98, 3.20 0.3 
Additional annual change in BI with SBI -0.90 -1.43, -0.36 0.001 
Change in BI per point of MMSE 0.02 -0.22, 0.27 0.8 
Additional annual change in BI per point of MMSE 0.05 -0.004, 0.11 0.068 
Model with 2-way SBI interactions, with MMSE centered:†    
Annual change in BI -0.82 -0.98, -0.66 <.0001 
Change in BI with SBI 1.28 -0.83, 3.39 0.2 
Additional annual change in BI with SBI -0.89 -1.42, -0.36 0.001 
Change in BI per point of MMSE 0.35 0.13, 0.57 0.0019 
Additional change in BI per point of MMSE in those with SBI -0.58 -1.19, 0.02 0.059 
Model with 3-way interactions with time, with MMSE 
centered:† 
   
Annual change in BI -0.86 -1.03, -0.68 <.0001 
Change in BI with SBI 0.99 -1.09, 3.06 0.4 
Additional annual change in BI with SBI -0.80 -1.32, -0.29 0.0023 
Change in BI per point of MMSE 0.04 -0.20, 0.29 0.7 
Additional annual change in BI per point of MMSE 0.07 0.01, 0.13 0.015 
Additional annual change in BI per point of MMSE in those with 
SBI 
-0.15 -0.28, -0.02 0.027 
*BI=Barthel index score; SD=standard deviation; SBI=silent brain infarct; MMSE=mini-mental state 
examination score 
†Model additionally adjusted for: age at time of MRI, sex, race-ethnicity, diabetes, hypertension, physical 
activity, alcohol use, body mass index, insurance status, depression, and stroke and myocardial infarction 













Model without interaction terms:†    
Annual change in BI -0.96 -1.12, -0.80 <.0001 
Change in BI with LI -2.95 -5.03, -0.87 0.0054 
Change in BI per point of MMSE 0.24 0.03, 0.45 0.025 
Model with time interaction, with MMSE centered:†    
Annual change in BI -0.99 -1.16, -0.83 <.0001 
Change in BI with LI -2.96 -5.04, -0.89 0.0052 
Change in BI per point of MMSE 0.02 -0.22, 0.26 0.9 
Additional annual change in BI per point of MMSE 0.05 -0.004, 0.11 0.069 
Model with time interactions, with MMSE centered:†    
Annual change in BI -0.83 -1.00, -0.67 <.0001 
Change in BI with LI 1.64 -0.59, 3.86 0.15 
Additional annual change in BI with LI -1.11 -1.70, -0.53 0.0002 
Change in BI per point of MMSE 0.03 -0.22, 0.27 0.8 
Additional annual change in BI per point of MMSE 0.05 -0.005, 0.11 0.073 
Model with 2-way SBI interactions, with MMSE centered:†    
Annual change in BI -0.81 -0.96, -0.65 <.0001 
Change in BI with LI 1.73 -0.49, 3.96 0.13 
Additional annual change in BI with LI -1.11 -1.69, -0.53 0.0002 
Change in BI per point of MMSE 0.31 0.09, 0.53 0.0056 
Additional change in BI per point of MMSE in those with LI -0.41 -1.03, 0.22 0.2 
Model with 3-way interactions with time, with MMSE 
centered:† 
   
Annual change in BI -0.84 -1.01, -0.68 <.0001 
Change in BI with LI 1.49 -0.72, 3.70 0.2 
Additional annual change in BI with LI -1.03 -1.60, -0.46 0.0004 
Change in BI per point of MMSE 0.04 -0.20, 0.29 0.7 
Additional annual change in BI per point of MMSE 0.07 0.01, 0.13 0.018 
Additional annual change in BI per point of MMSE in those with LI -0.15 -0.29, -0.01 0.037 
*BI=Barthel index score; SD=standard deviation; LI=lacunar infarct; MMSE=mini-mental state 
examination score 
†Model additionally adjusted for: age at time of MRI, sex, race-ethnicity, diabetes, hypertension, physical 
activity, alcohol use, body mass index, insurance status, depression, and stroke and myocardial infarction 









Figure B1. Distributions of white matter hyperintensity volume variables 
A) white matter hyperintensity volume 
 
 


























Analysis C:  
 









Background: Stroke may contribute to long-term functional decline apart from its acute effects on 
neurological function. Few studies have compared long-term disability trajectories before and after 
vascular events or considered the natural history of aging-related decline.  We hypothesized that the 
increase in long-term disability would be steeper post-event than pre-event for stroke but not myocardial 
infarction (MI).   
Methods:  In the Cardiovascular Health Study, 5888 Medicare-eligible participants were followed for a 
mean of 13 years for vascular events and had annual disability assessments with an activities of daily 
living (ADL) and instrumental ADL scale, modified from the National Center for Health Statistics 
Supplement on Aging (range 0-12, scored by number of ADLs and IADLs which the participant could not 
perform, analyzed continuously).  During follow-up, 382 participants had ischemic stroke and 395 had MI 
with >1 post-event disability assessment.  Generalized estimating equations models adjusted for baseline 
demographics, vascular risk factors, arthritis, cognition, and social support and included a test for different 
slopes of disability before and after event.   
Results:  Participants had a mean of 4 disability assessments each pre- and post-stroke and MI.  Stroke 
(0.88, 95% CI 0.57-1.20, p<0.0001) was associated with a greater acute increase in disability than MI 
(0.20, 0.06-0.35, p=0.006).  The annual increase in disability before stroke (0.06 points per year, 0.002-
0.12, p=0.04) more than tripled after stroke (0.15 additional points per year, 0.004-0.30, p=0.04).  The 
annual increase in disability before MI (0.04 points per year, 0.004-0.08, p=0.03) did not change 
significantly after MI (0.02 additional points per year, -0.07-0.11, p=0.7).   
Conclusions:  In this large population-based study, a trajectory of increasing disability became 
significantly steeper after stroke but not after MI.  This worsening trajectory could be due to delayed cell 
dysfunction in the brain surrounding stroke, long-term inflammatory profile changes, progressive 
cardiovascular impairment, or silent recurrent infarcts.  Stroke may be considered an ongoing, chronic 








The commonly held view is that stroke is a discrete event and that, following the 3-6 month recovery 
period after stroke, functional status would remain constant over time if no recurrent events occurred.34 
However, stroke is caused by vascular risk factors such as diabetes and hypertension that have an 
ongoing and cumulative effect on vessel dysfunction.  Also, there are several other biological 
mechanisms through which ischemic stroke may cause delayed functional decline.  One is delayed 
neuronal death in the ischemic penumbra through apoptosis and necrosis,210 which may cause delayed 
functional decline by gradual extension of tissue that is infarcted and not merely at risk of infarction.  
Furthermore, a single ischemic stroke may cause changes in inflammatory profiles123 that may have an 
ongoing deleterious effect on brain structure and function124 that may persist years after stroke.125 
Another possible mechanism involves progressive cardiovascular impairment and reduced fitness due to 
static functional impairment after stroke.  This cardiovascular, non-neurological impairment adversely 
effects performance in ADLs.211 Clinically silent infarcts may also account for long-term decline in function 
after stroke.   
Considering this evidence, stroke may be more effectively considered as an ongoing, chronic 
condition with effects on function, instead of just a discrete event.  We hypothesized that the slope of 
decline in functional status over the long term is steeper after stroke than before stroke, and that the 
slope of decline before and after myocardial infarction (MI) is unchanged.  There are several reasons for 
this comparison with MI.  MI is a vascular event whose risk factors overlap with those of stroke.  It can be 
considered a type of occlusive, sudden-onset vascular event involving a different area of the body’s 
vasculature than stroke.  However, an infarction of cardiac tissue does not result in the kind of impairment 
that results from an infarction of brain tissue.  Also, there is evidence that stroke is not just a “heart attack” 
of the brain; rather, there are distinct biological properties of the vascular bed of the brain compared to 
the heart that may have implications for ongoing functional decline.212 In order to delineate the unique 
effect of stroke on functional change that results particularly from vascular disease, we used MI as a 








The CHS cohort was recruited from a sex- and age-stratified random sample of Medicare-eligible 
individuals in North Carolina, California, Maryland, and Pennsylvania.213 Potential participants were 
sampled from Medicare eligibility lists in each area. Eligibility criteria included age >65 years, not 
institutionalized, expected to reside in the area for 3 years, and able to provide informed consent. 
Participants needing a wheelchair or receiving hospice care, radiation treatment, or chemotherapy were 
excluded. The initial sample of 5,201 participants, recruited from 1989 to 1990, was enriched with the 
addition of 687 African-American men and women meeting the same eligibility criteria who were recruited 
from 1992 to 1993, for a combined cohort of 5,888 participants.   
 
Baseline Evaluation  
Sociodemographic, functional, and health data were obtained from interviews, clinical examinations, 




CHS has collected data on functional status, extent of social network, cognitive status, and depression 
annually over 11 years of follow-up through in-person interviews and examinations. Potential events are 
identified through contact with participants or proxies. Data on incident vascular events such as stroke are 
collected at local sites, and this abstracted data is reviewed and adjudicated by a centralized 
cerebrovascular disease endpoint committee.  Events are classified as ischemic (lacunar, cardioembolic, 
atherosclerotic, or indeterminate), hemorrhagic (subarachnoid, intraparenchymal, or indeterminate), or 
unknown.  Since there is no data about stroke severity, we used stroke subtype as a proxy for severity in 
secondary analysis.  Potential MIs occurring during follow-up were reviewed by a specialist outcome 
committee and included review of clinical history of cardiac symptoms, elevated cardiac enzyme levels, 








Study outcomes   
Functional status was measured by the ADL/IADL scale, modified from the National Center for Health 
Statistics Supplement on Aging215 and the New Haven Established Populations for Epidemiologic Studies 
of the Elderly Study.216 The form assesses general level of physical functioning and mobility, and ability to 
carry out ADLs and instrumental ADLs (Appendix C1).  The scale was scored from 0 to 12 based on the 
number of ADLs and IADLs with which the participant reported having difficulty or could not perform.  The 
scores were analyzed as a continuous variable as in previous research in this cohort.214, 217 In secondary 
analysis, the scale was dichotomized as non-disabled (score of 0) and disabled (score >1). 
 
Explanatory variables   
The course of repeated measures of functional status were modeled, and the primary explanatory 
variable of interest was time of follow-up assessment in years, ranging from 0 (baseline) to the maximum 
time of follow-up.    
Other covariates were as follows.  Demographic variables included age, sex, race-ethnicity, and 
level of education, defined by self-assessment.  Vascular risk factors included hypertension, diabetes 
mellitus, cardiac disease, hyperlipidemia (defined as lipid lowering therapy use or fasting total cholesterol 
level >240 mg/dL), smoking, alcohol consumption, and physical activity, defined by self-report. The 
strength of participants’ social networks was assessed with the Lubben Social Network Scale,218 a 
validated 10-item measure that includes assessments of five aspects of social networks: family networks, 
friend networks, helping others, confidant relationships, and living arrangements.  The total score is a sum 
of the questions, with scores ranging from 0 to 50. Higher scores indicate larger social networks.  The 
mean total score ranged from 32.34 (SD 7.42) at baseline to 30.73 (SD 7.89) at 11 years of follow-up.  
Depression was measured by the Centers for Epidemiologic Studies Depression (CES-D) scale,219 using 
a cutoff score of >9 for diagnosis of depression.  The Mini-Mental State Examination score220 was 
assessed at 1 year of follow-up.  Personal income was defined as total family income before taxes from 
all sources in the past 12 months and was selected from a response card as one of the following: under 
$5000; $5000–$7999; $8000–$11,999; $12000–$15999; $16,000–$24,999; $25,000–$34,999; $35,000–






on three income groups (<$12,000, $12,000–$34,999, ⩾$35,000), based upon prior analyses in this 
cohort.221 
 
Statistical analysis  
The distributions of baseline characteristics were examined.  The distribution of follow-up time and the 
frequencies of occurrence of stroke and cardiac events during follow-up were examined.  The frequencies 
of functional assessments before and after stroke and MI were calculated.  The unadjusted distributions 
of functional scores were summarized among those who had stroke and those who had MI during follow-
up.   
Stroke cohort  The goal of the analysis was to determine whether the slope of functional status 
was different before and after stroke.  For this analysis, only those who experienced ischemic stroke 
during follow-up and had >1 follow-up disability assessment after stroke were included.  Due to 
correlations among repeated measures of outcomes in the same individual, regression models based 
upon GEE will be used, with an identity link function for continuous variables, and a logit link function for 
dichotomous variables.   
 Any assessments of functional status occurring within the 6 months after stroke were ignored, since 
the course of recovery during this period is well-documented, and our interest is the long-term course of 
functional status after this initial period of recovery.  There were 163 functional assessments within 6 
months of stroke.  Follow-up was censored at the time of recurrent stroke.  The primary covariate of 
interest was the time of follow-up, and the parameter term associated with this signified the slope of 
decline in functional status and QOL.  The model included a product term (between a dummy variable of 
post-stroke status, and time of follow-up) that allowed for a different slope before and after stroke, and 
allowed for a direct test for a significant difference in slope, as follows: 
 Y = intercept + β1*FU + β2*FU*poststroke + β3*poststroke + ∑ β *covariates, 
where FU=follow-up time, poststroke=0 if the time of follow-up was before the stroke, and 1 if after the 
stroke. 
In model building, we sequentially added groups of variables defined by epidemiological 






variables, vascular risk factors, social variables, and cognitive and mood factors.  These models 
assessed the relationship between explanatory variables and repeated measurements of functional 
status.  To assess whether the main explanatory variables were associated with the slope of change in 
outcomes over time, we included interaction terms between time of follow-up assessment and the 
variable.  All significant interactions with time were included in the final model.  We used QIC as the 
model selection criterion after considering candidate final models. Various model diagnostics including 
residual plots and goodness of fit measures were used to evaluate the final model, including linearity of 
the time trends.  There was no evidence for non-linearity of the time trend.  As a working correlation 
structure we chose the exchangeable (intraclass) structure and compared the QIC obtained with this 
model with one using the unstructured working correlation structure.  We chose the exchangeable model 
as the final model.   
 We performed several sensitivity analyses.  In one, we did not censor recurrent strokes and 
included these in the analysis, in order to model the course of function over time while also incorporating 
the effect of recurrent stroke events.  We also performed a sensitivity analyses in which we included 
measures of stroke severity, using stroke subtype as a proxy for severity.    
MI cohort We also conducted an analysis identical to that outlined above, except that the event of 
interest was MI instead of stroke.  Hence, the models assessed functional decline before and after MI in 
those who had MI during follow-up.  We first determined whether a drop in function post-MI occurs as with 
stroke.  The six-month period after MI was not ignored, since the 3-6 month course of recovery 
documented with stroke does not exist with the same biological implications as with stroke.222, 223 Follow-
up was censored at the time of recurrent MI.   
Stroke and MI cohort We also performed another analysis in which we included MI and stroke in the 
same model, with interaction terms with MI as with stroke above.  This allowed a direct comparison 
between MI and stroke in terms of trajectories of functional status.  We used another model in which 
hospitalization instead of MI was included, in order to directly compare the effect of hospitalization with 
that of stroke.  We used GEE models as above, and limited the cohort to those who had stroke or MI 
during follow-up.  For the determination of events, we considered the 1st stroke or 1st MI only.  We 






time trend before and after vascular events.  We tested 3-way interactions between follow-up time and all 
covariates and retained variables in the final model that were significant at a p 0.15 threshold (due to 
decreased power with 3-way interactions).   
 In secondary analysis, different cutoffs of the functional scale were tested systematically in 
unadjusted and adjusted models to determine whether there was a cutoff at which a threshold effect 
could be seen.  Also, a dichotomous definition of disability (0 versus any score above 0) was tested 
according to a similar modeling strategy as above.   
 In other secondary analyses, models were stratified by presence and absence of depression, as 
well as by income status (above and below the median income).  Also, the pre-stroke trajectory of 
disability was compared to the trajectory in the whole cohort excluding those who experienced stroke, MI, 
and both stroke and MI.  The slope of change in disability was compared in these 4 groups, in unadjusted 
and fully adjusted models.   
 The impact of ischemic stroke subtype on disability trajectories was examined in several ways.  
First, the fully adjusted model was additionally adjusted for stroke subtype (lacunar, cardioembolic, and 
“other” subtype as referent).  Then, models were stratified by stroke subtype and trajectories of disability 
were examined before and after stroke.  In sensitivity analyses, different cholesterol subtypes (total 
cholesterol, HDL, LDL, and log of lipoprotein-A) were tested as covariates in separate models.   
 In order to assess for bias due to differential mortality between MI and stroke, we performed 
survival analysis of mortality after MI and stroke. With a non-significant log-rank test, it appeared as if the 
timing of mortality was similar in both groups, hence no significant bias would exist due to differential 
mortality (Appendix C2).  A sensitivity analysis was performed in which the worst possible functional score 
was assigned at the time of death.   
  
Results 
Among the total CHS cohort of 5888 participants, 249 (4.23%) had a history of stroke at study entry and 
166 (2.82%) had history of TIA.  A history of cardiac and vascular disease was common: 562 (9.54% of 
5888) had MI, 964 (16.37% out of 4924) had angina, 275 had CHF (4.67% out of 5888), 1154 (19.6% out 






follow-up time was 12.87 years (SD 6.20, minimum 0.01, maximum 21.6 years, median 13.17 years).  
During follow-up, there were 1086 incident first strokes, 885 of which were ischemic (see Appendix C3 [A] 
for information on stroke subtypes).  Among those free of cardiac disease at baseline (n=4734), 850 had 
an incident MI during follow-up, 758 of which (89.2%) were nonfatal (see Appendix C3 [B] for further 
information on cardiac events during follow-up).   
At the time of analysis, 4637 (78.8%) of the total cohort had died (see Appendix C3 [C] for causes 
of death).  However, despite the large proportion of the cohort who had died at the time of analysis, there 
was a significant amount of data on functional status before and after vascular events due to the long 
follow-up in CHS.  Out of 415 incident strokes with at least 1 follow-up assessment, 382 were ischemic, 
all of whom had no history of previous stroke.  Among these 382 participants, the average maximum 
follow-up time was 11.1 (SD 5.0) years (minimum 1.20, maximum 21.5 years).  There were an average of 
3.7 (SD 2.4) visits before stroke (median 3) and 3.7 (SD 2.3) visits after stroke (median 3).  In terms of 
follow-up time, the minimum was -8.15 years and maximum was 8.91 years (with time centered at the 
time of stroke; see Appendix C4 for distributions of number of visits before and after stroke).  There were 
395 incident MIs with at least 1 follow-up assessment.  Among these 395 participants, the average 
maximum follow-up time was 12.4 (SD 5.4) years (minimum 1.4, maximum 21.5 years).  There were an 
average of 3.8 (SD 2.5) visits before MI (median 4) and 3.8 (SD 2.4) visits after MI (median 4).  In terms 
of follow-up time, the minimum was -8.00 years and the maximum was 9.52 years, with time centered at 
the time of MI.   
In the stroke cohort of 382 individuals, 86/319 (63 missing) had incident MI.  In the MI cohort of 
395 individuals, 89/375 (20 missing) had incident stroke.  In the combined dataset of those who had 
incident ischemic stroke and incident MI, the sample size was 727.  During follow-up, 125 individuals had 
both incident stroke and incident MI: 56 had incident stroke before incident MI; 54 had incident MI before 
incident stroke; and 15 had incident stroke and incident MI on the same day.   
 In terms of variable distributions (Table C1), the mean age was similar among the overall cohort, 
the stroke cohort, and MI cohort.  There was a higher proportion of males in the MI cohort.  The 






 The overall functional score increased over follow-up, from a mean of 0.59 (SD 1.13) at year 1, to 
1.29 (SD 2.38) at year 5, to 3.51 (SD 3.95) at year 10 (Appendix C5 [A]).  The mean of functional scores 
was <1.0 or close to 1.0 in the years before stroke but increased from 2.00 (SD 2.90) to 4.17 (SD 4.12) 
from the time of stroke to 9 years after stroke (Appendix C5 [H]).  For MI, the mean was <1.00 in the 
years before MI but increased from 1.32 (SD 2.19) at the time of MI to 2.40 (SD 3.69) at 9 years after MI 
(Appendix C5 [K]).   
 When the trajectory of functional status before and after stroke was examined among those who 
had stroke during follow-up (Table C2), in a fully adjusted model, there was an annual change in disability 
score before stroke of 0.06 points per year (95% CI 0.002, 0.12) and an additional 0.15 points per year 
(95% CI 0.004, 0.30) after stroke.  There was an average of 0.45 points of change (95% CI -0.05, 0.95) at 
the time of stroke.  In these models, assessments of disability were censored after recurrent stroke.   
When both recurrent stroke and incident MI were censored (Table C3), the magnitude and direction of 
associations was unchanged but the significance levels dropped slightly.  There was a similar pattern of 
associations when a dichotomous definition of disability was used (Appendix C6).  Different cutoffs of the 
functional scale were tested systematically (Appendix C10) in adjusted and adjusted models, and no 
definite threshold effect was found for a particular cutoff of the functional score.   
When a continuous measure of depressive symptoms was used instead of a categorical definition 
of depression, the relationships between stroke event and trajectories of disability did not change, and 
disability increased by 0.05 points per point increase in depression score (95% CI 0.01-0.08, p-value 
0.007).  Models were stratified by presence (n=55) and absence (n=325) of depression (Table C4).  
Though these models have limited power, several findings emerged.  First, in an unadjusted model, the 
magnitude of pre-stroke increase in disability was higher among those with baseline depression (0.25 
points per year, 95% CI 0.07, 0.44) than those without (0.15, 95% CI 0.09, 0.20).  A significant additional 
annual increase in disability was seen in those without depression (0.16 points per year, 95% CI 0.0003, 
0.31).   
 Models were also stratified by income (Table C5).  In unadjusted models, among those with 
income below the median, there was a greater annual increase in disability before stroke (0.21 points per 






0.03, 0.14).  Among those with income above the median, there was a trend for an additional annual 
increase in disability after stroke (0.17 points per year, 95% CI -0.02, 0.36) that was not seen among 
those with income below the median.  There was a greater average increase in disability at the time of 
stroke among those with income below the median (1.37, 95% CI 0.70, 2.03) compared to those with 
income above the median (1.05, 95% CI 0.50, 1.60).  In a fully adjusted model, there was a significant 
additional increase in the slope of disability after stroke among those with income above the median of 
0.23 points per year (95% CI 0.03, 0.43).   
 The pre-stroke trajectory of disability was compared, in unadjusted and fully adjusted models, to 
the trajectory in the whole cohort excluding stroke, MI, and both stroke and MI (Table C6).  In unadjusted 
models, there seemed to be a slightly higher slope of increase in disability pre-stroke in the stroke cohort 
(0.16 points per year, 95% CI 0.11, 0.21) compared to the whole cohort excluding stroke (0.12, 95% CI 
0.11, 0.13), MI (0.14, 95% CI 0.13, 0.15), and stroke and MI (0.12, 95% CI 0.11, 0.13).  However, the 
magnitude of annual change in disability was similar among all cohorts in fully adjusted models.     
 When trajectories of disability before and after MI were examined (Table C7), there was no 
difference in slope of change before and after MI in unadjusted or adjusted models with recurrent MI 
censored; there was, on average, an increase in disability score at the time of MI of 0.34 points (95% CI 
0.07 0.61) in a fully adjusted model.  With both stroke and recurrent MI censored (Table C8), there was 
no difference in the slope of change of functional score before and after MI, and there was a trend for 
increased disability at the time of MI of on average 0.23 points (95% CI -0.04, 0.49).   
 The trajectories of change in functional score before and after both stroke and MI were further 
examined in the same model in the entire CHS cohort (Table C9).  In unadjusted models, the overall 
slope of increase in disability was similar both without (0.13 points per year, 95% CI 0.13, 0.14) and with 
adjustment for stroke and MI (0.12 points per year, 95% CI 0.11, 0.13; and 0.11 points per year, 95% CI 
0.10, 0.12).  There was a higher magnitude of change at the time of stroke (0.88, 95% CI 0.57, 1.20) than 
at the time of MI (0.20, 95% CI 0.09, 0.20). Also, there was a greater slope of increase in disability after 
stroke compared to before stroke (0.14 additional points per year, 95% CI 0.09, 0.20), but no significant 






 The changes in functional score related to stroke and MI were examined in the entire cohort using 
a single model with terms for both stroke and MI (Table C10).  In a fully adjusted model, there was a 
significant increase in disability at the time of stroke (0.68 points, 95% CI 0.41, 0.96) but not MI (0.03, 
95% CI -0.14, 0.19).  Also, there was a greater slope of change in disability after stroke compared to 
before stroke (0.05 additional points per year, 95% CI -0.001, 0.10) but not change pre- and post-MI 
(0.02, 95% CI -0.02, 0.06).  
 Table C11 shows a model in which all covariates were included that had significant interactions 
with time.  As with prior models, there was a significant average increase in disability at the time of stroke 
(0.68 points, 95% CI 0.41, 0.96) but not MI (0.07, 95% CI -0.08, 0.22), and an increased slope of disability 
after stroke (0.05 additional points per year, 95% CI -0.001, 0.10) but not MI (0.01, 95% CI -0.02, 0.04).  
In addition, several factors were associated with a higher slope of increase in disability over time: age, 
education, and diabetes.  Higher values of the mini-mental state score and social network score were 
associated with reduced slope of increase in disability over time.   
A sensitivity analysis was performed in which the worst possible functional score was assigned at 
the time of death (Appendix C7).  Results were similar to the primary analysis.  Specifically, in a fully 
adjusted model, there was an average increase in functional score of 0.68 points (95% CI 0.41, 0.96) at 
the time of stroke but no significant change at the time of MI.  There was also an additional increase per 
year in slope of disability of 0.05 points per year (95% CI -0.001, 0.10) but no additional change after MI.   
 A model using three-way interaction terms was also used to compare trajectories of disability 
before and after stroke and MI (Table C12).  In a fully adjusted model, stroke was associated with a 0.27 
point overall increase in disability compared to MI (95% CI 0.02, 0.52), and there was a 0.19-point-per-
year additional increase in disability score after stroke (95% CI 0.10, 0.27) but no change after MI.  
In a fully adjusted model with additional adjustment for stroke subtype (using a dummy variable 
with “other” subtype as referent), the subtype term was not significant.  However, the influence of stroke 
subtype on functional trajectories was explored further.  In sensitivity analysis, the trajectories of disability 
before and after stroke were examined in ischemic stroke subtypes (Appendix C8).  Among those with 
lacunar stroke (n=75), there was no significant change in functional score at the time of stroke (and the 






(0.33 additional points per year, 95% CI -0.06, 0.72).  For cardioembolic stroke (n=107), there was a large 
and significant average increase in functional score at the time of stroke (1.52 points, 95% CI 0.67, 2.37), 
and a trend for an additional increase in disability after stroke (0.25 additional points per year, 95% CI -
0.02, 0.53).  For “other” ischemic strokes (n=211), there was no significant change in slope of functional 
change after stroke, but there was an average increase of 1.37 points at the time of stroke (95% CI 0.85, 
1.90).   
 In sensitivity analysis, different cholesterol subtypes were tested in separate models (Appendix 
C9), but the direction and significance of primary predictors did not change substantively when different 
subtypes were added (total cholesterol, HDL, LDL, and log of lipoprotein-A levels).      
 
Conclusions for Analysis C 
CHS is a large, nationally representative cohort of elderly community-dwelling individuals with long-term 
follow-up approaching an average of 13 years.  There is regular measurement of a sensitive measure of 
disability including both ADL and IADL items, as well as surveillance and accurate measurement of 
vascular events such as stroke and MI.  Although almost 80% of the cohort had died by the time of 
analysis, there was a significant amount of data surrounding vascular events to estimate trajectories, with 
almost 4 annual measurements of disability before and after both stroke and MI.  Hence, it is an ideal 
cohort to estimate disability trajectories before and after stroke and MI.   
 There were 4 overall groups of analysis in this study: a cohort of those who had stroke during 
follow-up, a cohort of those who had MI during follow-up, the cohort of those who had either event, and 
the entire CHS cohort.  Among all of these analytic cohorts, a consistent pattern emerged, in which the 
slope of increase in disability after recovery from stroke was higher compared to before stroke but not 
different before and after MI.  There was a significant increase in disability at the time of stroke and a 
smaller but also significant increase at the time of MI.  Among the cohort of those who had stroke during 
follow-up, the slope of increase in disability after stroke was more than 2 times the slope before stroke.  In 
all of these models, disability measurements after recurrent stroke were censored, so the estimated 






 Several factors modified trajectories of disability.  Among those with depression, the magnitude of 
pre-stroke increase in disability was higher compared to those without depression.  Among those with 
lower income, there was a greater annual increase in disability before stroke compared to those with 
higher income.  Among those with higher income, there was an additional increase in the slope of post-
stroke stroke, suggesting that there may be more room for disability to occur among those with higher 
income.  Several factors were associated with a higher slope of increase in disability over time: age, 
education, and diabetes.  Better cognitive status and a larger social network were associated with 
reduced slope of increase in disability over time.    
 It can be hypothesized that those individuals who eventually have a stroke may have a higher 
slope of increase in disability before stroke than those who do not eventually have a stroke. However, 
when we compared pre-stroke trajectories to disability trajectories among those who did not develop 
stroke, MI, or either event, we found no differences.   
 Although there was limited power to test subtypes of ischemic stroke, there were no evident 
differences in slopes of disability among different stroke subtypes.  Cardioembolic and “other” subtype 
strokes were associated with greater average increase in disability at the time of stroke compared to 
lacunar strokes, reflecting the relatively milder phenotype seen with lacunar strokes.   







Table C1. Baseline characteristics of study population 
Variable Entire cohort First ischemic 
stroke with >1 
follow-up 
assessment 
First MI with >1 
follow-up 
assessment 
Number of participants, No. (%) 5888 (100) 382 (100) 395 (100) 
Biological characteristics:    
Age, mean (SD), y 72.8 (5.6) 74.1 (5.7) 73.2 (5.3) 
Age at event, mean (SD), y -- 78.3 (5.8) 77.5 (5.7) 
Body mass index, mean (SD), kg/m2 26.7 (4.7) 26.6 (4.4) 26.9 (4.5) 
    
Demographics:    
Male, No. (%) 2495 (42.4) 162 (42.4) 221 (56.0) 
Non-Hispanic white, No. (%) 4925 (83.6) 332 (86.9) 351 (88.9) 
   Non-Hispanic black, No. (%) 924 (15.7) 49 (12.8) 42 (10.6) 
   American Indian/Alaskan Native, No. (%) 15 (0.3) 1 (0.3) 2 (0.5) 
   Other race, No. (%) 20 (0.3) 0 0 
Non-White, No. (%) 963 (16.4) 50 (13.1) 44 (11.1) 
Received at least high school education, No. (%)  3352 (57.1) 234 (61.6) 275 (69.6) 
Marital status, No. (%) married  3893 (66.2) 255 (66.9) 249 (63.2) 
Yearly income, No. (%) 
   <$12,000 
   $12,000–$34,999 













Yearly income, No. (%) 
   <$16,000 










Additional health insurance, No. (%)  
   None 
   Private 
   Medicaid 
















    
Vascular risk factors, No. (%)    
Hypertension  3457 (58.8) 281 (73.6) 265 (67.1) 
On hypertension medications  2789 (47.4) 244 (58.6) 196 (49.6) 
Systolic BP, mean (SD) 136.6 (21.8) 143.2 (24.6) 140.6 (20.3) 
Diastolic BP, mean (SD) 70.7 (11.4) 72.1 (12.3) 71.6 (11.7) 
Number of alcoholic beverages consumed per 
week, mean (SD) 
2.6 (6.3) 2.3 (5.5) 2.00 (5.5) 






Diabetes mellitus, No. (%)  1739 (29.9) 143 (37.9) 140 (35.6) 
Current smoking, No. (%)  601 (11.6) 38 (10.9) 48 (13.2) 
Hypercholesterolemia, No. (%) 1241 (21.1) 86 (22.5) 89 (22.5) 
Total cholesterol, mean (SD), mg/dL 211.2 (39.3) 215.8 (40.4) 212.6 (38.4) 
High-density lipoprotein, mean (SD), mg/dL 54.2 (15.7) 52.7 (17.2) 50.6 (14.2) 
Low-density lipoprotein, mean (SD), mg/dL 129.8 (35.7) 133.0 (36.2) 132.9 (34.8) 
Atrial fibrillation, No. (%)  236 (5.3) 31 (11.4) 15 (5.1) 
History of coronary heart disease, No. (%)  1154 (19.6) 106 (27.8) 76 (19.2) 
History of myocardial infarction, No. (%) 562 (9.5) 63 (16.5) 0 
C-reactive protein level, mean (SD)  4.8 (8.3) 5.4 (9.0) 5.2 (7.5) 














Lp(a) level, mean (SD)  54.0 (55.8) 54.0 (51.5) 50.0 (48.7) 
Log-C-reactive protein level, mean (SD)  1.09 (1.02)  
Log-lipoprotein-A level, mean (SD)  3.48 (1.19)  
    
Other medical conditions, No. (%)    
Depression  292 (5.4) 31(8.9) 23 (6.2) 
CES-D depression scale score, mean (SD)  4.7 (4.60) 5.0 (4.6) 4.7 (4.6) 
Depressed (CES-D score >9)  809 (13.8) 55 (14.5) 58 (14.8) 
Arthritis  3025 (52.0) 219 (57.9) 231 (58.8) 
Mini mental state score, mean (SD) 90.6 (5.7) 89.6 (6.1) 90.2 (5.7) 
    


















Table C2. Trajectories of a continuous measure of disability before and after stroke  





Unadjusted model:    
Annual change before stroke 0.16 0.11, 0.21 <.0001 
Additional annual change after stroke 0.09 0.22, 1.24 0.2 
Change in functional score at time of stroke 1.21 1.62, 5.75 <.0001 
Adjusted for demographics:†    
Annual change before stroke 0.15 0.10, 0.20 <.0001 
Additional annual change after stroke 0.12 -0.02, 0.26 0.09 
Change in functional score at time of stroke 1.21 0.78, 1.63 <.0001 
Adjusted for vascular risk factors:*    
Annual change before stroke 0.15 0.10, 0.20 <.0001 
Additional annual change after stroke 0.12 -0.02, 0.26 0.09 
Change in functional score at time of stroke 1.21 0.78, 1.63 <.0001 
Adjusted for other medical conditions:**    
Annual change before stroke 0.15 0.10, 0.20 <.0001 
Additional annual change after stroke 0.12 -0.01, 0.26 0.078 
Change in functional score at time of stroke 1.20 0.77, 1.62 <.0001 
Adjusted for lipid biomarkers:‡    
Annual change before stroke 0.14 0.09, 0.19 <.0001 
Additional annual change after stroke 0.12 -0.02, 0.26 0.09 
Change in functional score at time of stroke 1.19 0.75, 1.63 <.0001 
Adjusted for cognition:π    
Annual change before stroke 0.09 0.05, 0.13 <.0001 
Additional annual change after stroke 0.10 -0.01, 0.21 0.06 
Change in functional score at time of stroke 0.64 0.29, 1.00 0.0004 
Adjusted for social support: ††    
Annual change before stroke 0.06 0.002, 0.12 0.04 
Additional annual change after stroke 0.15 0.004, 0.30 0.04 
Change in functional score at time of stroke 0.45 -0.05, 0.95 0.08 
†adjusted for age at time of stroke, sex, race, marital status, and income 
*no additional adjustment 
**additionally adjusted for: arthritis and depression 
‡additionally adjusted for log of lipoprotein A levels 
πadditionally adjusted for mini-mental state score 






Table C3. Trajectories of a continuous measure of disability before and after stroke, with recurrent 
stroke and incident myocardial infarction censored  





Unadjusted model:    
Annual change before stroke 0.16 0.11, 0.21 <.0001 
Additional annual change after stroke 0.09 -0.06, 0.24 0.3 
Change in functional score at time of stroke 1.19 0.76, 1.62 <.0001 
Adjusted for demographics:†    
Annual change before stroke 0.15 0.11, 0.20 <.0001 
Additional annual change after stroke 0.12 -0.03, 0.27 0.1 
Change in functional score at time of stroke 1.17 0.73, 1.62 <.0001 
Adjusted for vascular risk factors:*    
Annual change before stroke 0.15 0.11, 0.20 <.0001 
Additional annual change after stroke 0.12 -0.03, 0.27 0.1 
Change in functional score at time of stroke 1.17 0.73, 1.62 <.0001 
Adjusted for other medical conditions:**    
Annual change before stroke 0.15 0.10, 0.20 <.0001 
Additional annual change after stroke 0.13 -0.02, 0.28 0.1 
Change in functional score at time of stroke 1.14 0.70, 1.59 <.0001 
Adjusted for lipid biomarkers:‡    
Annual change before stroke 0.14 0.09, 0.19 <.0001 
Additional annual change after stroke 0.12 -0.03, 0.27 0.1 
Change in functional score at time of stroke 1.13 0.67, 1.59 <.0001 
Adjusted for cognition:π    
Annual change before stroke 0.09 0.05, 0.13 <.0001 
Additional annual change after stroke 0.09 -0.02, 0.21 0.1 
Change in functional score at time of stroke 0.59 0.23, 0.94 0.0012 
Adjusted for social support: ††    
Annual change before stroke 0.07 0.01, 0.13 0.02 
Additional annual change after stroke 0.13 -0.03, 0.29 0.10 
Change in functional score at time of stroke 0.46 -0.07, 0.99 0.09 
†adjusted for age at time of stroke, sex, race, marital status, and income 
*no additional adjustment 
**additionally adjusted for: arthritis and depression 
‡additionally adjusted for log of lipoprotein A levels 
πadditionally adjusted for mini-mental state score 






Table C4. Trajectories before and after stroke using a continuous definition of disability, stratified 
by depression 











95% CI p-value 
Unadjusted model:       
Annual change before stroke 0.25 0.07, 0.44 0.008 0.15 0.09, 0.20 <.0001 
Additional annual change after 
stroke 
0.18 -0.25, 0.61 0.4 0.07 -0.08, 0.21 0.4 
Change in functional score at 
time of stroke 
1.30 0.20, 2.40 0.02 1.19 0.74, 1.63 <.0001 
Fully adjusted model:*       
Annual change before stroke 0.14 -0.06, 0.35 0.2 0.05 -0.01, 0.11 0.096 
Additional annual change after 
stroke 
0.04 -0.47, 0.54 0.9 0.16 0.003, 0.31 0.047 
Change in functional score at 
time of stroke 
1.01 -0.73, 2.75 0.3 0.39 -0.13, 0.91 0.14 
*adjusted for: age at time of stroke, sex, race, marital status, income, arthritis, log of lipoprotein A levels, 






Table C5. Trajectories before and after stroke using a continuous definition of disability, stratified 
by income 






95% CI p-value Change in 
functional 
score 
95% CI p-value 
Unadjusted model:       
Annual change before stroke 0.21 0.13, 0.28 <.0001 0.08 0.03, 0.14 0.005 
Additional annual change after 
stroke 
0.03 -0.17, 0.23 0.7 0.17 -0.02, 0.36 0.076 
Change in functional score at 
time of stroke 
1.37 0.70, 2.03 <.0001 1.05 0.50, 1.60 0.0002 
Fully adjusted model:*       
Annual change before stroke 0.07 -0.04, 0.17 0.21 0.05 -0.02, 0.12 0.1 
Additional annual change after 
stroke 
0.06 -0.16, 0.28 0.6 0.23 0.03, 0.43 0.03 
Change in functional score at 
time of stroke 
0.56 -0.18, 1.29 0.14 0.38 -0.29, 1.05 0.3 
*adjusted for: age at time of stroke, sex, race, marital status, depression, arthritis, log of lipoprotein A 






Table C6. Comparing pre-stroke trajectory in stroke cohort to whole cohort trajectories 










95% CI p-value 
Pre-stroke trajectory in stroke 
cohort 
0.16 0.11, 0.21 <.0001 0.06 0.002, 0.12 0.04 
Trajectory in whole cohort 
excluding: 
      
Stroke 0.12 0.11, 0.13 <.0001 0.07 0.07, 0.08 <.0001 
Myocardial infarction 0.14 0.13, 0.15 <.0001 0.08 0.07, 0.08 <.0001 
Stroke and myocardial 
infarction 
0.12 0.11, 0.13 <.0001 0.07 0.06, 0.08 <.0001 
*adjusted for: age at time of stroke, sex, race, marital status, income, arthritis, depression, log of 






Table C7. Trajectories of a continuous measure of disability before and after myocardial infarction 
(MI), with recurrent MI censored  





Unadjusted model:    
Annual change before MI 0.13 0.09, 0.18 <.0001 
Additional annual change after MI -0.04 -0.13, 0.04 0.3 
Change in functional score at time of MI 0.36 0.11, 0.60 0.004 
Adjusted for demographics:†    
Annual change before MI 0.15 0.10, 0.20 <.0001 
Additional annual change after MI -0.03 -0.12, 0.05 0.4 
Change in functional score at time of MI 0.35 0.11, 0.60 0.004 
Adjusted for vascular risk factors:*    
Annual change before MI 0.15 0.10, 0.20 <.0001 
Additional annual change after MI -0.03 -0.12, 0.05 0.5 
Change in functional score at time of MI 0.34 0.10, 0.58 0.006 
Adjusted for other medical conditions:**    
Annual change before MI 0.14 0.09, 0.19 <.0001 
Additional annual change after MI -0.03 -0.11, 0.06 0.5 
Change in functional score at time of MI 0.35 0.11, 0.59 0.005 
Adjusted for inflammatory biomarkers:‡    
Annual change before MI 0.14 0.09, 0.19 <.0001 
Additional annual change after MI -0.03 -0.11, 0.06 0.5 
Change in functional score at time of MI 0.35 0.11, 0.60 0.005 
Adjusted for cognition:π    
Annual change before MI 0.10 0.05, 0.14 <.0001 
Additional annual change after MI -0.05 -0.12, 0.02 0.16 
Change in functional score at time of MI 0.29 0.07, 0.51 0.01 
Adjusted for social support: ††    
Annual change before MI 0.04 0.00, 0.08 0.03 
Additional annual change after MI 0.02 -0.07, 0.11 0.7 
Change in functional score at time of MI 0.34 0.07, 0.61 0.014 
MI=myocardial infarction 
†adjusted for age at time of MI, sex, race, marital status, and body mass index 
*additionally adjusted for diabetes 
**additionally adjusted for: arthritis and depression 
‡additionally adjusted for log of C-reactive protein levels 
πadditionally adjusted for mini-mental state score 







Table C8. Trajectories of a continuous measure of disability before and after myocardial infarction 
(MI), with stroke and recurrent MI censored  






Unadjusted model:    
Annual change before MI 0.14 0.09, 0.19 <.0001 
Additional annual change after MI -0.05 -0.13, 0.04 0.3 
Change in functional score at time of MI 0.16 -0.07, 0.39 0.17 
Adjusted for demographics:†    
Annual change before MI 0.15 0.10, 0.20 <.0001 
Additional annual change after MI -0.04 -0.13, 0.04 0.3 
Change in functional score at time of MI 0.15 -0.08, 0.38 0.2 
Adjusted for vascular risk factors:*    
Annual change before MI 0.15 0.10, 0.20 <.0001 
Additional annual change after MI -0.04 -0.12, 0.05 0.4 
Change in functional score at time of MI 0.13 -0.09, 0.36 0.2 
Adjusted for other medical conditions:**    
Annual change before MI 0.15 0.10, 0.20 <.0001 
Additional annual change after MI -0.04 -0.12, 0.05 0.4 
Change in functional score at time of MI 0.14 -0.09, 0.37 0.2 
Adjusted for inflammatory biomarkers:‡    
Annual change before MI 0.15 0.10, 0.20 <.0001 
Additional annual change after MI -0.03 -0.12, 0.05 0.4 
Change in functional score at time of MI 0.14 -0.09, 0.37 0.2 
Adjusted for cognition:π    
Annual change before MI 0.11 0.06, 0.15 <.0001 
Additional annual change after MI -0.05 -0.12, 0.03 0.2 
Change in functional score at time of MI 0.12 -0.09, 0.32 0.3 
Adjusted for social support: ††    
Annual change before MI 0.05 0.02, 0.09 0.004 
Additional annual change after MI 0.02 -0.07, 0.11 0.7 
Change in functional score at time of MI 0.23 -0.04, 0.49 0.09 
MI=myocardial infarction 
†adjusted for age at time of MI, sex, race, marital status, and body mass index 
*additionally adjusted for diabetes and coronary heart disease 
**additionally adjusted for: arthritis and depression 
‡additionally adjusted for log of C-reactive protein levels 
πadditionally adjusted for mini-mental state score 






Table C9. Trajectories of a continuous measure of disability before and after stroke and myocardial infarction in the entire cohort 
(n=5888), in unadjusted models  
Model Overall change model Overall change plus average change 
due to stroke and MI 
Pre- and post-stroke and –MI 
trajectories 
Variable Change in 
functional 
score 
95% CI p-value Change in 
functional 
score 
95% CI p-value Change in 
functional 
score 
95% CI p-value 
Annual change 0.13 0.13, 0.14 <.0001 0.12 0.11, 0.13 <.0001 0.11 0.10, 0.12 <.0001 
Change in functional 
score at time of 
stroke 
-- 1.65 1.41, 1.89 <.0001 0.88 0.57, 1.20 <.0001 
Change in functional 
score at time of MI 
0.27 0.15, 0.39 <.0001 0.20 0.06, 0.35 0.006 
Additional annual 
change after stroke 
-- 0.14 0.09, 0.20 <.0001 
Additional annual 
change after MI 
0.01 -0.02, 0.04 0.4 








Table C10. Trajectories of a continuous measure of disability before and after stroke and 
myocardial infarction in the entire cohort (n=5888), in adjusted models  






Adjusted for demographics:†    
Annual change -0.83 -0.98, -0.67 <.0001 
Change in functional score at time of stroke 0.86 0.55, 1.17 <.0001 
Change in functional score at time of MI 0.22 0.07, 0.36 0.004 
Additional annual change after stroke 0.12 0.06, 0.17 <.0001 
Additional annual change after MI 0.01 -0.02, 0.04 0.5 
Adjusted for vascular risk factors:*    
Annual change -0.85 -1.01, -0.70 <.0001 
Change in functional score at time of stroke 0.85 0.54, 1.17 <.0001 
Change in functional score at time of MI 0.11 -0.08, 0.30 0.3 
Additional annual change after stroke 0.11 0.06, 0.17 <.0001 
Additional annual change after MI 0.01 -0.03, 0.04 0.7 
Adjusted for other medical conditions:**    
Annual change -0.86 -1.02, -0.70 <.0001 
Change in functional score at time of stroke 0.84 0.53, 1.16 <.0001 
Change in functional score at time of MI 0.14 -0.05, 0.32 0.15 
Additional annual change after stroke 0.11 0.06, 0.17 <.0001 
Additional annual change after MI 0.01 -0.03, 0.04 0.8 
Adjusted for inflammatory biomarkers:‡    
Annual change -0.87 -1.03, -0.71 <.0001 
Change in functional score at time of stroke 0.84 0.52, 1.16 <.0001 
Change in functional score at time of MI 0.13 -0.06, 0.32 0.17 
Additional annual change after stroke 0.11 0.06, 0.16 <.0001 
Additional annual change after MI 0.00 -0.03, 0.04 0.8 
Adjusted for cognition:π    
Annual change 0.10 -0.10, 0.31 0.3 
Change in functional score at time of stroke 0.76 0.50, 1.03 <.0001 
Change in functional score at time of MI 0.16 -0.01, 0.32 0.06 
Additional annual change after stroke 0.04 -0.002, 0.09 0.06 
Additional annual change after MI -0.02 -0.05, 0.02 0.3 
Adjusted for social support: ††    
Annual change 0.16 -0.08, 0.39 0.19 
Change in functional score at time of stroke 0.68 0.41, 0.96 <.0001 
Change in functional score at time of MI 0.03 -0.14, 0.19 0.7 
Additional annual change after stroke 0.05 -0.001, 0.10 0.056 
Additional annual change after MI 0.02 -0.02, 0.06 0.3 
†adjusted for age at time of stroke, sex, race, education, income, and interaction terms between time of 
follow-up and these variables 
*additionally adjusted for: diabetes, hypertension, coronary heart disease, and interaction terms between 
time of follow-up and these variables 
**additionally adjusted for: arthritis and depression, and interaction terms between time of follow-up and 
these variables 
‡additionally adjusted for log of C-reactive protein, and interaction terms between time of follow-up and 
these variables 
πadditionally adjusted for mini-mental state score, and interaction terms between time of follow-up and 
these variables 







Table C11. Trajectories of a continuous measure of disability before and after stroke and 
myocardial infarction in the entire cohort (n=5888), in final adjusted model with non-significant 
interaction terms excluded 










95% CI p-value 
Annual change 0.18 -0.05, 0.42 0.12   --   --   -- 
Change in functional 
score at time of stroke 
0.68 0.41, 0.96 <.0001   --   --   -- 
Change in functional 
score at time of MI 
0.07 -0.08, 0.22 0.4   --   --   -- 
Additional annual change 
after stroke 
  --   --   -- 0.05 -0.001, 
0.10 
0.055 
Additional annual change 
after MI 
  --   --   -- 0.01 -0.02, 0.04 0.4 
Age at baseline, per yr 0.02 0.02, 0.03 <.0001 0.004 0.002, 0.01 0.0009 
Male sex 0.22 0.16, 0.29 <.0001   --   --   -- 
Non-White race -0.04 -0.15, 0.06 0.4 -0.02 -0.05, 0.01 0.17 
At least high school 
education level 
0.00 -0.09, 0.09 0.99 0.02 0.00, 0.04 0.03 
Yearly income of $12000 
to $34999 
-0.05 -0.13, 0.04 0.3   --   --   -- 
Yearly income of 
>=$35000 
-0.03 -0.13, 0.06 0.5   --   --   -- 
Diabetes 0.05 -0.03, 0.13 0.2 0.03 0.01, 0.05 0.005 
Hypertension 0.06 -0.0002, 
0.11 
0.051   --   --   -- 
Coronary heart disease 0.17 0.06, 0.28 0.002   --   --   -- 
Arthritis 0.37 0.31, 0.42 <.0001   --   --   -- 
Depression 0.56 0.44, 0.68 <.0001   --   --   -- 
Log of C-reactive protein 
levels 
0.09 0.06, 0.13 <.0001   --   --   -- 
Mini-mental state score -0.02 -0.02, -
0.01 
<.0001 -0.004 -0.005, -
0.002 
<.0001 
Social network score -0.01 -0.01, -
0.002 










Table C12. Trajectories before and after stroke and myocardial infarction (MI) in the cohort of 
those with stroke or MI, with 3-way interactions 






Unadjusted model:    
Annual change before stroke or MI 0.17 0.13, 0.22 <.0001 
Overall increase due to stroke, compared to 
MI 
0.28 0.02, 0.55 0.04 
Change in functional score at time of stroke 
or MI 
0.74 0.33, 1.14 0.0003 
Additional annual change in those with stroke -0.03 -0.10, 0.04 0.4 
Additional annual change after MI -0.07 -0.14, 0.0009 0.053 
Additional annual change after stroke 0.24 0.16, 0.31 <.0001 
    
Adjusted model:*    
Annual change before stroke or MI 0.13 0.07, 0.20 <.0001 
Overall increase due to stroke, compared to 
MI 
0.27 0.02, 0.52 0.04 
Change in functional score at time of stroke 
or MI 
0.37 -0.01, 0.75 0.059 
Additional annual change in those with stroke -0.11 -0.19, -0.03 0.006 
Additional annual change after MI -0.04 -0.12, 0.04 0.3 
Additional annual change after stroke 0.19 0.10, 0.27 <.0001 
MI=myocardial infarction 
*Adjusted for: baseline age, sex, race, education, income, diabetes, hypertension, coronary heart 





























In the previous chapters, several hypotheses were tested related to the conception of cerebrovascular 
disease as a progressive condition, with chronic effects on disability and functional status.  Several main 
points emerged.  In Analysis A, increasing CRP levels were associated with lower overall mean functional 
score but not with change in slope of function over time.  Results were similar for LpPLA2 mass levels.  
However, for TNFR1, increasing levels were associated not only with overall reduced functional status, 
but also additional annual decline in function over time.  In Analysis B, using different measures of SBI, 
there was a strong, consistent, independent, and significant effect on accelerated decline in function over 
time, over and above the annual decline in function due to aging.  This pattern was seen with WMHV as 
well. This pattern of association was seen with MRI imaging markers believed to be caused by vascular 
impairment (SBI, lacunar infarcts, and WMHV) but not with other MRI structural findings, such as LPVS, 
which are not believed to be caused directly by a primary vascular pathology.  In Analysis C, trajectories 
of disability were examined not only in relation to baseline predictors but also in relation to vascular 
events occurring during follow-up.  The slope of increase in disability after recovery from stroke was 
higher compared to before stroke but not different before and after MI.  There was a significant increase 
in disability at the time of stroke and a smaller but also significant increase at the time of MI.  Among the 
cohort of those who had stroke during follow-up, the slope of increase in disability after stroke was more 
than 2 times the slope before stroke.  In all of these analyses, disability measurements after recurrent 
stroke were censored, so the estimated disability trajectories were independent of clinical recurrent 
stroke.  From these inter-related analyses, a pattern emerges of cerebrovascular disease having a 
progressive negative influence on functional status in the absence of clinical stroke events, with a strong 
and reproducible impact of subclinical ischemic brain injury and serum inflammatory biomarkers, 
especially TNFR1.  The following sections will compare these findings to those in previous studies and 




Many prior studies have examined the association between CRP and vascular outcomes and mortality.  






disease.  In a longitudinal analysis in the prospective cohort of NOMAS, elevated CRP was independently 
associated with MI and death, but not ischemic stroke.116 In a meta-analysis of 160,309 individuals 
without vascular disease from 54 prospective studies,224 each SD increase in log of CRP levels was 
independently associated with: coronary heart disease (RR 1.37, 95% CI 1.27–1.48), ischemic stroke (RR 
1.27, 95% CI 1.15–1.40), vascular death (RR 1.55, 95% CI 1.37–1.76), and non-vascular death (RR 1.54, 
95% CI 1.40–1.68).  In addition to those without vascular disease, stroke patients have also been 
examined.   Among 198 young ischemic stroke patients with a mean age of 48 years, higher CRP levels 
were associated with increased risk of mortality over a mean of 12 years of follow-up.225 Among 1244 
lacunar stroke patients followed for a median of 3 years in the Levels of Inflammatory Markers in the 
Treatment of Stroke study, higher CRP levels were associated with recurrent stroke, with an adjusted HR 
of 2.32 for the 4th quartile of CRP levels (95% CI 1.15–4.68), and major vascular events (HR 2.04, 95% CI 
1.14–3.67).226   
 In addition to vascular events, disability and functional status have been examined as outcomes 
in studies of the predictive ability of CRP.  For example, among 807 consecutively admitted ICH patients 
in Finland,227 elevated CRP levels at admission were associated with worse MRS scores at 3 months.  
We examined functional status over a longer time period related to ischemic stroke.  In the Survey of 
Midlife Development in the United States (MIDUS) study, a population-based sample of 1255 individuals 
with data on biomarkers, functional status, and comorbidity were studied.228 Inflammation, indicated by a 
latent factor contributed to be CRP, IL6, and fibrinogen, partially mediated the relationship between risk 
factors and disability.  In a cross-sectional analysis using 10 years of data from the National Health and 
Nutrition Examination Survey (NHANES) among 1729 adults with diabetes,229 elevated CRP was 
independently associated with disability in terms of ADL functioning as well as lower extremity mobility.  
Results were similar when 1403 individuals with cardiovascular disease were examined in NHANES.139 
Among 542 individuals with chronic obstructive pulmonary disease, congestive heart failure, 
cardiovascular risk, or physical disability, higher CRP and IL6 were associated with less grip strength and 
poor physical performance independent of demographics.230  
These associations between CRP and disability have also been found among specific race-ethnic 






multiple measures of increased impairment and disability, including ADLs and IADLs, upper and lower 
extremity functional impairments, and physical performance.231 Among 417 Korean acute ischemic stroke 
patients with CRP measured at admission and 7 days, CRP levels at both time points, but especially at 7 
days, was associated with 12-month MRS scores.232 
 In the only known study that has examined change of function over time, among 624 individuals 
>70 years of age in the Einstein Aging Study,233 elevated CRP was associated with mobility disability in 
the entire cohort, as well as incident disability and gait speed decline among those without vascular 
disease, over a median of 2 years of follow-up.  In our analysis, we had longer term follow-up and 
examined a larger cohort with and without vascular disease.  
Finally, one study examined the association of CRP with cognitive function.  In a cross-sectional 
analysis of a population-based cohort from Northern Manhattan, 1331 individuals without dementia were 
studied.234 Elevated CRP levels were independently associated with impaired memory and visuospatial 
function.   
 
Interleukin-6 
Several previous studies have examined outcomes related to IL6 levels among population-based cohorts.  
In a prior analysis in NOMAS among 1224 participants,235 IL6 levels above the median were associated 
with greater decline in cognitive ability measured by the TICS over a median of 3 years of follow-up.   In a 
cross-sectional meta-analysis of 6 cohorts, levels of circulating biomarkers were tested for associations 
with measures of physical performance.236 Higher levels of five inflammatory markers were associated 
with worse physical performance: IL6, TNFR2, TNFR1, TNFα, and GCSF.  Among 2979 individuals aged 
70-79 years in the Health, Aging and Body Composition Study,237 there was a greater risk of incident 
mobility limitation with higher IL6 (RR 1.19, 95% CI 1.10-2.8), CRP (RR 1.40, 95% CI 1.18–1.68), and 
soluble TNFR1 levels (RR 1.28, 95% CI 1.04–1.57) over 30 months of follow-up.  In the Health Aging and 
Body Composition study, 238 2234 elderly individuals were followed for a median of 11.4 years, and higher 
IL6 levels were associated with the onset of disability and mortality.  Higher IL6 levels have also been 
independently associated with periventricular and deep WMHV among 137 elderly women, suggesting a 






associated cross-sectionally with greater WMHV among 1841 individuals aged 65-80 years but not with 
WMH progression after 4 years, further complicating the relationship between IL6 and subclinical 
ischemic brain injury.240   
 The associations between IL6 and outcomes have also been examined in particular subgroups of 
people.  For example, in a meta-analysis of 4112 stroke patients from 20 studies,241 IL6 was associated 
with poor outcome, defined as MRS score of >2 or BI score of <85, as well as post-stroke infection.  
Among 80 individuals with vascular dementia, increasing IL6 levels were independently associated with 
lower BI scores in a cross-sectional analysis.242 Among 1727 individuals >70 years of age in the Duke 
Established Populations for Epidemiologic Studies of the Elderly study,243 higher IL6 levels were 
associated with disability and self-rated health, and IL6 levels were associated with cancer, heart attack, 
and hypertension.   Among 3925 men aged 60-79 years, higher IL6 levels were associated with incident 
mobility limitation over an average of 11.5 years of follow-up.244   
 
Tumor necrosis factor receptor-1 
In an early cross-sectional analysis in NOMAS among 279 individuals,245 elevated TNFR1 levels were 
associated with carotid atherosclerosis among those <70 years of age.  In a more recent longitudinal 
analysis in the NOMAS prospective cohort,246 1862 participants were followed for a mean of 8.4 years for 
mortality and cause of death.  Increasing TNFR1 levels were associated with increased risk of all-cause 
and non-vascular mortality, and the magnitude of association was higher among those with lower 
socioeconomic status.  In the population-based Oxford Vascular Study,247 15 biomarkers were tested in 
929 patients with minor stroke and TIA.  Among the biomarkers tested, 4 were associated with all-cause 
death: tumor necrosis factor-alpha receptor-1, von Willebrand factor, heart-type fatty-acid-binding protein, 
and N-terminal pro-B-type natriuretic peptide.   
 
Lipoprotein-associated phospholipase A2 
LpPLA2 has been associated with vascular outcomes in previous studies.  In a prior NOMAS analysis 






stroke (HR 2.08, 95% CI 1.04-4.18) and the composite outcome of recurrent stroke, MI, or vascular 
death.248 CRP was associated with mortality alone.  In another NOMAS analysis of 1946 participants in 
the prospective cohort,249 LpPLA2 mass levels were associated with the occurrence of large-artery 
subtype of ischemic stroke among non-Hispanic Whites.   In a NOMAS analysis examining WMHV as an 
outcome,207 CRP levels were associated with WMHV, as were LpPLA2 levels when 3 biomarkers were 
examined in the same model (CRP, LpPLA2, and myeloperoxidase).   
In a large collaborative study using data from 32 prospective studies and involving 79036 
patients,250 LpPLA2 mass and activity were independently associated with increased risk of vascular 
events, including MI and stroke, and vascular mortality.  In the Clopidogrel in High-Risk Patients with 
Acute Non-disabling Cerebrovascular Events (CHANCE) trial, a subset of participants (n=3201) enrolled 
with stroke or TIA had LpPLA2 activity measured at baseline.251 Higher LpPLA2 activity levels were 
independently associated with higher risk of 90-day stroke as well as a composite of ischemic stroke, 
myocardial infarction, or death, and there was no interaction with treatment assignment.  Expert panels 
have recommended measuring LpPLA2 to improve risk prediction of cardiovascular disease,252 and the 
current analyses suggest that it may also be effective to predict functional status.   
LpPLA2 activity has also been associated with SBI cross-sectionally in a cohort of 921 stroke-free 
individuals, but only among women, with OR of 2.14 per 1 SD increase in levels (95% CI 1.31-3.50).253 
 
Summary 
Multiple prior studies have demonstrated associations between inflammatory biomarkers and vascular 
outcomes, mortality, and disability measured at single time points.  However, the current analysis is the 
only known analysis, among studies of inflammatory biomarkers, in which both baseline functional status 
as well as the trajectory of change over time was analyzed, not only disability measured at a single time 
point.  One difficulty in finding biomarkers that can predict outcomes surrounding vascular events is the 
heterogeneity of events such as stroke and the variety of pathophysiological processes involved in 
cerebrovascular events.  For example, biomarkers originally conceived as representing cardiac 
pathophysiology have also been associated with subclinical brain injury.254 One approach to improve the 






pathophysiologic processes that can lead to stroke: coagulative, inflammatory, cardiac, and 
atherosclerotic.255, 256 Also, there has been a recognition that biomarkers for Alzheimer’s disease change 
in composition and levels over time, as the disease progresses (Figure D1).257 Future research will 
hopefully clarify the mechanisms underlying the progressive decline seen after stroke, which would allow 
researchers and clinicians to track the progression of biomarkers over time that reflect these processes. 
Future research would measure biomarkers repeatedly over time through the pre-event and post-event 
states and enable the identification of those susceptible to accelerated decline over time.   
 
Analysis B 
Several previous studies have examined the associations between patient-centered outcomes and brain 
imaging markers of ischemic and degenerative changes.  In a prior analysis in the NOMAS MRI cohort,258 
greater WMHV and smaller TCV were associated with poorer performance in learning a list of words.  The 
current analysis expands upon this previous research by analyzing longitudinal trends of repeated 
measures of functional status and confirming a long-term effect of SBI and WMHV on functional decline.  
Prior research on the associations between imaging findings and outcomes has focused on white matter 
disease, subclinical brain infarcts, and other novel imaging markers.   
 
White matter disease 
There have been multiple publications from the Leukoaraiosis and Disability Study (LADIS) on the 
association between WMHs and outcomes.  Overall, individuals aged 65-84 years with any degree of 
subcortical WMH on MRI and no or mild disability were eligible for the study.  In one cross-sectional 
analysis, increasing leukoaraiosis was associated with increasing disability.259 Among 619 participants 
with IADL measured at 1 year,260 the risk of transition at 1 year to >2 ADL impairments was higher with a 
greater degree of WMHV, with an OR of 3.02 (95% CI 1.34-6.78) among those with severe WMHV 
compared to mild WMHV who were non-disabled at baseline.  After a mean of 2.42 years of follow-up, 
these trends were maintained,261 with a HR for transition to disability or death of 2.36 (95% CI 1.65-3.81).  
When gait and balance were examined yearly over 3 years of follow-up, more WMHV predicted decline 






subcortical ischemic vascular disease had greater declines in performance on multiple cognitive tests, as 
well as a threefold increase in risk of developing dementia during follow-up.  Results were similar when 
age-related white matter change was the primary predictor.264 
Several other studies have examined outcomes among stroke-free individuals with WMH 
measurements.  Among 287 community-dwelling individuals aged 70-90 years,265 greater WMHV was 
associated with physical decline over 1 year (defined as being in the top quartile of change in 
Physiological Profile Assessment scores, with OR 3.02, 95% CI 1.02-8.95), and possibly WMHs in the 
deep frontoparietal and periventricular parietooccipital regions had the greatest impact on decline.  In the 
population-based Rotterdam Study,266 2025 individuals were assessed for change in disability over a 
mean of 5.7 years.  Lower brain volume was associated with greater disability, in terms of overall brain 
volume as well as gray matter and white matter volumes individually.  Greater diffusivity, a marker of brain 
microstructure, was associated with higher risk of incident impairment.  Among 99 individuals 75-89 years 
of age, global WMHV was associated with urinary incontinence, mobility deficits, and executive 
dysfunction.267  
In a prior analysis in CHS,268 among 3230 individuals without stroke who had MRI and were 
followed for up to 16 years, 5 clusters of MRI patterns of ischemic injury were identified through a data-
driven approach: Normal, Atrophy, Simple Infarct, Leukoaraiosis, and Complex Infarct. Mean years of life, 
years of healthy life, and years of able life were calculated, and these outcomes were worst among those 
with Complex Infarct, which had the greatest degree of sickness and disability among the clusters.  
Among 267 Japanese-American men aged 74-95 years in the Honolulu-Asia Aging Study,269 cognitive 
function was measured at baseline and at 5 years, and those with white matter lesions at baseline had 
twofold higher adjusted odds of having a 1 SD drop in cognitive performance at 5 years.    
 Besides disability, other patient-centered outcomes have been examined among stroke-free 
cohorts.  In a cross-sectional analysis among 1538 individuals aged 55-72 years in the ARIC study,270 
ventricular size, high-grade WMH, and SBI were associated with worse performance on memory, 
executive, and language tasks.  Among 390 male twins aged 69-80 years in the NHLBI Twin Study, 
WMHV above the median was associated with a greater drop in Digit Symbol Substitution test scores at 






 The associations between WMHV and outcomes have also been examined in stroke patients.  
For example, among 408 stroke patients followed at 2 weeks and 1 year from stroke,272 severe 
periventricular WMHs were associated with disability at both time points and were associated with poorer 
recovery at 1 year, but WMHs in deep locations were not associated with these outcomes.  Among 101 
first ischemic stroke patients followed at 1 year with the MRS,273 WMHV was associated with greater 
disability.  Three-month outcomes were examined among 185 minor stroke (NIHSS <5) patients,274 and 
WMHV was associated with 90-day change in NIHSS score and MRS.    
 
Subclinical brain infarcts 
Several studies have focused on SBIs as primary predictors of outcomes.  In the LADIS study, among 
387 individuals with yearly neuropsychological testing and repeat MRI at 3 years,275 incident lacunes were 
associated with decline in executive function and speed and motor control.  Increase in WMHV was 
independently associated with executive dysfunction.  In CHS, 2450 individuals were followed for a mean 
of 4 years, and WMHV and brain infarcts were associated with higher incidence of disability and 
accelerated decline in gait speed.70 Adjustment for incident stroke and dementia and mini-mental status 
score did not attenuate associations.  Among 350 elderly Japanese individuals without dementia, 
subclinical white matter lesions were cross-sectionally associated with global cognitive impairment and 
frontal lobe dysfunction.276 Finally, among 787 consecutively admitted stroke patients, prior subclinical 
stroke was associated with higher odds of having a 3-month BI score of <60.277   
 
Other predictors 
In this analysis, there was an association among education, cognitive ability, and functional status.  In a 
previous study, healthy adults ranging in age from 23-84 years, including 28 APOE-E4 carriers, had FDG-
PET and MRI.278  There was an interaction with education, such that APOE-E4 carriers showed an 
association between higher education and metabolism in the fronto-temporal lobes, which correlated with 
episodic memory performance.  The evidence of higher fronto-temporal metabolism may reflect the 
strength or density of neural networks and may be one of the biological effects of education.  Prior studies 






hundred eighty-one cognitively normal individuals were followed with yearly MRI and cognitive 
assessments up to 20 years in the Oregon Brain Aging Study.279 WMHV increased around 10 years 
before onset of mild cognitive impairment (MCI), and ventricular size increased approximately 4 years 
before onset.  In 24% of individuals who had MCI and autopsy, there was concomitant Alzheimer’s 
dementia pathology as well as significant cerebrovascular disease.  Among 61 patients with subcortical 
vascular dementia followed annually for 3 years,280 11C–Pittsburgh compound B (PiB) PET-positivity at 
baseline was associated with accelerated decline in attention, visuospatial ability, visual memory, and 
global cognition.  WMHV was associated with similar patterns of decline, but lacunar infarcts and 
microbleeds were not.   
In this analysis, no significant associations were found between measures of perivascular spaces 
and functional status.  In a Japanese population-based study of 1575 neurologically healthy adults who 
had MRI,281 basal ganglia perivascular spaces were associated with basal ganglia microbleeds, and 
centrum semiovale perivascular spaces were associated with lobar microbleeds.  There was a common 
coexistence of perivascular spaces, hypertension, lacunes, and WMHV.  However, no functional 
outcomes were examined in this study and it is difficult to deduct the impact of these findings on 
functional status.  In another study among 31 individuals without dementia who had brain MRI and 
Pittsburgh compound B-PET imaging,282 amyloid burden was associated with perivascular spaces in the 
centrum semiovale.  In a study among 201 ICH patients,283 enlarged perivascular spaces in the centrum 
semiovale region were associated with small acute DWI-positive lesions, suggesting a possible role of 
perivascular spaces in vascular risk.  The underlying mechanism(s) of which perivascular spaces may be 




Multiple prior studies have shown relationships between subclinical ischemic injury, measured by WMHV 
and SBI, and patient-centered outcomes.  However, a minority of prior studies has examined trajectories 






change over time.  More research is needed examining trajectories of cognition and disability over time, 
possibly in relation to progressive imaging changes on repeated MRIs as well.   
The field of neuroimaging is undergoing rapid technological advances, and paralleling these 
advances has been a reconceptualization of the ways in which subclinical ischemic disease causes 
pathological effects on function.  Recent research suggests that WMHs have different degrees of 
surrounding tissue that is susceptible to further injury – what has been called the “WMH penumbra” – but 
that interventions have yet to be found that modify the progression of such regions.285 Also, WMHV may 
be caused by ischemic processes but may also be caused by the processes that lead to 
neurodegenerative diseases such as Alzheimer’s dementia.  A measure of gray matter integrity, such as 
cortical thickness, may be a more accurate reflection of the effect of each process.286 Diffusion tensor 
imaging can identify impaired fractional anisotropy, and this measure of impaired white matter 
microstructure has been associated with subsequent risk of Alzheimer’s disease in those with mild 
cognitive impairment.287 Other studies have found associations between microstructural integrity 
measured by MRI DWI sequences and subsequent cognitive and functional changes.288 Future studies 
may find a similar association between early white matter structural damage and accelerated functional 
decline after stroke.  One issue caused by the advances in imaging technology is heterogeneity in 
imaging protocols used and definitions used for SBI and WMHs, requiring the development of standard 
definitions to allow comparison among studies.289 
 
Analysis C 
Several studies have examined the course of functional outcomes before and after vascular events.  In a 
much earlier publication in CHS of self-rated health with up to 8 years of follow-up,290 a drop in self-rated 
health similar to the increase in disability seen in the current analysis was seen at the time of MI.  There 
were significant declines after stroke but not MI, but this analysis was centered on self-rated health and 
had short follow-up in comparison to the current analysis.   
In an analysis in HRS, cognitive function as measured by the modified TICS-m scale was 
assessed every 2 years over a mean of 4.1 years of follow-up.159 Compared to Whites, Blacks had 






not differ by race, and there were no significant differences in slope of change over time post-stroke.  In 
another analysis in HRS, the course of functional and cognitive impairment was compared before and 
after stroke (with 432 hospitalizations) and MI (with 450 hospitalizations).160 Using a combined measure 
of ADLs and IADLs, there was a greater increase in disability at the time of stroke compared to MI, similar 
to our findings in CHS.  Difference in pre- and post-stroke slopes of change depended on initial 
impairment levels.  Stroke but not MI was associated with higher odds of cognitive impairment.  
In the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, the course of 
cognitive function was compared before and after stroke among 515 individuals who had stroke, and 
23057 who remained stroke-free, during a mean follow-up of 6.1 years.161 There was a significantly 
steeper decline in cognitive function after stroke in the areas of global cognition and executive function.  
The risk of cognitive impairment was higher after stroke compared to before stroke, with an odds ratio of 
1.23 per year (95% CI 1.10-1.38).  These findings paralleled our results for the course of disability after 
stroke.   
In HRS, trajectories of  biennially measured memory performance were analyzed before and after 
nonfatal stroke (n=1189), before fatal stroke (n=385), and among 15,766 individuals who did not 
experience stroke over 10 years of follow-up.162 Among stroke survivors, the pre-stroke decline in 
memory performance was greater than among those who remained stroke-free, and those who died of 
stroke had even greater declines.  There was no significant difference in slope of change in memory 
performance before and after stroke.  Limitations of this analysis were the long intervals between memory 
assessments, the self-report of stroke, and the large amount of missing data regarding stroke timing.   
In another analysis among 17341 participants in HRS,163 there were biennial assessments of a 
composite memory score over 10 years of follow-up.  There were 3 types of individuals: stroke survivors 
(n=1169), stroke decedents (n=405), and those who did not experience stroke during follow-up 
(n=15767).  As with the prior analysis, stroke was defined by self-report or report of a proxy but not 
confirmed by specialist review, and there was a significant amount of missing data on month (8.3%) and 
year (10.5%) of stroke.  Also, there was a significant amount of loss to follow-up (37%).  Overall, pre-
stroke decline in memory performance was greater in older individuals compared to younger individuals.  






were no significant differences among the stroke-free cohort.  For those in the older age stratum, there 
was a steeper decline in memory performance after stroke compared to before (-0.15 vs. -0.07 
points/year, p = 0.003), similar to our findings in CHS.     
In the ARIC study,164 a change score in 3 cognitive measures was calculated over approximately 
14 years, and 2 MRIs were performed over a similar time interval (10 years) and scored for presence of 
infarcts, WMHV, and ventricular size.  There was ongoing surveillance for hospitalizations, and type of 
hospitalization was categorized using ICD-9 codes.  For those who were hospitalized during follow-up, 
there was a decline in performance on the Digit Symbol Substitution Test.  When trajectories of change in 
cognitive performance were compared pre- and post-hospitalization, there was accelerated decline in the 
Digit Symbol Substitution test after hospitalization, with an additional 0.20 digit-symbol pairs/year (95% CI 
0.12–0.27), and accelerated decline in the Word Fluency Test after hospitalization, with an additional 0.09 
words/year (95% CI 0.02–0.17).  Hospitalized patients had greater development of atrophy.  Overall, 
critical illness and major surgical hospitalizations were associated with greater cognitive decline and MRI 
changes.   
In another ARIC study, trajectories of self-rated health were examined over a median of 17.6 
years in 11,188 individuals who remained disease-free, 1071 individuals who developed MI, and 809 who 
developed stroke.165 Higher neighborhood income was strongly associated with better self-rated health 
and less prevalent comorbidities.  There was no difference in the slope of change in self-rated health over 
time before and after stroke in this analysis.   
Among 687 community-dwelling elderly individuals assessed for life space mobility, those with 
surgical hospitalizations had greater drop in mobility at the time of hospitalization compared to those with 
non-surgical admissions, who had no significant recovery over time.166 
The concept of frailty may capture some of the observed variation in disability, and previous 
studies have examined the association between frailty and event-based outcomes.  Among 1521 
individuals <65 years of age with first acute MI in 8 Israeli hospitals, the Rockwood frailty index was 
assessed at baseline and 10-13 years later.291 The frailest individuals had twice the risk of mortality 






In the current analysis, male sex was associated with overall worse disability but no difference in 
slope of change over time.  This was true also among 3501 young MI patients (age 18-55 years) with 
patient-centered outcomes gathered at baseline, 1 month, and 1 year,222 in whom the trajectory of 
improvement in QOL and health status was similar among males and females, although females had 
lower scores in all domains at all time points of follow-up. 
We did not find an effect of race-ethnicity on disability trajectories in this analysis.  However, in an 
analysis from the Cooperative Cardiovascular Project,292 141095 Medicare beneficiaries, 6.3% of whom 
were Black, were hospitalized with MI and followed for 17 years.  A quarter of the Black patients lived in 
low-SES areas, compared to 5.7% of White patients, and life expectancy was lower for Black patients.  
Furthermore, the greatest discrepancy in life expectancy was seen in high- and medium-SES areas.  It is 
possible that this mortality disparity was not paralleled by a disparity in disability.  However, further 
dedicated research in race-ethnic disparities in trajectories of functional status is needed. 
 Depression was associated with worse overall disability in this analysis.  In an early analysis of 
CHS data with 4 years of follow-up, persistent depression (as compared to temporary depression or no 
depression) was associated with significantly higher odds of disability, with an adjusted OR of 5.27 (95% 
CI 3.03-9.16).217 These findings were confirmed in an analysis of 2102 individuals in the Health, Aging, 
and Body Composition Study over 9 years of follow-up.293 Also, among 425 individuals with an acute 
coronary syndrome, depression symptoms and physical health status were assessed after the event and 
12 months later.294 Persistent depressive symptoms were associated with poorer physical health status.  
Not only depression but also PTSD is common after sudden health events such as stroke and MI, and 
PTSD may play a role in social participation in the long term after recovery from events.  For example, 
among 40 MI survivors diagnosed with PTSD 5 months after MI, 2/3 had persistent PTSD more than 2 
years after MI.295 Psychological distress is also common over the long term after stroke, but its effect on 
trajectories of function is unclear.296 
 
Possible mechanisms 
Greater knowledge about population trends in disability, as discussed in the above analyses, would 






that incorporate long-term neurodegeneration or progressive damage into the range of stroke injury.  
Based on previous studies, there are several mechanisms that could cause the accelerated decline in 
functional status after stroke seen in the above analyses.  Some mechanisms have been discussed 
above in the opening chapter, and additional mechanisms will be discussed here. 
There are several brain structural changes that have been associated with cerebrovascular 
disease that may have impacts on cognition and functional status.  For example, brain infarcts have been 
associated with smaller hippocampal volumes, which are associated with poorer memory and cognitive 
function.297 Silent cerebral infarction has also been associated with reduced grey matter volume and 
concomitant cognitive deficits.298 WMHV, SBI, microbleeds, and atrophy have been associated with 
declines in gait speed, cadence of gait, and length of steps,299-301 which would affect the mobility aspects 
of ADL functioning.  WMHV and progression of WMHV have been associated with neurological 
examination findings such as gait and stance abnormalities, upper motor signs, and slowing of 
fingertaps,302 and presence and number of neurological deficits have an independent impact on 
performance of ADLs.303 Silent deep infarcts and WMHV have been associated with gait variability, which 
has been associated with falls and disability.304 
There has been some debate about the pathophysiology of white matter disease, but ischemia 
and vascular dysfunction have been confirmed to play a major role in the genesis of WMHs.  In a study 
among 5 individuals with moderate to severe WMHV who had weekly MRIs over 16 weeks of follow-up,305 
tiny asymptomatic acute infarcts were identified on repeat scans that eventually resembled WMHs 
radiographically over follow-up.  Vascular risk factors also cause WMHs, which then cause disability and 
cognitive impairment.  For example, in a prior analysis in CHS,71 hypertension was associated with 
baseline and incident disability, and WMHV mediated the association between hypertension and 
disability.  Among 976 hypertensive individuals, age, sex, and Framingham cardiovascular risk scores 
were associated with SBI in a cross-sectional analysis.306 Not only overt diabetes but also fasting glucose 
has been independently associated with WMHs and SBI among 172 healthy, non-institutionalized 
individuals.307 
Inflammation has also been implicated in the pathophysiology of WMHs, in genetic, epigenetic, 






reduced brain volume and SBI (but not WMHV) among 1965 healthy individuals in the Framingham 
Offspring Study, especially among older ages.309 Endothelial dysfunction has been implicated in the 
development of WMHV and SBIs, as shown in 2013 stroke-free individuals in the Framingham Offspring 
Study, in whom asymmetrical dimethylarginine, an inhibitor of endothelial nitric oxide synthase, was 
associated with subsequent SBIs and WMHV.310 Hemostatic factors have also been shown to be related 
to cerebrovascular disease; von Willebrand factor and D-dimer levels were associated with subclinical 
lacunar infarcts in a case-control analysis of 410 individuals in the ARIC study.311 
Possible mediators of the relationship between vascular risk factors and trajectories of disability 
and cognition would need to be clarified in future research.  Previous studies have identified possible 
mediators that could be potential targets for intervention.  For example, post-stroke apathy is a less well 
understood phenomenon that is common, follows variable trajectories, and has an impact on disability 
and social participation.312 When 118 individuals with lacunar stroke and WMHs were compared to 398 
healthy controls,313 both apathy and depression were associated with lower QOL.  However, impaired 
white matter structure, as measured by fractional anisotropy, was associated with apathy alone, 
especially when impaired anisotropy was present in limbic association areas.  Further research is needed 
on conditions such as apathy that are intermediate between brain ischemic damage and disability. 
 Several studies have suggested a role for socioeconomic status in long-term outcomes, including 
functional outcomes.  For example, all stroke admissions in Denmark from 2003-2012 in those >40 years 
of age were examined (n=56581, median follow-up 3.1 years), and linkage was performed with national 
registries with data on income and vital statistics.314 There was a strong and dose-dependent effect of 
income on post-stroke mortality, and the relative risk of death in those with the highest income quintile 
compared to the lowest was 0.70 (95% CI 0.65-0.74).  This finding is particularly striking considering that 
Denmark has free, universal health coverage.  In an another analysis of a nationwide registry with 
2,397,446 participants over 12 years in the Netherlands,315 lower socioeconomic status was associated 
with higher risk of stroke among all ethnic groups, and ethnic groups had higher stroke incidence within 
strata of income level compared to ethnic Dutch.  In an innovative environment-wide association study 






with 66 out of 330 tested factors, including infectious, biochemical, physiological, and environmental 
factors.316 It is likely that socioeconomic status has multifactorial influences on disability after stroke.   
Education has also been shown to have a strong association with outcomes.  In an analysis of 
851 individuals followed from age 85 to 90 years with 98.7% complete data on disability during follow-
up,317 four trajectories of disability were evident, and education protected against being in the most 
disabled group.  Among 3955 individuals over 10 years of follow-up, those with the most education had a 
23-45% reduced chance of disability compared to those with mean levels of education.318 There was a 
significant effect of income but with less of a magnitude of effect. 
Environmental and social factors may also play a role.  Leisure-time physical inactivity is common 
after MI (up to 37% up to 13 years after MI among 1410 individuals with first MI), and low neighborhood 
SES predicted low physical activity.319 Social isolation and changes in caregiver and friend networks 
during stroke recovery may also play a role in trajectories of performance in ADLs.320 Even the type of 
caregiving style may play a role, as suggested by research among TBI patients.321 Strain on caregiving 
networks and change in the constitution and effectiveness of these networks over time may play a role in 
late functional decline.322 
In the above analyses, baseline depression was associated with subsequent disability, 
suggesting causal directionality from depression to disability.  Several studies have shown an association 
of depression with disability, but at least one, among 442 Taiwanese elderly individuals with repeated 
measures of depression and disability over 10 years,323 has suggested that disability may lead to 
depression more often than depression leads to disability.  Repeated measures of both depression and 
functional status over time would allow the clarification of this directionality.   
It is also unclear whether measures of impairment, such as weakness, or sociodemographic 
factors are better predictors of functional trajectories.  In an analysis of 9471 individuals with 12 years of 
data from HRS,324 there were three trajectories of disability, and impairment indicators predicted these 
trajectories better than sociodemographic characteristics, suggesting that mediators of the relationship 
between sociodemographics and disability trajectories should be targeted in observational and 







Implications for clinical trial design 
If there is a progressive decline in functional status in the long-term after stroke that is independent of 
clinical events such as stroke and MI, the conventional 90-day functional outcome measure after an 
intervention is likely not adequate to evaluate the effectiveness of a treatment.325 Figure D2 shows 
several trajectories of change in functional status that all have the same 90-day functional outcome, each 
representing a drastically different course of change over time.  More data is needed about the expected 
course of recovery after specific stroke subtypes, or perhaps related to specific locations of infarct.  An 
enhanced ability to predict such trajectories would allow the design of trials of interventions that could 
modify expected trajectories, not only outcomes at discrete time points such as 90 days.326 In clinical 
trials, patient-centered outcomes should be assessed, but the use of standard scales may be limiting.  A 
qualitative study with several interviews over the first year after stroke found that fatigue was common 
and disabling, although standard scales of physical recovery showed little deficit.327 Also, a combination 
of qualitative and quantitative research may be required to develop scales to use in large datasets that 
are sensitive to the patterns of change in patient-centered outcomes over time.328, 329 
 Biomarkers that represent intermediate processes that occur prior to imaging-confirmed infarct 
and cerebrovascular disease could be used to identify those at risk as well as a surrogate marker for 
clinical trials.  For example, retinal microvascular abnormalities have been shown to be a powerful 
predictor of cerebral infarct and WMHV in the ARIC study over a median of 10.5 years of follow-up.330 The 
retinal vasculature is an effective marker of cerebrovascular dysfunction because it can be viewed and 
assessed non-invasively with relatively inexpensive equipment.   
 
Heterogeneous trajectories 
Several previous studies have identified distinct trajectories of change in patient-centered outcomes over 
time, primarily using statistical techniques such as latent class analysis that are tailored to the discovery 
of groups each with a distinct trajectory.  For example, several studies have shown heterogeneous 
trajectories of disability331 and cognitive function332 at older ages that may vary by sex.333 Almost 1000 
African American community-dwelling individuals aged 50-64 years had self-rated health assessed over 9 






health: “persistently good health, good but declining health, persistently fair health, and fair but declining 
health.”334 In a study examining psychological symptoms, 444 stroke patients had repeated measures of 
psychological symptoms over 4 years of follow-up and the Barthel index assessed at the end of follow-
up.335 At first assessment, 21% met criteria for a psychological disorder, but symptoms improved over 
time and 12% met criteria for a psychological disorder at final follow-up.  Four trajectories of change in 
psychological symptoms were identified over time, and psychological symptoms were associated with 
subsequent disability.  In a Dutch prospective study among 2867 elderly individuals, disability was 
measured several times over 6 years, and 9 distinct trajectories of disability were identified.336 
There is heterogeneity in the degenerative processes that accompany chronological aging, and 
these processes may involve inflammation, impaired coagulation, and endothelial dysfunction.  
Chronological age is related to these changes but there is not a 1:1 correspondence, and greater 
knowledge of the factors causing variations among individuals would allow the identification of those more 
prone to decline.  Considering the heterogeneous trajectories that may be seen in functional and 
cognitive recovery after stroke, different predictive risk factors may exist for each phase of recovery: pre-
stroke, acute post-stroke, and chronic post-stroke; further research, with an attention to diverse 
trajectories of function, is needed to clarify these factors.337   
 
Potential interventions to reduce long-term functional decline 
Further research is needed that assigns trajectories of functional status as the outcome and tests 
potential interventions to mitigate this decline.  The first step is to identify those at risk of deterioration.  
Then, several potential approaches may be effective: targeted rehabilitation; continual monitoring of 
functional status; optimal pharmaceutical secondary prevention strategies; and interventions to reduce 
social isolation and depression after stroke.325 For example, an ongoing trial will test whether low-dose 
aspirin is effective in reducing the progression of SBI and WMH over time.338 Another ongoing trial will 
compare whether angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are more 
effective to reduce progression of subclinical infarcts over 2 years of follow-up.339 
Other areas of potential intervention are suggested by recent research.  Statins and other 






mediated declines in function.  Medications specifically targeted to the mechanism of biomarkers, such as 
darapladib to inhibit the activity of LpPLA2, may also be effective252. In addition to medications, diet may 
have an important impact on cognitive decline.  A specific dietary intervention may modify cognitive 
decline in those susceptible to this.340  In a large observational analysis of 2 international clinical trials with 
27860 patients followed over 56 months,341 higher diet quality (assessed with the modified Alternative 
Healthy Eating Index) was associated with lower risk of cognitive decline (HR 0.76, 95% CI 0.66-0.86), 
independently of baseline cognitive status.  Adherence to the Mediterranean diet among 674 elderly 
individuals with a mean age of 80 years was cross-sectionally associated with less brain atrophy.342  A 
recent randomized trial assigned elderly (age 60-77 years) individuals to a multidomain intervention 
(including diet, exercise, cognitive training, and monitoring of vascular risk factors) or a control group of 
general health advice, who were followed for change in performance on neuropsychological testing.343  
There was a significantly greater improvement in the intervention arm, ranging from 25-150% 
improvement on primary and secondary cognitive outcomes.  In terms of specific dietary or supplement 
intake, lower vitamin D levels have been associated with cognitive decline, and further research would 
clarify whether supplementation modifies trajectories of cognitive change over time.344   
Traditionally there has been an emphasis on the acute treatment of stroke and rehabilitation 
targeted to the early period after the event.  Indeed, insurance coverage for inpatient and outpatient 
rehabilitation is limited to the few weeks or months after stroke; stroke specialists have minimal dedicated 
training in stroke rehabilitation; and a minority of research funding in stroke is targeted to rehabilitation 
and helping patients deal with the disability effects of stroke.345 It may be more beneficial to conceive of 
stroke as a chronic disease that can benefit from ongoing physical rehabilitation over a long time period, 
since rehabilitative interventions have been shown to be effective even in the chronic phase after stroke. 
Rehabilitation may also be effective if it targets cardiorespiratory fitness.  Among 565 middle-
aged healthy individuals in the Coronary Artery Risk Development in Young Adults Study,346 
cardiorespiratory fitness was measured by a maximal treadmill test duration, and individuals had brain 
MRI after 5 years.  In fully adjusted models, better cardiorespiratory fitness predicted greater brain volume 
and higher white matter integrity.   In the Lifestyle Interventions and Independence for Elders trial,347 1635 






intervention and followed for 2.6 years.  There was a benefit of the physical activity intervention on 
prevention of major disability, with a HR of 0.82 (95% CI 0.69-0.98).   Alternatively, better control of 
vascular risk factors may lead to better outcomes.  Among 2566 stroke patients in the Fukuoka Stroke 
Registry, day-to-day blood pressure variability 4-10 days after stroke predicted worse functional outcome 
at 3 months.348 
Neurorehabilitation techniques may be beneficial to arrest or reduce functional decline over time, 
considering the importance of cognitive ability on functional status.  Techniques targeting specific 
cognitive domains or abilities may be useful, but further research is needed.349 Indeed, cognitive ability 
and education have been associated with brain health and cognitive reserve that protects against decline.  
For example, among 1959 subjects who had cortical thickness measurements by MRI, higher education 
levels were independently associated with mean cortical thickness throughout the brain, as well as in 
particular brain regions.350 However, this effect was only seen in older individuals, suggesting that the 
effect of education may be to reduce atrophy due to effects of aging, which may be a structural 
manifestation of cognitive reserve.  The Austrian Polyintervention Study to Prevent Cognitive Decline 
after Ischemic Stroke (ASPIS) tested whether a 24-month intervention to enhance compliance reduced 
post-stroke cognitive decline among 202 individuals.351 There was no significant effect of the intervention 
but power was limited.  In TBI, environmental enrichment may improve post-injury recovery.352 
Finally, further elucidation of the early and late inflammatory responses with stroke may identify 
targeted immune modulatory treatments that were developed for other conditions (such as multiple 
sclerosis) but may have efficacy to prevent long-term cognitive and functional decline after stroke.353    
 
The next step: future studies on trajectories and vascular events 
The above analyses suggest several next steps, in terms of hypotheses and study designs, which would 
elucidate and expand upon the findings discussed above.  Some of these steps can leverage data 
available in existing datasets, but in most cases new data collection would be necessary due to the 
requirements for accurate repeated measurement of variables over time.  For example, in order to clarify 
the impact of inflammatory and imaging markers on functional trajectories, more formal and thorough 






change over time is necessary, for example with latent class analysis, in order to better understand the 
influences on the time course of disability in relation to vascular events.  Newer analytic techniques can 
also statistically estimate the stability of trajectories of disability over time and may useful in future 
studies.354 
Repeated measures of not only outcomes but also longitudinal measures of covariates may be 
necessary, with recent research showing various trajectories of variables such as depression after 
vascular events such as MI.355, 356 In the analyses conducted here, most covariates were measured once 
at baseline, but the status and severity of comorbid conditions is more likely to change over time rather 
than remain constant as one ages.  Many existing longitudinal epidemiological studies do not routinely re-
measure comorbidities over follow-up, and most do not measure severity or control of such conditions as 
hypertension and diabetes, which may have an impact on functional status.   
The inflammatory processes surrounding cerebrovascular disease are complex, and likely distinct 
inflammatory biomarkers vary simultaneously.  The variation of a single biomarker is unlikely to effectively 
capture the predictive potential of a panel of biomarkers varying together.  Hence, a future analysis will 
involve mixtures analysis of multiple biomarkers at once, or other data reduction techniques with even 
larger numbers of markers.  An early attempt at this was made in NOMAS in which the relative levels of 
CRP and IL6 were analyzed.201  A 3-level variable was created of CRP-dominant, IL6-dominant, or 
codominant levels, and there was increased risk of ischemic stroke in the CRP-dominant group and 
decreased risk in the IL-6–dominant group.  A similar approach was used among 718 women followed for 
5 years in the Women’s Health and Aging Study,357 in which the combination of low IGF-I levels and high 
IL6 levels were associated with cross-sectional disability subsequent death and disability.  Newer analytic 
techniques involving clustering and data reduction through machine learning algorithms may have better 
performance and would be able to incorporate larger numbers of biomarkers simultaneously.  Also, even 
when significant associations between biomarkers and outcomes are found, adding a biomarker to 
traditional risk factors may not always improve predictive ability of the models,358 and risk prediction is 
one important goal of biomarker development.    
 As imaging technology advances, studies will have to be designed to capture and translate 






outcomes.  For example, longitudinal functional MRI studies conducted in a small number of patients up 
to 3 months after stroke have shown change in functional networks in brain regions affected by stroke,359 
but longer term follow-up with repeated scans are necessary to elucidate mechanisms of long-term 
decline.  An ongoing study (“CANVAS”) will examine whether reduction in brain volume – measured with 
repeated MRIs over 3 years -- is associated with cognitive decline after stroke.360 
 
Conclusions 
There are several implications of the research discussed here.  One is that if there was an exclusive 
focus on events as outcomes, which has traditionally been the approach of many observational studies 
and clinical trials, the long-term declines seen in these analyses would be missed and the burden of 
disease would be underestimated.  These points highlight the importance of measuring patient-centered 
outcomes, analyzing not only single time-points but trajectories over time, and the use of epidemiologic 
and not only administrative (claims-based and event-based) data, due to the need to reliably measure 
outcomes.  This research also highlights the likely central role that “subclinical” disease plays in functional 
ability and health.  By identifying subclinical markers (such as SBI and WMHV) and inflammatory 
biomarkers (such as TNFR1) that have an impact on functional trajectories, these previously ignored or 
unmeasured elements should move to the forefront of disease prediction, out of the realm of the 
“subclinical” and into the realm of active and regular use in disease management and prevention.   
 There are several possible future directions.  One is that trial outcomes may move from the 
surveillance of events to the regular measurement of trajectories.  In order to increase precision and 
reduce costs, trials and observational studies may begin to employ novel technologies to repeatedly 
measure functional outcomes, such as smartphone apps or passive activity trackers.361  As 
measurements of subclinical disease become more refined, there should be a greater focus on the 
detection of previously unseen outcomes.  This would hopefully lead to the development of targeted 
therapeutics and more effective prevention not only of vascular events but also unfavorable functional 








Figure D1. Model integrating Alzheimer's disease immunohistology and biomarkers (Reproduced 




“The threshold for biomarker detection of pathophysiological changes is denoted by the black horizontal 
line. The grey area denotes the zone in which abnormal pathophysiological changes lie below the 
biomarker detection threshold. In this figure, tau pathology precedes Aβ deposition in time, but only early 
on at a subthreshold biomarker detection level. Aβ deposition then occurs independently and rises above 
the biomarker detection threshold (purple and red arrows). This induces acceleration of tauopathy and 
CSF tau then rises above the detection threshold (light blue arrow). Later still, FDG PET and MRI (dark 
blue arrow) rise above the detection threshold. Finally, cognitive impairment becomes evident (green 
arrow), with a range of cognitive responses that depend on the individual's risk profile (light green-filled 
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Appendix A1. Distribution of Barthel index scores in the entire prospective cohort 




0 182 0.48 182 0.48 
5 148 0.39 330 0.87 
10 145 0.38 475 1.25 
15 125 0.33 600 1.57 
20 108 0.28 708 1.86 
25 117 0.31 825 2.16 
30 137 0.36 962 2.52 
35 135 0.35 1097 2.88 
40 145 0.38 1242 3.26 
45 207 0.54 1449 3.80 
50 267 0.70 1716 4.50 
55 283 0.74 1999 5.25 
60 373 0.98 2372 6.22 
65 434 1.14 2806 7.36 
70 506 1.33 3312 8.69 
75 713 1.87 4025 10.56 
80 1032 2.71 5057 13.27 
85 1445 3.79 6502 17.06 
90 2622 6.88 9124 23.94 
95 5923 15.54 15047 39.48 







Appendix A2. Distributions of C-reactive protein and other biomarkers 
A) C-reactive protein distributions according to CDC/AHA risk stratification levels 




<1mg/L 524 23.39 524 23.39 
1-3 mg/L 710 31.70 1234 55.09 
>3 mg/L 1006 44.91 2240 100.00 
Frequency Missing = 873 
 
B) CRP-dominant versus IL-6-dominant profiles: conceptual description 
 
Jorge Luna et al. Stroke. 2014; 45: 979-987201 
 
C) Frequencies of CRP-dominant versus IL-6-dominant profiles 
Dominance 
profile 




Reference 593 35.81 593 35.81 
IL-6-dominant 561 33.88 1154 69.69 








Appendix A3. Associations between log of tumor necrosis factor receptor-1 protein levels and 




95% CI p-value 
Unadjusted model:    
Annual change in BI score -1.03 -1.12, -0.94 <.0001 
Change in BI score per unit increase in log of TNFR1 
levels 
-4.50 -6.18, -2.82 <.0001 
Additional annual change in BI score per unit 
increase in log of TNFR1 levels 
-0.16 -0.40, 0.09 0.2 
Adjusted for demographics:*    
Annual change in BI score -1.02 -1.11, -0.93 <.0001 
Change in BI score per unit increase in log of TNFR1 
levels 
-2.60 -4.19, -1.01 0.0014 
Additional annual change in BI score per unit 
increase in log of TNFR1 levels 
-0.11 -0.34, 0.13 0.4 
Adjusted for vascular risk factors:**    
Annual change in BI score -1.03 -1.12, -0.94 <.0001 
Change in BI score per unit increase in log of TNFR1 
levels 
-1.76 -3.35, -0.17 0.03 
Additional annual change in BI score per unit 
increase in log of TNFR1 levels 
-0.11 -0.35, 0.12 0.3 
Adjusted for social variables:†    
Annual change in BI score -1.02 -1.11, -0.93 <.0001 
Change in BI score per unit increase in log of TNFR1 
levels 
-1.51 -3.11, 0.10 0.066 
Additional annual change in BI score per unit 
increase in log of TNFR1 levels 
-0.13 -0.37, 0.11 0.3 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.51 -0.73, -0.28 <.0001 
Change in BI score per unit increase in log of TNFR1 
levels 
-1.06 -1.86, -0.25 0.01 
Additional annual change in BI score per unit 
increase in log of TNFR1 levels 
0.06 -0.49, 0.61 0.8 
Adjusted for stroke and MI:π    
Annual change in BI score -0.39 -0.61, -0.17 0.0005 
Change in BI score per unit increase in log of TNFR1 
levels 
-1.22 -2.02, -0.42 0.003 
Additional annual change in BI score per unit 
increase in log of TNFR1 levels 
-0.04 -0.51, 0.42 0.9 
TNFR1=tumor necrosis factor receptor-1; BI=Barthel index; MI=myocardial infarction 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 









Appendix A4. Associations between log of tumor necrosis factor receptor-1 protein levels and 




95% CI p-value 
Unadjusted model:    
Annual change in BI score -1.03 -1.12, -0.94 <.0001 
Change in BI score per unit increase in log of TNFR1 
levels 
-5.30 -6.64, -3.97 <.0001 
Additional annual change in BI score per unit 
increase in log of TNFR1 levels 
-0.18 -0.43, 0.06 0.15 
Adjusted for demographics:*    
Annual change in BI score -1.03 -1.12, -0.94 <.0001 
Change in BI score per unit increase in log of TNFR1 
levels 
-3.19 -4.58, -1.79 <.0001 
Additional annual change in BI score per unit 
increase in log of TNFR1 levels 
-0.13 -0.37, 0.11 0.3 
Adjusted for vascular risk factors:**    
Annual change in BI score -1.03 -1.12, -0.94 <.0001 
Change in BI score per unit increase in log of TNFR1 
levels 
-2.36 -3.74, -0.98 0.0008 
Additional annual change in BI score per unit 
increase in log of TNFR1 levels 
-0.14 -0.38, 0.10 0.3 
Adjusted for social variables:†    
Annual change in BI score -1.02 -1.11, -0.93 <.0001 
Change in BI score per unit increase in log of TNFR1 
levels 
-2.11 -3.50, -0.73 0.003 
Additional annual change in BI score per unit 
increase in log of TNFR1 levels 
-0.15 -0.39, 0.09 0.2 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.60 -0.80, -0.40 <.0001 
Change in BI score per unit increase in log of TNFR1 
levels 
-0.89 -1.74, -0.05 0.04 
Additional annual change in BI score per unit 
increase in log of TNFR1 levels 
-0.32 -0.67, 0.03 0.072 
Adjusted for stroke and MI:π    
Annual change in BI score -0.47 -0.67, -0.27 <.0001 
Change in BI score per unit increase in log of TNFR1 
levels 
-1.12 -1.97, -0.27 0.0096 
Additional annual change in BI score per unit 
increase in log of TNFR1 levels 
-0.34 -0.67, -0.01 0.046 
TNFR1=tumor necrosis factor receptor-1; BI=Barthel index; MI=myocardial infarction 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 








Appendix A5. Associations between quartiles of tumor necrosis factor receptor-1 protein levels 




95% CI p-value 
Unadjusted model:    
Annual change in BI score -0.90 -1.07, -0.73 <.0001 
Change in BI score with 2nd quartile of TNFR1 levels€ -1.03 -2.19, 0.14 0.08 
Change in BI score with 3rd quartile of TNFR1 levels€ -1.13 -2.35, 0.09 0.07 
Change in BI score with 4th quartile of TNFR1 levels€ -5.52 -7.09, -3.94 <.0001 
Additional annual change in BI score with 2nd quartile of 
TNFR1 levels€ 
0.09 -0.13, 0.31 0.4 
Additional annual change in BI score with 3rd quartile of 
TNFR1 levels€ 
-0.17 -0.41, 0.07 0.17 
Additional annual change in BI score with 4th quartile of 
TNFR1 levels€ 
-0.62 -0.92, -0.32 <.0001 
Adjusted for demographics:*    
Annual change in BI score -0.93 -1.10, -0.76 <.0001 
Change in BI score with 2nd quartile of TNFR1 levels€ -0.90 -2.22, 0.42 0.18 
Change in BI score with 3rd quartile of TNFR1 levels€ -0.04 -1.37, 1.28 0.9 
Change in BI score with 4th quartile of TNFR1 levels€ -2.35 -4.03, -0.67 0.006 
Additional annual change in BI score with 2nd quartile of 
TNFR1 levels€ 
0.11 -0.11, 0.34 0.3 
Additional annual change in BI score with 3rd quartile of 
TNFR1 levels€ 
-0.12 -0.36, 0.12 0.3 
Additional annual change in BI score with 4th quartile of 
TNFR1 levels€ 
-0.53 -0.82, -0.23 0.0004 
Adjusted for vascular risk factors:**    
Annual change in BI score -0.94 -1.11, -0.76 <.0001 
Change in BI score with 2nd quartile of TNFR1 levels€ -0.67 -2.01, 0.67 0.3 
Change in BI score with 3rd quartile of TNFR1 levels€ 0.29 -1.04, 1.62 0.7 
Change in BI score with 4th quartile of TNFR1 levels€ -0.96 -2.63, 0.71 0.3 
Additional annual change in BI score with 2nd quartile of 
TNFR1 levels€ 
0.11 -0.11, 0.33 0.3 
Additional annual change in BI score with 3rd quartile of 
TNFR1 levels€ 
-0.10 -0.34, 0.14 0.4 
Additional annual change in BI score with 4th quartile of 
TNFR1 levels€ 
-0.54 -0.83, -0.24 0.0004 
Adjusted for social variables:†    
Annual change in BI score -0.92 -1.09, -0.75 <.0001 
Change in BI score with 2nd quartile of TNFR1 levels€ -0.44 -1.77, 0.89 0.5 
Change in BI score with 3rd quartile of TNFR1 levels€ 0.52 -0.81, 1.85 0.4 
Change in BI score with 4th quartile of TNFR1 levels€ -0.62 -2.28, 1.04 0.5 
Additional annual change in BI score with 2nd quartile of 
TNFR1 levels€ 
0.10 -0.12, 0.32 0.4 
Additional annual change in BI score with 3rd quartile of 
TNFR1 levels€ 
-0.11 -0.35, 0.13 0.4 
Additional annual change in BI score with 4th quartile of 
TNFR1 levels€ 
-0.56 -0.85, -0.26 0.0002 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.39 -0.61, -0.16 0.0007 
Change in BI score with 2nd quartile of TNFR1 levels€ -0.23 -0.90, 0.45 0.5 
Change in BI score with 3rd quartile of TNFR1 levels€ 0.38 -0.49, 1.25 0.4 






Additional annual change in BI score with 2nd quartile of 
TNFR1 levels€ 
0.23 -0.11, 0.58 0.18 
Additional annual change in BI score with 3rd quartile of 
TNFR1 levels€ 
-0.56 -1.25, 0.12 0.11 
Additional annual change in BI score with 4th quartile of 
TNFR1 levels€ 
-0.73 -1.38, -0.09 0.03 
Adjusted for stroke and MI:π    
Annual change in BI score -0.21 -0.42, 0.003 0.054 
Change in BI score with 2nd quartile of TNFR1 levels€ -0.18 -0.83, 0.47 0.6 
Change in BI score with 3rd quartile of TNFR1 levels€ 0.28 -0.58, 1.15 0.5 
Change in BI score with 4th quartile of TNFR1 levels€ -0.56 -1.60, 0.47 0.3 
Additional annual change in BI score with 2nd quartile of 
TNFR1 levels€ 
0.13 -0.19, 0.46 0.4 
Additional annual change in BI score with 3rd quartile of 
TNFR1 levels€ 
-0.65 -1.34, 0.04 0.06 
Additional annual change in BI score with 4th quartile of 
TNFR1 levels€ 
-0.72 -1.34, -0.10 0.02 
TNFR1=tumor necrosis factor receptor-1; BI=Barthel index; MI=myocardial infarction; SD=standard 
deviation 
€compared to the 1st quartile of TNFR1 levels 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 







Appendix A6. Associations between the highest quartile of tumor necrosis factor receptor-1 
protein levels and trajectories of functional status 
Variable Change in 
BI score 
95% CI p-value 
Unadjusted model:    
Annual change in BI score -0.92 -1.01, -0.82 <.0001 
Change in BI score with highest quartile of TNFR1 
levels€ 
-4.78 -6.22, -3.33 <.0001 
Additional annual change in BI score with highest 
quartile of TNFR1 levels€ 
-0.60 -0.87, -0.34 <.0001 
Adjusted for demographics:*    
Annual change in BI score -0.93 -1.02, -0.83 <.0001 
Change in BI score with highest quartile of TNFR1 
levels€ 
-2.01 -3.51, -0.50 0.009 
Additional annual change in BI score with highest 
quartile of TNFR1 levels€ 
-0.53 -0.79, -0.27 <.0001 
Adjusted for vascular risk factors:**    
Annual change in BI score -0.93 -1.02, -0.83 <.0001 
Change in BI score with highest quartile of TNFR1 
levels€ 
-0.81 -2.28, 0.66 0.3 
Additional annual change in BI score with highest 
quartile of TNFR1 levels€ 
-0.55 -0.80, -0.29 <.0001 
Adjusted for social variables:†    
Annual change in BI score -0.92 -1.01, -0.82 <.0001 
Change in BI score with highest quartile of TNFR1 
levels€ 
-0.62 -2.09, 0.84 0.4 
Additional annual change in BI score with highest 
quartile of TNFR1 levels€ 
-0.56 -0.82, -0.30 <.0001 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.43 -0.60, -0.26 <.0001 
Change in BI score with highest quartile of TNFR1 
levels€ 
-0.19 -1.20, 0.82 0.7 
Additional annual change in BI score with highest 
quartile of TNFR1 levels€ 
-0.69 -1.32, -0.06 0.03 
Adjusted for stroke and MI:π    
Annual change in BI score -0.29 -0.46, -0.12 0.0009 
Change in BI score with highest quartile of TNFR1 
levels€ 
-0.49 -1.48, 0.51 0.3 
Additional annual change in BI score with highest 
quartile of TNFR1 levels€ 
-0.64 -1.25, -0.04 0.04 
TNFR1=tumor necrosis factor receptor-1; BI=Barthel index; MI=myocardial infarction; SD=standard 
deviation 
€versus all other quartiles 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 







Appendix A7. Associations between log of interleukin-6 levels and trajectories of functional 
status; sensitivity analysis with 0 values set to missing 
Variable Change in 
BI score 
95% CI p-value 
Unadjusted model:    
Annual change in BI score -0.97 -1.07, -0.88 <.0001 
Change in BI score per unit increase in log of IL6 levels -0.45 -0.88, -0.03 0.04 
Additional annual change in BI score per unit increase in 
log of IL6 levels 
-0.13 -0.23, -0.03 0.01 
Adjusted for demographics:*    
Annual change in BI score -0.98 -1.07, -0.88 <.0001 
Change in BI score per unit increase in log of IL6 levels -0.05 -0.47, 0.38 0.8 
Additional annual change in BI score per unit increase in 
log of IL6 levels 
-0.13 -0.23, -0.03 0.009 
Adjusted for vascular risk factors:**    
Annual change in BI score -0.98 -1.08, -0.89 <.0001 
Change in BI score per unit increase in log of IL6 levels 0.06 -0.37, 0.48 0.8 
Additional annual change in BI score per unit increase in 
log of IL6 levels 
-0.13 -0.23, -0.03 0.008 
Adjusted for social variables:†    
Annual change in BI score -0.97 -1.06, -0.88 <.0001 
Change in BI score per unit increase in log of IL6 levels 0.07 -0.36, 0.50 0.8 
Additional annual change in BI score per unit increase in 
log of IL6 levels 
-0.13 -0.23, -0.03 0.01 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.44 -0.59, -0.29 <.0001 
Change in BI score per unit increase in log of IL6 levels -0.11 -0.37, 0.15 0.4 
Additional annual change in BI score per unit increase in 
log of IL6 levels 
-0.06 -0.17, 0.06 0.3 
Adjusted for stroke and MI:π    
Annual change in BI score -0.32 -0.47, -0.16 <.0001 
Change in BI score per unit increase in log of IL6 levels -0.16 -0.42, 0.11 0.2 
Additional annual change in BI score per unit increase in 
log of IL6 levels 
-0.09 -0.21, 0.02 0.11 
IL6=interleukin-6; BI=Barthel index; MI=myocardial infarction 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 







Appendix A8. Associations between dichotomized interleukin-6 levels and trajectories of 
functional status 
Variable Change in 
BI score 
95% CI p-value 
Unadjusted model:    
Annual change in BI score -0.89 -1.01, -0.77 <.0001 
Change in BI score with IL-6 levels above median -1.10 -2.18, -0.02 0.046 
Additional annual change in BI score with IL-6 levels 
above median 
-0.20 -0.38, -0.01 0.04 
Adjusted for demographics:*    
Annual change in BI score -0.90 -1.02, -0.78 <.0001 
Change in BI score with IL-6 levels above median -0.12 -1.25, 1.02 0.8 
Additional annual change in BI score with IL-6 levels 
above median 
-0.18 -0.36, 0.002 0.052 
Adjusted for vascular risk factors:**    
Annual change in BI score -0.91 -1.03, -0.79 <.0001 
Change in BI score with IL-6 levels above median 0.27 -0.86, 1.41 0.6 
Additional annual change in BI score with IL-6 levels 
above median 
-0.17 -0.36, 0.01 0.06 
Adjusted for social variables:†    
Annual change in BI score -0.90 -1.02, -0.78 <.0001 
Change in BI score with IL-6 levels above median 0.31 -0.81, 1.43 0.6 
Additional annual change in BI score with IL-6 levels 
above median 
-0.16 -0.34, 0.02 0.076 
Adjusted for mood and cognitive variables:‡    
Annual change in BI score -0.43 -0.64, -0.22 <.0001 
Change in BI score with IL-6 levels above median -0.31 -0.99, 0.36 0.4 
Additional annual change in BI score with IL-6 levels 
above median 
-0.05 -0.40, 0.31 0.8 
Adjusted for stroke and MI:π    
Annual change in BI score -0.19 -0.36, -0.03 0.02 
Change in BI score with IL-6 levels above median -0.41 -1.08, 0.26 0.2 
Additional annual change in BI score with IL-6 levels 
above median 
-0.22 -0.55, 0.10 0.2 
IL-6=interleukin-6; BI=Barthel index; MI=myocardial infarction 
*adjusted for: baseline age, sex, and race-ethnicity 
**additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, 
physical activity, alcohol use, smoking, and body mass index 
†additionally adjusted for: marital status, insurance, number of friends, and years lived in the 
neighborhood 
‡additionally adjusted for: depression, mini-mental state score, and Spitzer quality of life index 







Appendix A9. Data on hospitalizations 
A) Number of hospitalizations in entire follow-up dataset: 
Event: hospitalized since our last contact 




Not hospitalized 30119 79.80 30119 79.80 
Hospitalized 7625 20.20 37744 100.00 
Frequency Missing = 4184 
 
B) Distribution of number of hospitalizations per person: 




0 807 24.47 807 24.47 
1 711 21.56 1518 46.03 
2 591 17.92 2109 63.95 
3 406 12.31 2515 76.26 
4 289 8.76 2804 85.02 
5 179 5.43 2983 90.45 
6 124 3.76 3107 94.21 
7 77 2.33 3184 96.54 
8 45 1.36 3229 97.91 
9 31 0.94 3260 98.85 
10 19 0.58 3279 99.42 
11 12 0.36 3291 99.79 
12 2 0.06 3293 99.85 
13 2 0.06 3295 99.91 
14 2 0.06 3297 99.97 
17 1 0.03 3298 100.00 
 
C) Distribution of number of follow-ups per person: 




1 127 3.85 127 3.85 
2 81 2.46 208 6.31 
3 99 3.00 307 9.31 
4 104 3.15 411 12.46 










6 122 3.70 643 19.50 
7 102 3.09 745 22.59 
8 92 2.79 837 25.38 
9 95 2.88 932 28.26 
10 130 3.94 1062 32.20 
11 107 3.24 1169 35.45 
12 110 3.34 1279 38.78 
13 181 5.49 1460 44.27 
14 319 9.67 1779 53.94 
15 393 11.92 2172 65.86 
16 377 11.43 2549 77.29 
17 240 7.28 2789 84.57 
18 335 10.16 3124 94.72 
19 117 3.55 3241 98.27 
20 45 1.36 3286 99.64 
21 8 0.24 3294 99.88 
22 3 0.09 3297 99.97 
24 1 0.03 3298 100.00 
 
D) Summary statistics for the ratio of (number of hospitalizations):(number of follow-ups): 




Std Dev Minimum Maximum N 
Miss 
N 
0.1952870 0.1428571 0.0526316 0.3076923 0.1873152 0 0.9285714 0 3298
 
E) Amount of time (in years) between post-non-stroke/MI hospitalization assessment and previous 
assessment (in dataset that excludes stroke and MI hospitalizations) 




Std Dev Minimum Maximum N 
Miss 
N 
1.0923451 1.0184805 0.9363450 1.1143053 0.5232751 0 11.4934976 32611 5965
 
F) Amount of time (in years) between post-hospitalization assessment and previous assessment 
(including stroke and MI hospitalizations and non-“vascular” hospitalizations) 




Std Dev Minimum Maximum N 
Miss 
N 












Appendix A10. Examination of the impact of loss to follow-up and death 
A) Time between last functional assessment and death: 
N=  1604 
N missing= 11 
Mean=   0.74 years 
Std dev=  0.76 years 
Median=  0.60 years 
Max=   7.62 years 
Q3 =   0.93 years 
Q1 =   0.29 years 
 
B) Distribution of last ADL scores among those who died 




0 90 5.57 90 5.57 
5 51 3.16 141 8.73 
10 41 2.54 182 11.27 
15 25 1.55 207 12.82 
20 19 1.18 226 13.99 
25 29 1.80 255 15.79 
30 31 1.92 286 17.71 
35 34 2.11 320 19.81 
40 34 2.11 354 21.92 
45 38 2.35 392 24.27 
50 50 3.10 442 27.37 
55 40 2.48 482 29.85 
60 55 3.41 537 33.25 
65 55 3.41 592 36.66 
70 43 2.66 635 39.32 
75 75 4.64 710 43.96 
80 76 4.71 786 48.67 
85 82 5.08 868 53.75 
90 147 9.10 1015 62.85 
95 179 11.08 1194 73.93 
100 421 26.07 1615 100.00 
 
















BI score Interval between last ADL and death (yr) 












































































E) Distribution of last ADL score among survivors: 
 
 
F) Distribution of maximum follow-up times among survivors: 




Std Dev Minimum Maximum N 
Miss
N 















Appendix B1. Location of silent brain infarcts, based on original dataset 
A) Brain location of infarcts 
Infarct location Frequency Percent 
Basal ganglia 49 18.4 
Brain stem 4 1.5 
Caudate 20 7.5 
Cerebellum 28 10.5 
External capsule 15 5.6 
Extreme capsule 8 3.0 
Frontal cortex 23 8.6 
Frontal white matter 42 15.8 
Hippocampus 1 0.4 
Internal capsule 12 4.5 
Occipital cortex 1 0.4 
Occipital white matter 4 1.5 
Parietal cortex 11 4.1 
Parietal white matter 23 8.6 
Posterior cerebral artery territory 2 0.8 
Temporal cortex 3 1.1 
Temporal white matter 2 0.8 
Thalamus 18 6.8 
 
B) Number of superficial/cortical silent brain infarcts (52 missing) 




0 1133 91.52 1133 91.52 
1 89 7.19 1222 98.71 
2 11 0.89 1233 99.60 
3 4 0.32 1237 99.92 
4 1 0.08 1238 100.00 
 
C) Number of non-superficial/subcortical silent brain infarcts (52 missing) 




0 1128 91.11 1128 91.11 
1 88 7.11 1216 98.22 
2 19 1.53 1235 99.76 
3 3 0.24 1238 100.00 
 
D) Superficial versus non-superficial silent brain infarct location (52 missing) 




None 1045 84.41 1045 84.41 
Superficial 83 6.70 1128 91.11 
Other 88 7.11 1216 98.22 







Appendix B2. Silent brain infarcts, perivascular spaces, and lacunar infarcts based on new 
dataset 
A) Frequency of silent brain infarcts (lacunar + cortical + cerebellar, 82 missing) 




No silent brain infarct 964 79.80 964 79.80 
Silent brain infarct 244 20.20 1208 100.00 
 
B) Frequency of large perivascular spaces (82 missing) 




No large perivascular spaces 700 57.95 700 57.95 
At least one perivascular space 508 42.05 1208 100.00 
  
C) Number of large perivascular spaces per individual (82 missing) 




0 700 57.95 700 57.95 
1 255 21.11 955 79.06 
2 169 13.99 1124 93.05 
3 52 4.30 1176 97.35 
4 18 1.49 1194 98.84 
5 9 0.75 1203 99.59 
6 3 0.25 1206 99.83 
8 2 0.17 1208 100.00 
 
D) Frequency of lacunar infarct (82 missing) 




No lacunar infarct 993 82.20 993 82.20 
Lacunar infarct 215 17.80 1208 100.00 
 
E) Distribution of the number of lacunar infarcts (82 missing) 




0 993 82.20 993 82.20 
1 116 9.60 1109 91.80 
2 55 4.55 1164 96.36 
3 27 2.24 1191 98.59 
4 10 0.83 1201 99.42 
5 3 0.25 1204 99.67 
6 3 0.25 1207 99.92 
7 1 0.08 1208 100.00 
 
F) Total perivascular space score (82 missing) 




0 110 9.11 110 9.11 
1 34 2.81 144 11.92 
2 107 8.86 251 20.78 
3 113 9.35 364 30.13 
4 193 15.98 557 46.11 
5 141 11.67 698 57.78 






7 84 6.95 908 75.17 
8 74 6.13 982 81.29 
9 58 4.80 1040 86.09 
10 36 2.98 1076 89.07 
11 47 3.89 1123 92.96 
12 28 2.32 1151 95.28 
13 12 0.99 1163 96.27 
14 14 1.16 1177 97.43 
15 9 0.75 1186 98.18 
16 9 0.75 1195 98.92 
17 6 0.50 1201 99.42 
18 2 0.17 1203 99.59 
19 2 0.17 1205 99.75 
20 2 0.17 1207 99.92 







Appendix B3. Location of lacunar infarct, in new dataset 
A) Three-level location variable (83 missing) 




None 2154 85.10 2154 85.10 
Subcortical 122 4.82 2276 89.92 
Cortical 255 10.08 2531 100.00 
 
B) Four-level location variable (83 missing) 




None 2154 85.10 2154 85.10 
Subcortical 109 4.31 2263 89.41 
Cortical 255 10.08 2518 99.49 
Brainstem and 
cerebellum 
13 0.51 2531 100.00 
 
C) Separate location variables, with number of infarcts in each location 
 1) Subcortical location (total infarcts=109) 




0 1203 93.26 1203 93.26 
1 70 5.43 1273 98.68 
2 13 1.01 1286 99.69 
3 3 0.23 1289 99.92 
4 1 0.08 1290 100.00 
 
 2) Cortical location (total infarcts=255) 




0 1129 87.52 1129 87.52 
1 102 7.91 1231 95.43 
2 40 3.10 1271 98.53 
3 10 0.78 1281 99.30 
4 6 0.47 1287 99.77 
6 2 0.16 1289 99.92 
7 1 0.08 1290 100.00 
 
 3) Brainstem location (total infarcts=13) 




0 1277 98.99 1277 98.99 
1 13 1.01 1290 100.00 
 
D) Location of silent brain infarcts 




None 1076 83.41 1076 83.41 
Cortical 117 9.07 1193 92.48 
Subcortical 53 4.11 1246 96.59 
Both cortical and 
subcortical 







Appendix B4. Distribution of time (in years) from baseline enrollment to time of MRI 




Std Dev Minimum Maximum N 
Miss 
N 








Appendix B5. Distributions of inflammatory biomarkers in those with MRI data 
A) Distributions 
















2.23 2.16 1.71 2.65 0.85 0.09 6.40 639 651 
Interleukin-6 42.93 1.35 0.81 2.39 451.02 0.00 5000.00 680 610 
LpPLA2 
activity 
301.78 297.64 237.25 361.07 90.06 28.12 888.54 595 695 
LpPLA2 
mass 
116.58 113.38 96.10 136.23 29.03 37.67 216.58 605 685 
LpPLA2=lipoprotein phospholipase A2 
 
B) Distribution plots of each inflammatory biomarker 
 1) C-reactive protein: 
 
 







 3) Interleukin-6, with 5 values of 5000 set to missing: 
 
 
 4) log of interleukin-6 levels: 
 
 
 5) Tumor necrosis factor receptor-1: 
 
 
















Appendix B6. Baseline characteristics of the MRI cohort, by availability of inflammatory labs 








Number of participants, No. (%) 911 (70.6) 379 (29.4)  
Biological characteristics:    
Age, mean (SD), y 64.7 (8.1) 64.1 (9.1) 0.3 
Body mass index, mean (SD), kg/m2 28.0 (4.7) 27.6 (5.1) 0.3 
    
Demographics:    
Male, No. (%) 366 (40.2) 144 (38.0) 0.5 
Race-ethnicity: 
  Non-Hispanic white, No. (%) 
  Non-Hispanic black, No. (%) 
  Hispanic, No. (%) 












Received at least high school education, No. (%) 410 (45.0) 182 (48.0) 0.3 
Marital status, No. (%) married  345 (37.9) 198 (52.2) <0.0001 
Health insurance, No. (%)  
   Medicaid or no insurance 
   Medicare or private insurance 
 
441 (48.4) 





Medicaid health insurance, No. (%)  299 (32.8) 119 (31.4) 0.6 
Medicare health insurance, No. (%)  416 (45.7) 181 (47.8) 0.5 
Private insurance, No. (%) 373 (40.9) 168 (44.3) 0.3 
    
Vascular risk factors, No. (%)    
Hypertension  626 (68.7) 235 (62.0) 0.02 
Systolic BP, mean (SD) 140.6 (19.8) 140.7 (1.5) 0.9 
Diastolic BP, mean (SD) 83.8 (10.6) 82.8 (10.6) 0.3 
Alcohol consumption [NR] [NR] 0.2 
Physical activity [NR] [NR] 0.8 
Diabetes mellitus  168 (18.4) 77 (20.3) 0.4 
Smoking: 
   Never 
   Former 










Hypercholesterolemia 588 (64.5) 209 (55.2) 0.002 
Total cholesterol, mean (SD), mg/dL  202.7 (38.7) 201.0 (36.7) 0.6 
High-density lipoprotein, mean (SD), mg/dL  45.7 (14.0) 47.2 (13.4) 0.2 
Low-density lipoprotein, mean (SD), mg/dL  130.5 (35.2) 127.0 (32.0) 0.2 
History of atrial fibrillation 25 (2.7) 6 (1.6) 0.2 
History of coronary heart disease  134 (14.7) 43 (11.4) 0.1 
    
Other medical conditions, No. (%)    
Hamilton depression scale score, mean (SD) 3.2 (3.8) 2.8 (3.8) 0.2 
Hamilton depression score >12    
Chronic bronchitis, asthma, or emphysema 85 (9.4) 35 (9.3) 0.97 
Mini mental state score, mean (SD)  26.6 (3.4) 27.0 (3.2) 0.1 
History of migraine headaches  171 (18.8) 60 (15.9) 0.2 
Spitzer quality of life index score  9.36 (0.99) 9.24 (1.16) 0.2 
    






Number of people known well enough to visit with 
in their homes:  
   None 
   1 or 2 
   3 or 4 














Number of times talked to someone on telephone 
in past week:  
   Not at all  
   Once  
   Two to six times  














Number of times in past week spent with 
someone who does not live with you:  
   Not at all  
   Once  
   Two to six times  














Have someone you can trust and confide in  [NR] [NR] 0.2 
Feeling lonely:  
   Quite often  
   Sometimes  










See relatives and friends [NR] [NR] 0.2 
Is there someone who would give you help if sick [NR] [NR] 0.2 








Appendix B7. Distribution of baseline Barthel index scores 




45 3 0.23 3 0.23 
55 2 0.16 5 0.39 
60 3 0.23 8 0.63 
65 5 0.39 13 1.02 
70 5 0.39 18 1.41 
75 9 0.70 27 2.11 
80 20 1.56 47 3.67 
85 41 3.20 88 6.88 
90 56 4.38 144 11.25 
95 267 20.86 411 32.11 








Appendix B8. Unadjusted and adjusted models of the association between number of lacunar 
infarcts (categorical variable) and functional status, using the new dataset 
Variable Change in 
BI score 
95% CI p-value 
Unadjusted model:    
Annual change in BI -0.86 -1.01, -0.70 <.0001 
Change in BI with 1 lacunar infarct, vs. none 1.78 -0.03, 3.58 0.054 
Change in BI with 2 lacunar infarcts, vs. none -2.15 -4.48, 0.18 0.07 
Change in BI with 3 lacunar infarcts, vs. none -4.80 -12.24, 2.63 0.2 
Change in BI with >=4 lacunar infarcts, vs. none -6.64 -20.47, 7.19 0.3 
Additional annual change with 1 lacunar infarct, vs. none -1.12 -1.81, -0.44 0.001 
Additional annual change with 2 lacunar infarcts, vs. 
none 
-0.84 -1.58, -0.10 0.03 
Additional annual change with 3 lacunar infarcts, vs. 
none 
-2.68 -4.84, -0.51 0.02 
Additional annual change with >=4 lacunar infarcts, vs. 
none 
-0.87 -3.70, 1.96 0.5 
Adjusted for demographics:†    
Annual change in BI -0.87 -1.02, -0.72 <.0001 
Change in BI with 1 lacunar infarct, vs. none 2.94 0.88, 5.01 0.005 
Change in BI with 2 lacunar infarcts, vs. none -0.35 -2.83, 2.12 0.8 
Change in BI with 3 lacunar infarcts, vs. none -0.91 -9.70, 7.89 0.8 
Change in BI with >=4 lacunar infarcts, vs. none -4.80 -18.43, 8.83 0.5 
Additional annual change with 1 lacunar infarct, vs. none -1.14 -1.84, -0.43 0.003 
Additional annual change with 2 lacunar infarcts, vs. 
none 
-0.84 -1.58, -0.10 0.04 
Additional annual change with 3 lacunar infarcts, vs. 
none 
-2.97 -5.32, -0.62 0.01 
Additional annual change with >=4 lacunar infarcts, vs. 
none 
-0.83 -3.67, 2.02 0.6 
Adjusted for vascular risk factors:*    
Annual change in BI -0.91 -1.08, -0.75 <.0001 
Change in BI with 1 lacunar infarct, vs. none 3.20 0.76, 5.64 0.01 
Change in BI with 2 lacunar infarcts, vs. none 0.09 -2.48, 2.66 0.9 
Change in BI with 3 lacunar infarcts, vs. none -1.42 -11.15, 8.32 0.8 
Change in BI with >=4 lacunar infarcts, vs. none -5.03 -19.68, 9.62 0.5 
Additional annual change with 1 lacunar infarct, vs. none -1.33 -2.14, -0.52 0.001 
Additional annual change with 2 lacunar infarcts, vs. 
none 
-0.70 -1.44, 0.04 0.06 
Additional annual change with 3 lacunar infarcts, vs. 
none 
-2.52 -4.79, -0.26 0.03 
Additional annual change with >=4 lacunar infarcts, vs. 
none 
-0.41 -3.30, 2.48 0.8 
Adjusted for social variables:**    
Annual change in BI -0.91 -1.08, -0.75 <.0001 
Change in BI with 1 lacunar infarct, vs. none 3.28 0.85, 5.71 0.008 
Change in BI with 2 lacunar infarcts, vs. none 0.61 -1.99, 3.21 0.6 
Change in BI with 3 lacunar infarcts, vs. none -1.34 -11.21, 8.53 0.8 
Change in BI with >=4 lacunar infarcts, vs. none -5.44 -20.22, 9.34 0.5 
Additional annual change with 1 lacunar infarct, vs. none -1.33 -2.15, -0.52 0.001 
Additional annual change with 2 lacunar infarcts, vs. 
none 
-0.70 -1.44, 0.04 0.06 
Additional annual change with 3 lacunar infarcts, vs. 
none 






Additional annual change with >=4 lacunar infarcts, vs. 
none 
-0.41 -3.31, 2.48 0.8 
Adjusted for cognition:π    
Annual change in BI -0.91 -1.08, -0.75 <.0001 
Change in BI with 1 lacunar infarct, vs. none 3.31 0.91, 5.72 0.007 
Change in BI with 2 lacunar infarcts, vs. none 0.59 -2.05, 3.22 0.7 
Change in BI with 3 lacunar infarcts, vs. none -1.39 -11.27, 8.49 0.8 
Change in BI with >=4 lacunar infarcts, vs. none -5.08 -19.84, 9.68 0.5 
Additional annual change with 1 lacunar infarct, vs. none -1.34 -2.15, -0.52 0.001 
Additional annual change with 2 lacunar infarcts, vs. 
none 
-0.70 -1.44, 0.04 0.06 
Additional annual change with 3 lacunar infarcts, vs. 
none 
-2.51 -4.76, -0.25 0.03 
Additional annual change with >=4 lacunar infarcts, vs. 
none 
-0.43 -3.32, 2.47 0.8 
Adjusted for quality of life and depression: ††    
Annual change in BI -0.92 -1.09, -0.76 <.0001 
Change in BI with 1 lacunar infarct, vs. none 3.16 0.71, 5.62 0.01 
Change in BI with 2 lacunar infarcts, vs. none 0.58 -2.11, 3.27 0.7 
Change in BI with 3 lacunar infarcts, vs. none -1.41 -11.33, 8.52 0.8 
Change in BI with >=4 lacunar infarcts, vs. none -5.20 -19.90, 9.49 0.5 
Additional annual change with 1 lacunar infarct, vs. none -1.32 -2.13, -0.51 0.001 
Additional annual change with 2 lacunar infarcts, vs. 
none 
-0.68 -1.42, 0.05 0.07 
Additional annual change with 3 lacunar infarcts, vs. 
none 
-2.48 -4.73, -0.24 0.03 
Additional annual change with >=4 lacunar infarcts, vs. 
none 
-0.43 -3.32, 2.47 0.8 
Adjusted for stroke and MI: ‡    
Annual change in BI -0.81 -0.97, -0.65 <.0001 
Change in BI with 1 lacunar infarct, vs. none 3.38 0.91, 5.85 0.007 
Change in BI with 2 lacunar infarcts, vs. none 1.14 -1.77, 4.05 0.4 
Change in BI with 3 lacunar infarcts, vs. none -1.18 -10.17, 7.81 0.8 
Change in BI with >=4 lacunar infarcts, vs. none -4.61 -17.45, 8.24 0.5 
Additional annual change with 1 lacunar infarct, vs. none -1.27 -2.08, -0.45 0.002 
Additional annual change with 2 lacunar infarcts, vs. 
none 
-0.67 -1.33, -0.02 0.04 
Additional annual change with 3 lacunar infarcts, vs. 
none 
-2.00 -4.19, 0.19 0.07 
Additional annual change with >=4 lacunar infarcts, vs. 
none 
-0.49 -3.34, 2.36 0.7 
BI=Barthel index; CI=confidence interval; MI=myocardial infarction 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 






Appendix B9. Unadjusted and adjusted models of the association between silent brain infarcts 
and functional status, stratified by mobility vs. non-mobility domains, using the original dataset 











Unadjusted model:       
Annual change in BI -0.39 -0.46, -0.32 <.0001 -0.49 -0.59, -0.40 <.0001 
Change in BI with SBI -0.43 -1.38, 0.53 0.4 -0.40 -1.76, 0.95 0.6 
Additional annual change with 
SBI 
-0.45 -0.67, -0.23 <.0001 -0.64 -0.99, -0.29 0.0003 
Adjusted for demographics:†       
Annual change in BI -0.40 -0.47, -0.33 <.0001 -0.50 -0.60, -0.41 <.0001 
Change in BI with SBI 0.39 -0.61, 1.40 0.4 0.58 -0.87, 2.02 0.4 
Additional annual change with 
SBI 
-0.46 -0.68, -0.23 <.0001 -0.64 -1.00, -0.28 0.0005 
Adjusted for vascular risk 
factors:* 
      
Annual change in BI -0.40 -0.47, -0.33 <.0001 -0.51 -0.60, -0.41 <.0001 
Change in BI with SBI 0.44 -0.56, 1.45 0.4 0.63 -0.82, 2.08 0.4 
Additional annual change with 
SBI 
-0.46 -0.68, -0.23 <.0001 -0.64 -1.00, -0.28 0.0005 
Adjusted for social variables:**       
Annual change in BI -0.40 -0.47, -0.33 <.0001 -0.51 -0.60, -0.41 <.0001 
Change in BI with SBI 0.50 -0.50, 1.51 0.3 0.70 -0.75, 2.15 0.3 
Additional annual change with 
SBI 
-0.46 -0.68, -0.23 <.0001 -0.64 -1.00, -0.28 0.0005 
Adjusted for cognition:π       
Annual change in BI -0.40 -0.47, -0.33 <.0001 -0.51 -0.60, -0.41 <.0001 
Change in BI with SBI 0.52 -0.48, 1.53 0.3 0.72 -0.73, 2.17 0.3 
Additional annual change with 
SBI 
-0.45 -0.67, -0.22 <.0001 -0.63 -0.99, -0.27 0.0006 
Adjusted for quality of life and 
depression: †† 
      
Annual change in BI -0.42 -0.50, -0.35 <.0001 -0.54 -0.64, -0.44 <.0001 
Change in BI with SBI 0.34 -0.73, 1.42 0.5 0.56 -1.01, 2.14 0.5 
Additional annual change with 
SBI 
-0.43 -0.66, -0.20 0.0003 -0.59 -0.96, -0.22 0.002 
Adjusted for stroke and MI: ‡       
Annual change in BI -0.38 -0.45, -0.30 <.0001 -0.47 -0.57, -0.37 <.0001 
Change in BI with SBI 0.43 -0.59, 1.45 0.4 0.68 -0.81, 2.17 0.4 
Additional annual change with 
SBI 
-0.37 -0.59, -0.14 0.0016 -0.51 -0.86, -0.15 0.006 
BI=Barthel index; CI=confidence interval; SBI=silent brain infarct; MI=myocardial infarction 
NOTE: The mobility domain includes transfers, mobility, and stair use; the non-mobility domain includes 
feeding, bathing, grooming, dressing, bowels, bladder, and toilet use 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 







Appendix B10. Unadjusted and adjusted models of the association between standardized white 
matter hyperintensity volume (WMH/TCV), stratified by mobility vs. non-mobility domains, using 
the original dataset 











Unadjusted model:       
Annual change in BI -0.49 -0.55, -0.42 <.0001 -0.63 -0.73, -0.54 <.0001 
Change in BI with 1 unit increase 
in WMH 
-0.55 -0.98, -0.12 0.013 -0.55 -1.16, 0.06 0.08 
Additional annual change with 1 
unit increase in WMH 
-0.31 -0.41, -0.21 <.0001 -0.49 -0.65, -0.34 <.0001 
Adjusted for demographics:†       
Annual change in BI -0.49 -0.56, -0.43 <.0001 -0.64 -0.74, -0.54 <.0001 
Change in BI with 1 unit increase 
in WMH 
0.05 -0.39, 0.49 0.8 0.07 -0.57, 0.71 0.8 
Additional annual change with 1 
unit increase in WMH 
-0.32 -0.42, -0.22 <.0001 -0.50 -0.65, -0.34 <.0001 
Adjusted for vascular risk 
factors:* 
      
Annual change in BI -0.51 -0.58, -0.44 <.0001 -0.66 -0.76, -0.55 <.0001 
Change in BI with 1 unit increase 
in WMH 
0.16 -0.34, 0.66 0.5 0.13 -0.60, 0.86 0.7 
Additional annual change with 1 
unit increase in WMH 
-0.30 -0.40, -0.19 <.0001 -0.47 -0.64, -0.31 <.0001 
Adjusted for social variables:**       
Annual change in BI -0.51 -0.58, -0.44 <.0001 -0.66 -0.76, -0.55 <.0001 
Change in BI with 1 unit increase 
in WMH 
0.18 -0.33, 0.68 0.5 0.16 -0.58, 0.89 0.7 
Additional annual change with 1 
unit increase in WMH 
-0.30 -0.40, -0.19 <.0001 -0.48 -0.64, -0.31 <.0001 
Adjusted for cognition:π       
Annual change in BI -0.51 -0.58, -0.44 <.0001 -0.66 -0.76, -0.55 <.0001 
Change in BI with 1 unit increase 
in WMH 
0.17 -0.34, 0.67 0.5 0.14 -0.60, 0.87 0.7 
Additional annual change with 1 
unit increase in WMH 
-0.30 -0.40, -0.19 <.0001 -0.47 -0.64, -0.31 <.0001 
Adjusted for quality of life and 
depression: †† 
      
Annual change in BI -0.51 -0.58, -0.44 <.0001 -0.66 -0.77, -0.56 <.0001 
Change in BI with 1 unit increase 
in WMH 
0.19 -0.30, 0.68 0.5 0.15 -0.57, 0.88 0.7 
Additional annual change with 1 
unit increase in WMH 
-0.30 -0.40, -0.19 <.0001 -0.47 -0.64, -0.31 <.0001 
Adjusted for stroke and MI: ‡       
Annual change in BI -0.45 -0.52, -0.38 <.0001 -0.58 -0.69, -0.48 <.0001 
Change in BI with 1 unit increase 
in WMH 
0.29 -0.18, 0.76 0.2 0.29 -0.38, 0.96 0.4 
Additional annual change with 1 
unit increase in WMH 
-0.28 -0.38, -0.18 <.0001 -0.45 -0.61, -0.30 <.0001 







NOTE: The mobility domain includes transfers, mobility, and stair use; the non-mobility domain includes 
feeding, bathing, grooming, dressing, bowels, bladder, and toilet use 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 







Appendix B11. Unadjusted and adjusted models of the association between silent brain infarcts 
and functional status, stratified by mobility vs. non-mobility domains, using the new dataset 











Unadjusted model:       
Annual change in BI -0.39 -0.46, -0.32 <.0001 -0.47 -0.56, -0.38 <.0001 
Change in BI with SBI -0.72 -1.51, 0.06 0.07 -0.48 -1.61, 0.65 0.4 
Additional annual change with 
SBI 
-0.38 -0.58, -0.18 0.0002 -0.61 -0.92, -0.29 0.0002 
Adjusted for demographics:†       
Annual change in BI -0.40 -0.46, -0.33 <.0001 -0.48 -0.58, -0.39 <.0001 
Change in BI with SBI 0.0002 -0.84, 0.84 0.99 0.37 -0.85, 1.58 0.6 
Additional annual change with 
SBI 
-0.38 -0.58, -0.18 0.0002 -0.61 -0.93, -0.29 0.0002 
Adjusted for vascular risk 
factors:* 
      
Annual change in BI -0.41 -0.49, -0.34 <.0001 -0.50 -0.61, -0.40 <.0001 
Change in BI with SBI -0.04 -1.00, 0.91 0.9 0.53 -0.86, 1.91 0.5 
Additional annual change with 
SBI 
-0.38 -0.60, -0.17 0.0005 -0.61 -0.95, -0.26 0.0007 
Adjusted for social variables:**       
Annual change in BI -0.41 -0.49, -0.34 <.0001 -0.50 -0.60, -0.40 <.0001 
Change in BI with SBI 0.05 -0.91, 1.01 0.9 0.63 -0.77, 2.03 0.4 
Additional annual change with 
SBI 
-0.38 -0.60, -0.16 0.0005 -0.60 -0.95, -0.26 0.0007 
Adjusted for cognition:π       
Annual change in BI -0.41 -0.49, -0.34 <.0001 -0.50 -0.61, -0.40 <.0001 
Change in BI with SBI 0.05 -0.91, 1.01 0.9 0.63 -0.77, 2.03 0.4 
Additional annual change with 
SBI 
-0.38 -0.60, -0.16 0.0005 -0.60 -0.95, -0.26 0.0007 
Adjusted for quality of life and 
depression: †† 
      
Annual change in BI -0.42 -0.49, -0.34 <.0001 -0.51 -0.61, -0.41 <.0001 
Change in BI with SBI 0.02 -0.94, 0.97 0.97 0.58 -0.83, 1.99 0.4 
Additional annual change with 
SBI 
-0.38 -0.59, -0.16 0.0006 -0.60 -0.95, -0.25 0.0007 
Adjusted for stroke and MI: ‡       
Annual change in BI -0.37 -0.44, -0.30 <.0001 -0.45 -0.55, -0.35 <.0001 
Change in BI with SBI 0.22 -0.70, 1.14 0.6 0.86 -0.49, 2.20 0.2 
Additional annual change with 
SBI 
-0.34 -0.55, -0.12 0.002 -0.55 -0.89, -0.20 0.0018 
BI=Barthel index; CI=confidence interval; SBI=silent brain infarct; MI=myocardial infarction 
NOTE: The mobility domain includes transfers, mobility, and stair use; the non-mobility domain includes 
feeding, bathing, grooming, dressing, bowels, bladder, and toilet use 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 







Appendix B12. Unadjusted and adjusted models of the association between lacunar infarcts and 
functional status, stratified by mobility vs. non-mobility domains, using the new dataset 











Unadjusted model:       
Annual change in BI -0.39 -0.45, -0.32 <.0001 -0.47 -0.56, -0.37 <.0001 
Change in BI with LI -0.50 -1.31, 0.31 0.2 -0.24 -1.46, 0.98 0.7 
Additional annual change with LI -0.45 -0.67, -0.24 <.0001 -0.73 -1.08, -0.38 <.0001 
Adjusted for demographics:†       
Annual change in BI -0.39 -0.46, -0.32 <.0001 -0.47 -0.57, -0.38 <.0001 
Change in BI with LI 0.33 -0.55, 1.21 0.5 0.72 -0.59, 2.03 0.3 
Additional annual change with LI -0.46 -0.68, -0.24 <.0001 -0.74 -1.10, -0.38 <.0001 
Adjusted for vascular risk 
factors:* 
      
Annual change in BI -0.41 -0.49, -0.34 <.0001 -0.50 -0.60, -0.40 <.0001 
Change in BI with LI 0.31 -0.69, 1.31 0.5 0.85 -0.65, 2.35 0.3 
Additional annual change with LI -0.46 -0.70, -0.22 0.0001 -0.74 -1.13, -0.34 0.0002 
Adjusted for social variables:**       
Annual change in BI -0.41 -0.48, -0.34 <.0001 -0.50 -0.60, -0.40 <.0001 
Change in BI with LI 0.38 -0.63, 1.39 0.5 0.94 -0.58, 2.45 0.2 
Additional annual change with LI -0.46 -0.70, -0.22 0.0001 -0.73 -1.12, -0.34 0.0002 
Adjusted for cognition:π       
Annual change in BI -0.41 -0.49, -0.34 <.0001 -0.50 -0.60, -0.40 <.0001 
Change in BI with LI 0.39 -0.61, 1.40 0.4 0.96 -0.55, 2.47 0.2 
Additional annual change with LI -0.46 -0.70, -0.22 0.0001 -0.74 -1.13, -0.35 0.0002 
Adjusted for quality of life and 
depression: †† 
      
Annual change in BI -0.41 -0.49, -0.34 <.0001 -0.51 -0.61, -0.41 <.0001 
Change in BI with LI 0.36 -0.65, 1.37 0.5 0.91 -0.62, 2.44 0.2 
Additional annual change with LI -0.45 -0.69, -0.22 0.0002 -0.73 -1.12, -0.34 0.0003 
Adjusted for stroke and MI: ‡       
Annual change in BI -0.37 -0.44, -0.30 <.0001 -0.44 -0.54, -0.35 <.0001 
Change in BI with LI 0.51 -0.47, 1.48 0.3 1.11 -0.34, 2.56 0.13 
Additional annual change with LI -0.42 -0.65, -0.19 0.0004 -0.68 -1.06, -0.30 0.0005 
BI=Barthel index; CI=confidence interval; LI=lacunar infarct; MI=myocardial infarction 
NOTE: The mobility domain includes transfers, mobility, and stair use; the non-mobility domain includes 
feeding, bathing, grooming, dressing, bowels, bladder, and toilet use 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 







Appendix B13. Unadjusted and adjusted models of the association between number of lacunar 
infarcts and functional status, stratified by mobility vs. non-mobility domains, using the new 
dataset 











Unadjusted model:       
Annual change in BI -0.41 -0.48, -0.34 <.0001 -0.49 -0.59, -0.40 <.0001 
Change in BI with 1 additional LI -0.50 -1.06, 0.06 0.08 -0.55 -1.41, 0.30 0.2 
Additional annual change with 1 
additional LI 
-0.18 -0.30, -0.06 0.004 -0.33 -0.54, -0.12 0.002 
Adjusted for demographics:†       
Annual change in BI -0.41 -0.48, -0.35 <.0001 -0.50 -0.60, -0.41 <.0001 
Change in BI with 1 additional LI -0.13 -0.73, 0.47 0.7 -0.12 -1.03, 0.79 0.8 
Additional annual change with 1 
additional LI 
-0.18 -0.31, -0.06 0.004 -0.33 -0.54, -0.11 0.003 
Adjusted for vascular risk 
factors:* 
      
Annual change in BI -0.44 -0.51, -0.37 <.0001 -0.53 -0.63, -0.43 <.0001 
Change in BI with 1 additional LI -0.18 -0.82, 0.46 0.6 -0.13 -1.13, 0.86 0.8 
Additional annual change with 1 
additional LI 
-0.15 -0.28, -0.03 0.015 -0.29 -0.51, -0.07 0.011 
Adjusted for social variables:**       
Annual change in BI -0.44 -0.51, -0.37 <.0001 -0.53 -0.63, -0.43 <.0001 
Change in BI with 1 additional LI -0.17 -0.82, 0.48 0.6 -0.12 -1.12, 0.89 0.8 
Additional annual change with 1 
additional LI 
-0.15 -0.28, -0.03 0.016 -0.29 -0.51, -0.07 0.011 
Adjusted for cognition:π       
Annual change in BI -0.44 -0.51, -0.37 <.0001 -0.53 -0.63, -0.43 <.0001 
Change in BI with 1 additional LI -0.16 -0.81, 0.49 0.6 -0.10 -1.11, 0.90 0.8 
Additional annual change with 1 
additional LI 
-0.15 -0.28, -0.03 0.015 -0.29 -0.51, -0.07 0.01 
Adjusted for quality of life and 
depression: †† 
      
Annual change in BI -0.44 -0.52, -0.37 <.0001 -0.54 -0.64. -0.44 <.0001 
Change in BI with 1 additional LI -0.17 -0.82, 0.48 0.6 -0.12 -1.13, 0.89 0.8 
Additional annual change with 1 
additional LI 
-0.15 -0.28, -0.03 0.016 -0.29 -0.51, -0.07 0.01 
Adjusted for stroke and MI: ‡       
Annual change in BI -0.39 -0.46, -0.32 <.0001 -0.47 -0.57, -0.38 <.0001 
Change in BI with 1 additional LI -0.10 -0.67, 0.48 0.7 -0.02 -0.93, 0.89 0.96 
Additional annual change with 1 
additional LI 
-0.13 -0.25, -0.02 0.03 -0.26 -0.48, -0.05 0.014 
BI=Barthel index; CI=confidence interval; LI=lacunar infarct; MI=myocardial infarction 
NOTE: The mobility domain includes transfers, mobility, and stair use; the non-mobility domain includes 
feeding, bathing, grooming, dressing, bowels, bladder, and toilet use 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 






Appendix B14. Unadjusted and adjusted models of the association between perivascular space 
score and functional status, stratified by mobility vs. non-mobility domains, using the new dataset 











Unadjusted model:       
Annual change in BI -0.39 -0.51, -
0.27 
<.0001 -0.43 -0.60, -0.27 <.0001 
Change in BI with 1 point 
increase in SPVS 
-0.06 -0.14, 0.01 0.11 -0.03 -0.13, 0.08 0.6 
Additional annual change with 1 
point increase in SPVS 
-0.01 -0.03, 0.01 0.19 -0.03 -0.05, 0.002 0.066 
Adjusted for demographics:†       
Annual change in BI -0.39 -0.51, -
0.27 
<.0001 -0.44 -0.61, -0.27 <.0001 
Change in BI with 1 point 
increase in SPVS 
0.01 -0.07, 0.09 0.8 0.05 -0.06, 0.16 0.4 
Additional annual change with 1 
point increase in SPVS 
-0.01 -0.03, 0.01 0.18 -0.03 -0.05, 0.002 0.07 
Adjusted for vascular risk 
factors:* 
      
Annual change in BI -0.43 -0.55, -
0.30 
<.0001 -0.48 -0.65, -0.30 <.0001 
Change in BI with 1 point 
increase in SPVS 
0.01 -0.08, 0.11 0.8 0.06 -0.06, 0.18 0.3 
Additional annual change with 1 
point increase in SPVS 
-0.01 -0.03, 0.01 0.3 -0.02 -0.05, 0.01 0.11 
Adjusted for social variables:**       
Annual change in BI -0.43 -0.55, -
0.30 
<.0001 -0.48 -0.65, -0.30 <.0001 
Change in BI with 1 point 
increase in SPVS 
0.01 -0.08, 0.11 0.8 0.06 -0.06, 0.19 0.3 
Additional annual change with 1 
point increase in SPVS 
-0.01 -0.03, 0.01 0.3 -0.02 -0.05, 0.01 0.11 
Adjusted for cognition:π       
Annual change in BI -0.43 -0.55, -
0.30 
<.0001 -0.47 -0.65, -0.30 <.0001 
Change in BI with 1 point 
increase in SPVS 
0.01 -0.08, 0.11 0.8 0.06 -0.06, 0.19 0.3 
Additional annual change with 1 
point increase in SPVS 
-0.01 -0.03, 0.01 0.3 -0.02 -0.05, 0.01 0.10 
Adjusted for quality of life and 
depression: †† 
      
Annual change in BI -0.43 -0.55, -
0.30 
<.0001 -0.47 -0.65, -0.29 <.0001 
Change in BI with 1 point 
increase in SPVS 
0.04 -0.05, 0.13 0.3 0.09 -0.03, 0.21 0.14 
Additional annual change with 1 
point increase in SPVS 
-0.01 -0.03, 0.01 0.3 -0.03 -0.06, 0.003 0.078 
Adjusted for stroke and MI: ‡       
Annual change in BI -0.39 -0.51, -
0.27 
<.0001 -0.42 -0.59, -0.25 <.0001 






increase in SPVS 
Additional annual change with 1 
point increase in SPVS 
-0.01 -0.02, 0.01 0.5 -0.02 -0.05, 0.01 0.15 
BI=Barthel index; CI=confidence interval; SPVS=score of perivascular spaces; MI=myocardial infarction 
NOTE: The mobility domain includes transfers, mobility, and stair use; the non-mobility domain includes 
feeding, bathing, grooming, dressing, bowels, bladder, and toilet use 
†adjusted for age at time of MRI, sex, race 
*additionally adjusted for: diabetes, hypertension, coronary artery disease, hypercholesterolemia, physical 
activity, alcohol use, smoking, and body mass index at the time of MRI 
**additionally adjusted for: marital status, insurance, number of friends, and years lived in the community 
πadditionally adjusted for mini-mental state score 
†† additionally adjusted for Spitzer quality of life index and depression 







Appendix B15. Sensitivity analysis of the association between MRI findings and functional status among those with baseline Barthel 
index score of 95 to 100, in adjusted models* 











Models testing SBI, original dataset       
Annual change in BI -0.85 -1.01, -0.69 <.0001 -0.76 -0.92, -0.60 <.0001 
Change in BI with SBI 1.02 -1.38, 3.43 0.4 1.07 -0.95, 3.09 0.3 
Additional annual change with SBI -0.88 -1.44, -0.32 0.0019 -0.79 -1.34, -0.24 0.005 
Models testing WMH, original dataset       
Annual change in BI -1.03 -1.19, -0.87 <.0001 -0.94 -1.10, -0.78 <.0001 
Change in BI with 1 SD increase in WMH 0.43 -0.69, 1.55 0.5 1.17 0.14, 2.20 0.026 
Additional annual change with 1 SD 
increase in WMH 
-0.73 -0.98, -0.48 <.0001 -0.68 -0.94, -0.41 <.0001 
Models testing SBI, new dataset       
Annual change in BI -0.82 -0.98, -0.66 <.0001 -0.76 -0.92, -0.61 <.0001 
Change in BI with SBI 1.01 -1.09, 3.12 0.3 0.77 -1.12, 2.66 0.4 
Additional annual change with SBI -0.90 -1.43, -0.37 0.0009 -0.61 -1.13, -0.10 0.0203 
Models testing LI, new dataset       
Annual change in BI -0.80 -0.96, -0.65 <.0001 -0.76 -0.91, -0.60 <.0001 
Change in BI with LI 1.57 -0.66, 3.80 0.2 1.11 -0.90, 3.12 0.3 
Additional annual change with LI -1.12 -1.70, -0.54 0.0002 -0.78 -1.36, -0.21 0.0077 
Models testing LPVS, new dataset       
Annual change in BI -0.92 -1.11, -0.72 <.0001 -0.81 -1.00, -0.62 <.0001 
Change in BI with 1 point increase in LPVS 0.65 -0.73, 2.04 0.4 1.03 -0.16, 2.21 0.089 
Additional annual change with 1 point 
increase in LPVS 
-0.13 -0.46, 0.19 0.4 -0.16 -0.49, 0.16 0.3 
*BI=Barthel index; SBI=silent brain infarct; CI=confidence interval; WMH=white matter hyperintensity volume; SD=standard deviation; LI=lacunar 
infarct; LPVS=large perivascular space score 
Models are adjusted for: age at the time of MRI, sex, race-ethnicity, diabetes, hypertension, hypercholesterolemia, physical activity, alcohol use, 







Appendix C1. Functional scales in the Cardiovascular Health Study 
Activities of daily living: Number of tasks the participant has difficulty with:  
-walking around your home 
-getting out of bed or chair 
-eating including feeding yourself 
-dressing yourself 
-bathing or showering 
-using the toilet 
  
Instrumental activities of daily living: Number of tasks the participant has difficulty with:  
-doing heavy housework 
-doing light housework 
-doing shopping for personal items 
-preparing your own meals 
-paying bills / managing money 








Appendix C2. Kaplan-Meier survival estimates for MI (event=0) and stroke (event=1) 
 






Appendix C3. Incident events during follow-up 
A) INCIDENT STROKE SUBTYPES: 
1086 incident first strokes: 
885 ischemic: 
139 lacunar 
304 cardioembolic  
69 atherosclerotic 




(Note: There were 820 with only one subtype, 58 with 2 subtypes, and 3 with 3 subtypes) 




(Note: There were 117 with only one subtype, 2 with 2 subtypes) 
 
B) CARDIAC EVENTS DURING FOLLOW-UP – whole cohort: 
Incident, among whole cohort: 
Incident CHD:   1754/4734 (37.1%) 
Incident angina:  1395/4924 (28.3%) 
Incident angioplasty: 300/5793 (5.2%) 
Incident bypass surg: 367/5641 (6.5%) 
Incident CHF:  1868/5613 (33.3%) 
Incident MI:  1007/5326 (18.9%) 
 Fatal MI:  119 (11.8% of MI) 
 Nonfatal MI:  888 (88.2% of MI) 
 Definite MI:  848 (84% of MI) 
 Probable MI:  135 (13.4% of MI) 
 Other MI:  24 (2.4% of MI) 
 
Incident, among those free of CHD at baseline: 
Incident CHD:   1754/4734 (37.1%) 
Incident angina:  1319/4734 (27.9%) 
Incident angioplasty: 216/4734 (4.6%) 
Incident bypass surg: 270/4734 (5.7%) 
Incident CHF:  1428/4634 (30.8%) 
Incident MI:  850/4734 (18.0%) 
 Fatal MI:  92 (10.8% of MI) 
 Nonfatal MI:  758 (89.2% of MI) 
 Definite MI:  718 (84.5% of MI) 
 Probable MI:  111 (13.1% of MI) 
 Other MI:  21 (2.5% of MI) 
 
C) DEATHS DURING FOLLOW-UP:  4637/5888 (78.8%) 
 Atherosclerotic CHD:   1165/4628 (25.2%) 
 Cerebrovascular disease:  379/4628 (8.2%) 
 Other atherosclerotic disease: 105/4628 (2.3%) 
 Other cardiovascular:    141/4628 (3.1%) 
 Non-cardiovascular:    2837/4628 (61.3%) 







Appendix C4. Number of assessments before and after stroke 
Among cohort with first ischemic stroke and at least one follow-up assessment: 
# of visits bfr stroke  Frequency  Percent  Cumulative Freq Cumulative %  
0    46   12.04   46    12.04  
1    38   9.95   84    21.99  
2    62   16.23   146    38.22  
3    48   12.57   194    50.79  
4    38   9.95   232    60.73  
5    46   12.04   278    72.77  
6    42   10.99   320    83.77  
7    40   10.47   360    94.24  
8    22   5.76   382    100.00  
 
# of visits after stroke  Frequency  Percent  Cumulative Freq  Cumulative %  
1    77   20.16   77    20.16  
2    69   18.06   146    38.22  
3    59   15.45   205    53.66  
4    53   13.87   258    67.54  
5    39   10.21   297    77.75  
6    25   6.54   322    84.29  
7    25   6.54   347    90.84  
8    20   5.24   367    96.07  







Appendix C5: distributions of functional outcome scores 
A) Distributions of overall functional score: 












































































B) Summary statistics of function variable in stroke dataset: 
Mean Lower Quartile Median Upper Quartile Std Dev Minimum Maximum N Miss N 
1.83 0 1 2 2.90 0 12 346 2469
 
C) Summary statistics of function variable in MI dataset: 
Mean Lower Quartile Median Upper Quartile Std Dev Minimum Maximum N Miss N 
1.09 0 0 1 2.00 0 12 253 2754
 
D) Distributions of continuous functional scores by year of follow-up after enrollment: 
Year  Score (%) Missing 

































































































































































































































































E) Distributions of categorical functional outcome by year of follow-up after enrollment (Number 
[%]): 
Year Not disabled (Score=0) Disabled (Score>1) Missing 
2 231 (66.6) 116 (33.4) 35 
3 206 (63.0) 121 (37.0) 55 
4 180 (59.2) 124 (40.8) 78 
5 186 (56.2) 145 (43.8) 51 
6 158 (53.7) 136 (46.3) 88 
7 126 (44.1) 160 (55.9) 96 
8 100 (34.5) 190 (65.5) 92 
9 77 (33.5) 153 (66.5) 152 
10 71 (31.6) 154 (68.4) 157 
11 55 (30.2) 127 (69.8) 200 
 
F) Distributions of continuous functional scores by year of follow-up centered on stroke: 
Yr Score (%) Missing N 





0 0 0 0 1 
(11.1) 























































































































































































































































































































































0 0 0 0 0 0 0 1 
(16.7) 
1 6 
Note: The year includes 6 months before and 6 months after the stated year: for example, year 8 includes 
values >-8.5 and <-7.5 
 
G) Distributions of categorical functional outcome by year of follow-up centered on stroke 
(Number [%]): 
Year Not disabled (Score=0) Disabled (Score>1) Missing N 






-7 30 (66.7) 15 (33.3) 2 45 
-6 62 (77.5) 18 (22.5) 1 80 
-5 93 (69.4) 41 (30.6) 2 134 
-4 102 (63.0) 60 (37.0) 10 162 
-3 127 (62.3) 77 (37.8) 12  204 
-2 138 (55.9) 109 (44.1) 20 247 
-1 150 (54.2) 127 (45.9) 22 277 
0 127 (41.5) 179 (58.5) 47 306 
1 93 (34.6) 176 (65.4) 48 269 
2 78 (35.1) 144 (64.9) 50 222 
3 52 (31.1) 115 (68.9) 39 167 
4 32 (26.0) 91 (74.0) 30 123 
5 28 (29.5) 67 (70.5) 21 95 
6 19 (30.0) 45 (70.3) 21 64 
7 14 (37.8) 23 (62.2) 12  37 
8 6 (27.3) 16 (72.7) 7 22 
9 1 (16.7) 5 (83.3) 1 6 
Note: The year includes 6 months before and 6 months after the stated year: for example, year 8 includes 
values >-8.5 and <-7.5 
 
H) Summary statistics of continuous functional scores by year of follow-up centered on stroke: 






Minimum Maximum N Miss 
-8 0.78 0 0 0 1.99 0 6 1 
-7 0.51 0 0 1 0.94 0 4 2 
-6 0.31 0 0 0 0.67 0 3 1 
-5 0.71 0 0 1 1.48 0 8 2 
-4 0.62 0 0 1 1.00 0 4 10 
-3 0.77 0 0 1 1.49 0 12 12 
-2 1.06 0 0 1 1.82 0 10 20 
-1 1.09 0 0 1 1.84 0 11 22 
0 2.00 0 1 2 2.90 0 12 47 
1 2.66 0 1 4 3.47 0 12 48 
2 2.80 0 1 4 3.50 0 12 50 
3 2.92 0 1 5 3.53 0 12 39 
4 3.20 0 1 5 3.81 0 12 30 
5 3.16 0 2 4 3.71 0 12 21 
6 3.59 0 2 6 4.14 0 12 21 
7 2.86 0 1 5 3.58 0 12 12 
8 2.95 0 2 4 3.23 0 11 7 
9 4.17 2 3.5 4 4.12 0 12 1 
 
I) Distributions of continuous functional scores by year of follow-up centered on MI: 
Yr Score (%) Missing N 










































1 (0.7) 1 
(0.7) 











0 1 (0.5) 0 1 
(0.5) 
0 0 0 0 8 187 













































































































































































































0 0 1 
(1.4) 





































0 0 1 
(10.0) 
0 0 0 0 2 
(20.0) 
0 0 0 1  10 
10 0 0 0 0 0 0 1 
(100.0) 
0 0 0 0 0 0 0 1 
Note: The year includes 6 months before and 6 months after the stated year: for example, year 8 includes 
values >-8.5 and <-7.5 
 
J) Distributions of categorical functional outcome by year of follow-up centered on MI (Number 
[%]): 
Year Not disabled (Score=0) Disabled (Score>1) Missing N 
-8 14 (82.4) 3 (17.7) 0 17 
-7 34 (58.6) 24 (41.4) 1 58 
-6 60 (69.8) 26 (30.2) 3 86 
-5 96 (70.6) 40 (29.4) 2 136 
-4 127 (67.9) 60 (32.1) 8 187 
-3 137 (62.0) 84 (38.0) 13 221 
-2 171 (62.0) 105 (38.0) 10 276 
-1 173 (57.3) 129 (42.7) 16 302 
0 147 (46.4) 170 (53.6) 35 317 
1 149 (48.5) 158 (51.5) 46 307 
2 121 (52.6) 109 (47.4) 35 230 
3 98 (51.0) 94 (49.0) 28 192 
4 72 (47.7) 79 (52.3) 24 151 
5 55 (48.7) 58 (51.3) 10 113 
6 36 (51.4) 34 (48.6) 8 70 
7 29 (54.7) 24 (45.3) 10 53 
8 15 (55.6) 12 (44.4) 3 27 
9 5 (50.0) 5 (50.0) 1 10 
10 0 1 (100.0) 0 1 
Note: The year includes 6 months before and 6 months after the stated year: for example, year 8 includes 
values >-8.5 and <-7.5 
 
K) Summary statistics of continuous functional scores by year of follow-up centered on MI: 






Minimum Maximum N Miss 






-7 0.78 0 0 1 1.34 0 6 1 
-6 0.49 0 0 1 0.88 0 3 3 
-5 0.63 0 0 1 1.28 0 7 2 
-4 0.67 0 0 1 1.26 0 8 8 
-3 0.68 0 0 1 1.15 0 7 13 
-2 0.84 0 0 1 1.61 0 11 10 
-1 0.93 0 0 1 1.64 0 11 16 
0 1.32 0 1 2 2.19 0 12 35 
1 1.35 0 1 1 2.32 0 12 46 
2 1.44 0 0 2 2.39 0 12 35 
3 1.46 0 0 1 2.56 0 11 28 
4 1.48 0 1 2 2.45 0 11 24 
5 1.27 0 1 2 2.11 0 11 10 
6 1.13 0 0 1 2.01 0 11 8 
7 1.32 0 0 1 2.44 0 12 10 
8 2.11 0 0 3 3.30 0 10 3 
9 2.40 0 0.5 4 3.69 0 9 1 








Appendix C6. Trajectories before and after stroke using a dichotomous definition of disability 






Unadjusted model:    
Annual change before stroke 1.22 1.14, 1.30 <.0001 
Additional annual change after stroke 0.90 0.82, 0.99 0.04 
Change in functional score at time of stroke 1.84 1.42, 2.38 <.0001 
Adjusted for demographics:†    
Annual change before stroke 1.24 1.16, 1.32 <.0001 
Additional annual change after stroke 0.90 0.82, 0.99 0.03 
Change in functional score at time of stroke 1.93 1.47, 2.53 <.0001 
Adjusted for vascular risk factors:*    
Annual change before stroke 1.24 1.16, 1.32 <.0001 
Additional annual change after stroke 0.91 0.82, 1.00 0.05 
Change in functional score at time of stroke 1.88 1.41, 2.51 <.0001 
Adjusted for other medical conditions:**    
Annual change before stroke 1.24 1.16, 1.33 <.0001 
Additional annual change after stroke 0.91 0.82, 1.00 0.057 
Change in functional score at time of stroke 1.91 1.42, 2.57 <.0001 
Adjusted for inflammatory biomarkers:‡    
Annual change before stroke 1.24 1.16, 1.33 <.0001 
Additional annual change after stroke 0.91 0.82, 1.01 0.06 
Change in functional score at time of stroke 1.91 1.42, 2.57 <.0001 
Adjusted for cognition:π    
Annual change before stroke 1.23 1.15, 1.32 <.0001 
Additional annual change after stroke 0.90 0.81, 1.00 0.056 
Change in functional score at time of stroke 1.77 1.30, 2.42 0.0003 
Adjusted for social support: ††    
Annual change before stroke 1.23 1.15, 1.32 <.0001 
Additional annual change after stroke 0.90 0.81, 1.00 0.056 
Change in functional score at time of stroke 1.77 1.30, 2.42 0.0003 
†adjusted for age at time of stroke, sex, race, marital status, and body mass index 
*additionally adjusted for: coronary heart disease 
**additionally adjusted for: arthritis and depression 
‡additionally adjusted for log of C-reactive protein levels 
πadditionally adjusted for mini-mental state score 







Appendix C7. Trajectories of a continuous measure of disability before and after stroke and 
myocardial infarction in the entire cohort (n=5888), in unadjusted and adjusted models, with 
functional score set to worst possible value at death 





    
Unadjusted overall change model    
Annual change 0.62 0.61, 0.63 <.0001 
Unadjusted overall change plus average 
change due to stroke and MI model 
   
Annual change 0.58 0.57, 0.59 <.0001 
Change in functional score at time of stroke 2.37 2.14, 2.59 <.0001 
Change in functional score at time of MI 1.19 1.02, 1.35 <.0001 
Unadjusted pre- and post-stroke and –MI 
trajectories model 
   
Annual change 0.55 0.54, 0.56 <.0001 
Change in functional score at time of stroke 1.55 1.20, 1.90 <.0001 
Change in functional score at time of MI 0.33 0.11, 0.56 0.003 
Additional annual change after stroke 0.11 0.08, 0.14 <.0001 
Additional annual change after MI 0.13 0.11, 0.15 <.0001 
Fully adjusted model:†    
Annual change 0.16 -0.08, 0.39 0.2 
Change in functional score at time of stroke 0.68 0.41, 0.96 <.0001 
Change in functional score at time of MI 0.03 -0.14, 0.19 0.7 
Additional annual change after stroke 0.05 0.00, 0.10 0.056 
Additional annual change after MI 0.02 -0.02, 0.06 0.3 
Fully adjusted model, with non-significant 
interaction terms removed:* 
   
Annual change 0.18 -0.05, 0.42 0.12 
Change in functional score at time of stroke 0.68 0.41, 0.96 <.0001 
Change in functional score at time of MI 0.07 -0.08, 0.22 0.4 
Additional annual change after stroke 0.05 -0.001, 0.10 0.055 
Additional annual change after MI 0.01 -0.02, 0.04 0.4 
MI=myocardial infarction 
†adjusted for: baseline age, sex, race, marital status, education, income, diabetes, hypertension, 
coronary heart disease, arthritis, depression, log of C-reactive protein levels, mini-mental state score, 
social network score, and interaction terms between time of follow-up and these variables 
*adjusted for: age, sex, race, marital status, education, income, diabetes, hypertension, coronary heart 
disease, arthritis, depression, log of C-reactive protein levels, mini-mental state score, social network 
score, and interaction terms between time of follow-up and baseline age, race, education, diabetes, mini-







Appendix C8. Trajectories before and after stroke using a continuous definition of disability, by stroke subtype 





95% CI p-value Change in 
functional 
score 
95% CI p-value Change in 
functional 
score 
95% CI p-value 
Annual change before 
stroke 
0.19 0.07, 0.31 0.003 0.08 0.01, 0.14 0.03 0.18 0.12, 0.25 <.0001 
Additional annual change 
after stroke 
0.33 -0.06, 0.72 0.09 0.25 -0.02, 0.53 0.067 -0.03 -0.18, 0.12 0.7 
Change in functional score 
at time of stroke 







Appendix C9. Trajectories before and after stroke using a continuous definition of disability, testing different cholesterol subtypes* 
 Model 1: adjusting for TC Model 2: adjusting for HDL and 
LDL 
Model 3: adjusting for HDL, 
LDL, and logLPA 
Model 4: adjusting for TC, 
HDL, LDL, and logLPA 
Variable Change in 
functional 
score 
95% CI p-value Change in 
functional 
score 
95% CI p-value Change in 
functional 
score 
95% CI p-value Change in 
functional 
score 







0.02 0.09 0.03, 
0.14 
0.003 0.07 0.02, 
0.13 










0.04 0.14 -0.01, 
0.29 
0.065 0.13 -0.01, 
0.28 










0.079 0.45 -0.05, 
0.95 
0.076 0.46 -0.05, 
0.96 
0.076 0.46 -0.04, 
0.96 
0.07 
TC 0.00 0.00, 
0.01 
0.4 -- -- -- -- -- -- 0.01 0.00, 
0.02 
0.09 
HDL -- -- -- 0.01 0.00, 
0.02 
0.1 0.01 0.00, 
0.02 
0.16 0.00 -0.01, 
0.01 
0.6 
LDL -- -- -- 0.00 -0.01, 
0.00 
0.98 0.00 0.00, 
0.01 
0.7 -0.01 -0.02, 
0.00 
0.18 
logLPA  -- -- -- -- -- -- 0.13 0.02, 
0.24 
0.03 0.14 0.03, 
0.25 
0.01 
*TC=total cholesterol levels, mg/dL; HDL=high-density lipoprotein levels, mg/dL; LDL=low-density lipoprotein levels, mg/dL; logLPA=log of 
lipoprotein A levels; models are additionally adjusted for: age at time of stroke, sex, race, marital status, income, arthritis, depression, mini-mental 







Appendix C10. Exploring different cutoffs of the functional scale 
  Unadjusted model Model A* Model B** 
























Annual change before 
stroke 
1.22 1.14, 1.30 <.0001 1.23 1.15, 
1.32 
<.0001 1.18 1.08, 
1.28 
0.0002 




0.038 0.90 0.81, 
1.002 
0.056 0.96 0.85, 
1.09 
0.5 
Change in functional 
score at time of stroke 
1.84 1.42, 2.38 <.0001 1.77 1.30, 
2.42 






Annual change before 
stroke 
1.26 1.16, 1.37 <.0001 1.26 1.16, 
1.38 
<.0001 1.19 1.06, 
1.34 
0.003 




0.053 0.9 0.80, 
1.005 
0.06 0.97 0.83, 
1.14 
0.7 
Change in functional 
score at time of stroke 
1.98 1.53, 2.55 <.0001 1.93 1.40, 
2.66 






Annual change before 
stroke 
1.25 1.13, 1.39 <.0001 1.22 1.10, 
1.37 
0.0003 1.23 1.04, 
1.45 
0.01 
Additional annual change 
after stroke 
0.90 0.80, 1.02 0.09 0.93 0.81, 
1.07 
0.3 0.91 0.73, 
1.13 
0.4 
Change in functional 
score at time of stroke 
2.37 1.71, 3.28 <.0001 2.5 1.65, 
3.80 






Annual change before 
stroke 
1.36 1.16, 1.59 0.0002 1.30 1.11, 
1.52 
0.001 1.18 0.92, 
1.51 
0.2 
Additional annual change 
after stroke 
0.82 0.69, 0.97 0.02 0.87 0.73, 
1.03 
0.1 0.93 0.71, 
1.23 
0.6 
Change in functional 
score at time of stroke 
2.97 2.00, 4.41 <.0001 3.36 2.04, 
5.52 






Annual change before 
stroke 
1.49 1.21, 1.83 0.0001 1.43 1.17, 
1.75 
0.0006 1.42 1.00, 
2.00 
0.048 
Additional annual change 
after stroke 
0.73 0.59, 0.90 0.003 0.76 0.60, 
0.94 
0.01 0.79 0.54, 
1.14 
0.2 
Change in functional 
score at time of stroke 
3.26 2.09, 5.08 <.0001 3.34 2.02, 
5.54 











Annual change before 
stroke 
1.56 1.18, 2.06 0.002 1.46 1.10, 
1.93 
0.009 1.38 0.90, 
2.13 
0.14 
Additional annual change 
after stroke 
0.69 0.52, 0.92 0.01 0.74 0.55, 
0.99 
0.04 0.81 0.51, 
1.27 
0.4 
Change in functional 
score at time of stroke 
3.73 2.16, 6.46 <.0001 3.79 1.90, 
7.55 






Annual change before 
stroke 
1.68 1.22, 2.32 0.001 1.44 1.06, 
1.95 
0.02 1.48 0.92, 
2.40 
0.11 
Additional annual change 
after stroke 
0.66 0.48, 0.92 0.01 0.77 0.56, 
1.06 
0.1 0.76 0.46, 
1.25 
0.3 
Change in functional 
score at time of stroke 
3.71 1.98, 6.94 <.0001 4.42 1.96, 
9.97 






Annual change before 
stroke 
1.62 1.04, 2.50 0.03 1.51 0.89, 
2.59 
0.13 1.64 0.72, 
3.73 
0.2 
Additional annual change 
after stroke 
0.68 0.44, 1.06 0.09 0.71 0.41, 
1.21 
0.21 0.59 0.26, 
1.36 
0.2 
Change in functional 
score at time of stroke 
4.88 2.24, 
10.61 
<.0001 5.21 1.98, 
13.73 






Annual change before 
stroke 
1.98 1.20, 3.26 0.007 2.37 1.22, 
4.61 
0.01 3.74 1.11, 
12.66 
0.03 
Additional annual change 
after stroke 
0.55 0.33, 0.92 0.02 0.44 0.22, 
0.86 
0.02 0.24 0.07, 
0.84 
0.03 
Change in functional 
score at time of stroke 
4.66 1.85, 
11.72 
0.001 3.27 1.09, 
9.78 






Annual change before 
stroke 
1.75 1.02, 3.02 0.043 1.77 0.98, 
3.17 
0.055 3.22 0.59, 
17.42 
0.18 
Additional annual change 
after stroke 
0.64 0.37, 1.11 0.11 0.64 0.35, 
1.17 
0.14 0.28 0.05, 
1.62 
0.15 
Change in functional 
score at time of stroke 
6.02 2.27, 
15.96 
0.0003 3.14 0.77, 
12.80 






Annual change before 
stroke 
1.17 0.78, 1.77 0.4 1.57 1.23, 
1.996 
0.0003 1.52 1.02, 
2.27 
0.04 
Additional annual change 
after stroke 
0.93 0.60, 1.43 0.7 0.69 0.50, 
0.947 
0.02 0.61 0.35, 
1.05 
0.07 
Change in functional 
score at time of stroke 
26.05 4.57, 
148.7 
0.0002 9.98 0.91, 
109.3 
0.0597 5.90 1.31, 
26.6 
0.02 
*Model A is adjusted for: age at time of stroke, sex, race, marital status, body mass index, coronary heart disease, arthritis, depression, log of C-






**Model B is adjusted for: age at time of stroke, sex, race, marital status, income, arthritis, depression, log of lipoprotein A levels, mini-mental state 
score, and social network score 
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